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Hepatitis B virus
Hepatitis B virus (HBV) belongs to the hepatotropic hepadnaviridae, which represent a family 
of small enveloped DNA viruses that primarily infect the liver. Worldwide, approximately 
250 million people are chronically infected and thereby at increased risk to develop liver 
fibrosis, cirrhosis and hepatocellular carcinoma over a course of 20-50 years [1]. Hepatitis 
B virions, also known as Dane particles, consist of a nucleocapsid surrounded by core 
antigens (HBcAg) that is in turn enveloped by an outer lipid membrane containing small, 
middle and large surface antigens (HBsAg) (Figure 1) [2]. The nucleocapsid comprises the 
double-stranded relaxed-circular (RC)-DNA of approximately 3200 base pairs that contains 
four major open reading frames: C, encoding both HBcAg and hepatitis B e antigen (HBeAg); 
S, encoding the surface antigens (Ag); P, encoding polymerase, the reverse transcriptase 
enzyme; and X, encoding the HBV X protein (HBx), which has been described to be involved 
in regulation of virus replication [3, 4].
HBV specifically targets hepatocytes. Upon entry of HBV via the sodium taurocholate 
cotransporting polypeptide (NTCP) into these cells, the nucleocapsid is released into the 
cytoplasm and transported to the nucleus [5, 6]. The RC-DNA is released into the nucleus 
and “repaired” to form covalently closed circular (ccc)DNA [7]. cccDNA is a minichromosome 
that can persist in the liver for years. Since it functions as a template for all viral RNAs, 
incomplete eradication of cccDNA can lead to reinitiation of an infection. The small mRNAs 
transcribed from the cccDNA are translated into viral proteins and over-length pregenomic 
(pg)RNA is packaged together with the viral polymerase into a newly-formed nucleocapsid. 
In this core particle reverse transcriptase takes place to synthesize viral DNA. The RC-
DNA-containing nucleocapsids are either transported to the nucleus to amplify cccDNA or 
enveloped and released as Dane particles via the endoplasmic reticulum [8]. In addition 
to infectious virions, also soluble HBeAg proteins and virus-like particles (VLPs) consisting 
of small, middle and large HBsAg, are secreted by virus-infected hepatocytes. HBeAg 
represents a non-structural, secreted form of the nucleoprotein, which is not required for 
viral replication, but is detected during the early stages of chronic hepatitis B (CHB) and 
exhibits immune-modulating functions [2]. HBsAg VLPs can accumulate to more than 100 
µg/ml in peripheral blood of HBV patients and outnumber infectious virions at least 100-fold 
[9] and like HBeAg exhibit immune-modulating functions [2]. 
Figure 1. Schematic 
representation of an HBV 
virion.
An HBV virion consists of a 
nucleocapsid of core antigens, 
which contains viral DNA and 
polymerase, and is enveloped 
by an outer lipid membrane 
made up of small, middle and 
large surface antigens.
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Natural course of HBV infection
HBV can be transmitted from mother to child (vertical transmission) or via exposure to blood 
or infected body fluids (horizontal transmission). During the first 4-7 weeks post-infection, 
HBV DNA and HBV Ags are not detectable in serum or the liver. After this lag phase HBV starts 
expanding exponential, and can reach levels up to 109-1010 copies per ml [10]. Infection with 
HBV leads to acute hepatitis, which can be either symptomatic or asymptomatic. During 
the acute phase an adequate innate and adaptive immune response, strong and broad 
antiviral CD4+ and CD8+ T cell responses as well as HBsAg-specific antibodies, are induced, 
which control and eradicate the virus [11-14]. However, lack of an effective antiviral immune 
response leads to the development of CHB [14-16]. Approximately 90% of the people 
that encounter infection during adulthood are able to clear the virus and develop lifelong 
protective immunity, while 90% of perinatal infections in contrast result in CHB. Factors 
determining the risk of development of CHB in adulthood are route of infection, age, dose 
of inoculum and HLA class II genetic profile of the individual [17-20]. Thus far, it is unknown 
what factors cause that especially neonates cannot clear the infection.
HBV in itself is a non-cytopathic virus, but the ineffective and persistent immune response in 
CHB patients induces liver damage [21]. The natural history of CHB follows 4 clinical phases 
that differ in levels of HBeAg , viral replication, and liver damage as indicated by alanine 
aminotransferase (ALT). The 4 phases include the immune tolerant (IT) phase, the immune 
active (IA) phase, inactive carrier (IC) phase and HBeAg-negative (ENEG) CHB phase, also 
called reactivation phase [8, 22]. The IT phase is characterized by HBeAg positivity, high HBV 
DNA titers (>20,000 IU/ml) as well as ALT levels within the normal range (<40 IU/L), and the 
IA phase is also characterized by HBeAg positivity but with low HBV DNA titers and elevated 
ALT levels as a result of the recognition of HBV by the immune system. After the IA phase 
seroconversion from HBeAg to anti-HBe antibodies can take place which leads to the control 
of viral replication and again a reduction of immune damage. The IC phase is therefore 
characterized by lack of HBeAg, low or undetectable HBV DNA titers, and ALT levels within 
the normal range. The IC phase can be followed by the ENEG phase, in which viral replication 
is reactivated. This phase is thus characterized by elevated levels of HBV DNA and ALT, as 
well as a lack of HBeAg.
Although an effective prophylactic vaccine is available, there is no effective treatment for 
established infections and the few drugs that are beneficial, often are not accessible in 
poor countries where the prevalence of HBV infection is highest. Treatment with pegylated 
interferon α (PEG-IFNα), which has both antiviral and immunomodulatory activity, induces 
persistent immune control in 20-30% of patients but is associated with severe side effects. 
Treatment with nucleos(t)ide analogues, which interfere with viral reverse transcriptase, 
can reduce HBV DNA replication, but has to be given life-long as it does not eliminate HBV 
cccDNA and is prone to selection of escape mutants [23]. Therefore, there is still a high 
demand for more effective therapies that induce immune control of viral replication in a 
more lasting and patients-friendly manner or fully clear the virus. In order to develop such 
immunomodulatory treatment strategies, it is crucial to better understand why adequate 
HBV-specific immune responses are lacking in CHB patients. 
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Antiviral immunity in general
Upon viral infection, the innate immune system forms the first line of defense. The innate 
immune system involves monocytes, macrophages, natural killer (NK) cells, the complement 
system, and cytokines. Innate immune cells sample the environment for invading pathogens 
and recognize these via pattern recognition receptors (PRR). Upon pathogen recognition, 
the cells become activated and start producing chemokines, to attract other immune cells, 
as well as antiviral and/or immunoregulatory cytokines, such as interferons (IFNs) [24]. IFNs 
play a crucial role in the host defense against viral infections as they possess a direct antiviral 
function by inhibiting cell infection and virus replication, as well as an immunoregulatory 
function by affecting the activation and cytokine production of immune cells [25]. Different 
types of IFN exist, which can be divided into three main classes; type I IFNs, including 13 
IFN-α homologs, IFN-β and several poorly defined subtypes, type II IFN, i.e. IFN-γ, and type 
III IFNs, including IFN-λ1, IFN-λ2, IFN-λ3 and IFN-λ4. 
In addition, innate recognition can trigger further adaptive immune responses, involving B 
cells that produce antibodies, CD8+ cytotoxic T lymphocytes (CTL) that can eradicate virus-
infected cells, and CD4+ T helper cells that can regulate B cell and CTL activation [26]. In 
contrast to the innate immune system, which acts in a generic way, the adaptive immune 
system acts specific and is required for induction of long-lasting and protective immunity.
The role of DCs in antiviral immunity
As stated above, effective antiviral immunity involves the production of antiviral cytokines 
such as IFNs, and the induction of  a virus-specific adaptive immune response to clear virus-
infected cells. Dendritic cells (DCs) play an essential role in induction of antiviral immunity 
because they can both produce high levels of type I and type III IFNs and are the most potent 
Ag-presenting cells that can activate virus-specific naïve T cells [27-29].  In contrast to other 
Ag-presenting cells such as macrophages, DCs harbor the unique capacity to migrate from 
peripheral tissues to lymphoid tissues, allowing efficient communication with LN-resident 
adaptive immune cells. In the periphery, DCs continuously sample their environment for 
invading pathogens, including viruses and virus-infected cells. Upon recognition of such 
foreign antigens by PRR, such as Toll-like receptors (TLRs) and C-type lectins, DCs internalize 
this material and become activated as a result of signaling cascades emanating from ligand-
bound PRRs [30]. DC activation is associated with upregulation of maturation markers 
and/or co-stimulatory molecules such as CD40, CD80, CD83 and CD86, the production of 
cytokines and with the migration of DCs from the periphery to the draining lymph nodes. 
In addition to direct activation by pathogens via PRR ligation, DCs can also be activated 
indirectly by signals from other immune cells or virus-infected non-immune cells (e.g. by 
cytokines or surface receptors on these cells) [31]. 
Concomitant to PRR-triggered DC activation, ingested pathogens or infected cells are 
processed intracellularly by DCs into peptides and DCs present these peptides on major 
histocompatibility complexes (MHC) to activate T cells. Peptides presented on MHC class II 
can activate CD4+ helper T cells (direct presentation) and those on MHC class I can activate 
cytolytic /IFN-y-producing CD8+ T cells (cross-presentation) [32].  
Optimal activation of T cells by DCs requires recognition of peptides in MHC molecules by 
the T cell receptor (TCR) (signal 1) combined with co-stimulatory molecules such as CD40 
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and CD86 (signal 2) and cytokines such as IL-12, IL-4, and IFN-α (signal 3) that polarize T cells 
towards a specific type of immune response (e.g. antibody mediated/humoral, cytolytic, 
tolerogenic) [33-36]. Cross-presentation of exogenous antigens in MHC class I is especially 
important for the defense against viruses that do not infect DCs themselves, such as HBV. It 
is required for the induction of an effective CD8+ T cells response against such antigens. An 
extensive overview of the mechanisms underlying MHC class I presentation of viral antigens 
by DCs is provided in chapter 2.
Activation and skewing of CD4+ T cells in combination with the right cytokines is also 
important because IL-12-induced T helper 1 (Th1) cells provide adequate help for CD8+ T 
cell activation by producing cytokines such as IFN-γ and licensing signals such as CD40 [37]. 
IL-4-induced T helper 2 (Th2) cells in contrast will skew the immune response more towards 
the production of antibodies. Similarly, other T helper cells including Th17, follicular helper 
T cells (Tfh) or regulatory T cells (Treg) may be induced by IL-17, IL-21 and IL-10/TGF-β, 
respectively, that each have a different effect  on the resulting immune response [38]. A 
wrong balance between T cell skewing cytokines could divert an immune response into 
the wrong direction.  Moreover, when DCs are not fully mature and lack sufficient T cell 
activation/skewing signals, T cell stimulation can also result in induction of tolerogenic/
regulatory T cells instead of immunogenic T cells [39]. 
Figure 2. The role of DCs in induction of antiviral immunity.
Upon recognition of a virus, DCs become activated and start producing cytokines that can inhibit viral replication, 
and  attract as well as activate (bold) or inhibit (regular) cells of the innate and adaptive immune system, including 
monocytes, macrophages, NK cells and B cells. In addition, DCs can process and present antigens in MHC molecules, 
which together with cytokine production can induce CD4+ and CD8+ T cell responses. These activated immune cells 
can in turn also secrete cytokines that inhibit viral replication. Furthermore, activated B cells produce antibodies 
that neutralize the virus and activated T cells and NK cells can kill virus-infected cells via induction of apoptosis. 
Mono, monocyte; Mφ, macrophage; NK, NK cell; DC, dendritic cell; CD8+, CD8+ T cell; CD4+, CD4+ T cell; B, B cell.
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Besides induction of T cell responses, DCs can interact with and activate other immune 
cells, including B cells, NK cells, monocytes and macrophages (Figure 2). Furthermore, DCs 
regulate the magnitude and quality of immune responses via production of pro-inflammatory 
cytokines such as TNF-α, IL-1β, IL-6 and IL-8 or anti-inflammatory cytokines such as IL-10 
and TGF-β [40]. Because of this capacity to bridge and control innate and adaptive immune 
responses, DCs play an essential role in induction of virus-specific immunity. 
Dendritic cell subsets
Human DCs consists of several subsets that differ in ontogeny, localization, phenotype and 
specialized immune functions [41, 42]. The blood DC subsets can be subdivided into two 
main categories; CD11c+ myeloid DCs (mDCs) and BDCA2+BDCA4+CD123+ plasmacytoid 
DCs (pDCs). pDCs are mainly found in peripheral blood and lymphoid organs and are 
characterized by expression of CD123, CD303 (BDCA2) and CD304 (BDCA4). pDCs are 
known to produce high amounts of antiviral type I interferon (IFN) upon endosomal TLR7 
or TLR9 ligation by nucleic acid derivatives [43]. mDCs are located in peripheral blood and 
peripheral and lymphoid tissues and comprise two main populations: CD1c+ (BDCA1+) DCs 
and the more recently discovered CD141hi(BDCA3hi)CLEC9A+XCR1+ DCs (further referred to 
as BDCA3+ DCs). Compared to pDCs, mDCs are better inducers of T cell activation. BDCA1+ 
DCs are known for their high production of IL-12 in response to TLR ligation [44]. BDCA3+ 
DCs are the most potent producers of IFN-λ in response to viruses or the synthetic RNA 
polyinosinic:polycyticylic acid (polyI:C) [45-48]. In addition, BDCA3+ DCs are superior at 
cross-presentation of cell-derived Ag to CD8+ T cells [49-53]. Because of these capacities 
BDCA3+ DCs are thought to be of importance for anti-viral responses. The presumed murine 
equivalents of human BDCA3+ DCs and the main cross-presenting cells in mice are the 
CD8α+ DCs and CD103+ DCs [54, 55] which have been shown to be crucial for generating 
optimal virus-specific CD8+ T cell responses to for example herpes simplex virus, influenza 
virus, vaccinia virus and West Nile virus [56-59]. In addition, lymph node-resident CD8α+ DC 
have been shown to uniquely function as a platform for activation of antiviral CTL and the 
associated delivery of CD4+ T cell help [60, 61]. Compared to other DC subsets, BDCA3+ DCs 
are very rare, and were more recently discovered and are thus least well studied. In chapter 
3 it is extensively described what is currently known of the developmental, phenotypic and 
functional characteristics of BDCA3+ DCs. 
Dendritic cells in HBV infection
As outlined above, DCs are key players in induction of adaptive immunity. Consequently, 
these cells are expected to also play an important role in induction of HBV-specific immunity. 
In the liver, BDCA1+ DCs and pDCs are mainly located at the portal tract and central veins 
where they sample the environment for invasive pathogens [62]. Upon capture of antigens, 
DCs can translocate to the space of Disse and migrate to the secondary lymphoid organs [63, 
64]. As the liver is continuously exposed to foreign antigens that are present in blood coming 
from the gastrointestinal tract, it has a tolerogenic microenvironment to prevent chronic 
inflammation. In line with this, intrahepatic DCs have been shown to be less immunogenic 
than their counterparts in blood [65, 66].
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Several studies have previously assessed the frequency and function of BDCA1+ DCs and 
pDCs in HBV-infected patients [67]. This has revealed that the frequencies of both BDCA1+ 
DCs and pDCs in the blood of CHB are either unaffected or decreased, depending on the 
phase of disease. Both DC subtypes however, were found at increased numbers in the liver 
of CHB patients. [68-73]. This is not completely surprising as it can be expected that the 
frequency of intrahepatic DC populations will be affected by liver inflammation leading to 
the increased recruitment of immune cells to the liver and/or the migration of DCs from the 
liver to secondary lymphoid organs. 
DCs themselves are not permissive to HBV infection [74, 75]. However, DCs containing HBsAg 
have been detected in liver and blood of HBV patients, indicating that DCs can interact with, 
and ingest viral material [74, 76]. It remains to be determined whether HBV virions or viral 
proteins activate DCs and if so, via which receptors this occurs. Interaction between HBV 
and DCs could also impair the function of DCs. Functional analysis of circulating BDCA1+ DCs 
showed that in CHB patients these cells are impaired in their capacity to mature, produce 
TNF-α and activate T cells [70, 77, 78]. For pDCs it was demonstrated that IFN-α-production 
was impaired in CHB patients [68, 70, 79, 80]. This reduced pDC function may be (partially) 
due to an effect of the virus or viral proteins, because HBV virions, HBsAg and HBeAg reduced 
the IFN-α production by pDCs in vitro [79, 81, 82]. HBV and HBsAg were shown to inhibit 
IFN-α production by interfering with TLR9-induced mTOR-mediated S6 phosphorylation that 
in turn drives phosphorylation of IRF7 and IFN-α production [79, 83]. Because it is difficult 
to obtain liver tissue for research of intrahepatic DCs, most studies on DC function in HBV 
infection so far were performed with peripheral blood DCs and were restricted to BDCA1+ 
DCs and pDCs. DCs have been characterized in the liver of healthy controls, but except for 
HBsAg uptake, no information is available on intrahepatic DC function in HBV infection [76].
Furthermore, as outlined above, BDCA3+ DCs may be of particular importance in anti-viral 
responses, yet BDCA3+ DCs have been least well studied in general and their function in 
HBV infection is still unknown. It remains to be determined whether HBV also interferes 
with BDCA3+ DC function. More insight into the frequency, distribution and function of 
BDCA3+ DCs in healthy donors as well as CHB patients may help to better understand their 
role in intrahepatic immune regulation both in steady state and HBV infection. Moreover, 
knowledge on the local presence and functional state of these cells may aid the development 
of immunotherapeutic strategies exploiting these cells to improve immune responses to 
HBV (see below). 
Type I and type III IFNs in HBV infection
IFNs play a key role in the induction and regulation of antiviral responses. These antiviral 
cytokines restrict viral replication and infection of neighbouring cells by induction of 
interferon-stimulated genes (ISGs), and possess immunoregulatory capacities as they can 
stimulate responses of several immune cells, such as DCs, NK cells and Th1 cells. Type I 
IFNs have been thoroughly studied and their antiviral and immunoregulatory characteristics 
are well known. HBV infection by itself does not induce production of type I IFNs and the 
capacity of IFN-α to combat HBV is the rationale for the current use of PEG-IFN-α as therapy 
for CHB infection.  
Like type I IFNs, type III IFNs (IFN-λs) are important antiviral cytokines with antiviral 
activity against multiple viruses, including influenza virus, hepatitis C virus (HCV), human 
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immunodeficiency virus (HIV), encephalomyocarditis virus, vesicular stomatitis virus (VSV), 
cytomegalovirus (CMV) and herplexsimplex virus (HSV) [84-90]. Moreover, IFN-λ has a 
crucial role in the defense against rotavirus and West Nile virus [91-93] and is the major 
IFN type induced upon infection with influenza virus [94]. Importantly, IFN-λ can also inhibit 
HBV replication, indicating IFNλ may also have therapeutic potential for HBV [88, 95, 96]. 
Compared to type I and type II IFNs, knowledge on the regulation of IFN-λ production is still 
limited. Recent studies have shown that the promotor regions of IFN-λ1-3 contain binding 
elements for IRF3, IRF7, and NFκB, and that these transcription factors are indeed involved 
in the regulation of IFN-λ1-3 production [97-103]. These studies on IFN-λ-regulating 
pathways have been performed with several cell types, such as hepatocytes, HEK293 cells, 
monocyte-derived DCs (moDCs) and colon epithelial cells. As said however, BDCA3+ DCs are 
the major producers of IFN-λ upon recognition of synthetic dsRNA or viruses [45, 46]. Yet, 
the molecular pathways underlying IFN-λ regulation in primary DCs have not been studied. 
Insight into these regulatory mechanisms will help to better understand by what properties 
BDCA3+ DCs excel in IFN-λ production.
The IFN-λ family consists of four subtypes, including IFN-λ1 (IL-29), IFN-λ2 (IL-28A), IFN-λ3 
(IL-28B) and IFN-λ4 [104, 105]. IFN-λ4 is only expressed in individuals who have a frameshift 
variant in their genome, resulting in a novel gene that encodes IFN-λ4 [106]. 
All IFN-λ subtypes signal via the IFN-λ receptor, which forms a complex of two subunits; the 
IL-28 receptor α (IL-28Rα) chain and IL-10Rβ chain. Signaling via this receptor induces, like 
IFN-α signaling, activation of the JAK-STAT and MAPK pathways and subsequent induction 
of ISGs [107]. The ISGs induced by type III IFNs are comparable to those induced by type I 
IFNs, yet, type I and III IFN differ in expression kinetics and bioactivity, which is mostly due to 
the restricted expression of the IFN-λ receptor. [108-110]. In contrast to the IFN-α receptor, 
which is expressed by most cells, expression of the IFN-λ receptor is present only on a 
limited group of cell types, including epithelial cells, B cells, pDCs, macrophages, neutrophils 
and hepatocytes, and the latter points towards an important role for IFN-λ in the liver [105, 
110-113]. 
In addition to direct antiviral activity by the induction of ISGs, IFN-λ also has important 
immunoregulatory properties, including effects on macrophages, NK cells, B cells, 
neutrophils, pDCs and T cells (Figure 3) [107, 114, 115]. IFN-λ has been shown to stimulate 
IFN-γ production by NK cells via induction of IL-12 production by macrophages, to augment 
TLR-mediated function of B cells, and to enhance the anti-viral response of pDCs by increasing 
IFN-α and IFN-λ production [116-118]. In addition, IFN-λ promotes production of the Th1 
cytokine IFN-γ and reduces production of Th2 cytokines IL-4, IL-5 and IL-13, indicating that 
IFN-λ supports skewing towards a Th1 response, and in this way may also promote effective 
antiviral immunity [86, 119]. 
Given these antiviral and immunoregulatory functions, IFN-λ may aid the induction of HBV-
specific immunity. 
Recently it was shown HBV induces IFN-λ production rather than IFN-α by primary human 
hepatocytes via activation of the intracellular RNA receptor RIG-I [120]. However, despite 
the potential of HBV to induce IFN-λ in vitro, IFN-λ transcripts were hardly detectable in 
HBV-infected livers, and serum of CHB patients contains IFN-λ levels that are comparable 
to those of control individuals [121-125]. HBV is considered to be a stealth virus as it does 
not seem to induce type I IFN responses upon infection [126]. These data on IFN-λ now 
suggest that HBV intervenes not only with induction of type I IFN responses, but also with 
the induction of IFN-λ. Indeed, it was recently shown that HBV is able to actively inhibit IFN-λ 
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production in hepatocytes [120, 127]. When present however, IFN-λ may help to combat 
HBV infection, given that SNPs near the IL28B gene are associated with better response to 
PEG-IFN-α therapy in HBeAg-positive CHB patients [128]. Nevertheless, the link between 
these SNPs and response to PEG-IFN-α therapy has not been unraveled yet.
In a recent clinical trial patients have now also been treated directly with PEG-IFN-λ. This 
study showed that, in HBeAg-positive patients, during the first 24 weeks of treatment, PEG-
IFN-λ induced greater reduction in HBV DNA and HBsAg levels than was seen with PEG-
IFN-α. However, at end of treatment (48 weeks), serologic and virologic responses were 
comparable for PEG-IFN-λ and PEG-IFN-α [129]. As expected from expression of the IFN-λ 
receptor by only a limited group of cell types however, the rates of interferon-associated 
side effects of PEG-IFN-λ were lower than those of PEG-IFN-α, indicating IFN-λ may have a 
therapeutic advantage. 
Treatment opportunities for chronic hepatitis B currently under investigation
Currently, there are several new therapies proposed based on intervention with different 
specific stages of the HBV life-cycle or the expression of viral proteins, such as intervention 
with HBV entry into hepatocytes by Myrcludex B [130, 131], cleavage of cccDNA upon 
activation of the CRISPR-Cas9 system, cleavage of cccDNA upon activation of lymphotoxin 
beta receptor (LTβR) and APOBEC3 proteins [132, 133], and inhibition of HBsAg as well as 
HBcAg production by silencing RNA (siRNA; Figure 4) [134]. However, it remains challenging 
to reach the ultimate goal, complete elimination of HBV cccDNA, by these approaches. 
The loss of cccDNA can also be achieved by immune-mediated killing of cccDNA-containing 
hepatocytes. As HBV-specific T cells together with HBV-specific antibodies can recognize 
and eliminate infected hepatocytes that express or present viral antigens on their surface, 
immunotherapy aiming to restore anti-viral B and T cell responses therefore also represents 
a promising treatment strategy [135-137]. The potency of the immune system to fight HBV 
is illustrated by the observation that upon bone marrow transplantation, CHB patients 
mounted effective HBV-specific T cell responses as well as HBsAg-specific antibodies, and 
Figure 3. Effects of IFN-λ on immune cells and IFN-λ receptor-expressing non-immune cells.
IFN-λ exhibits direct antiviral effects, via induction of ISGs, and immunoregulatory effects. Depicted are the 
stimulatory (↑) or inhibitory (↓) effects of IFN-λ. NK, NK cell; pDC, plasmacytoid DC; Mφ, macrophage; T, T cell; 
B, B cell.
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were able to clear the infection [138-140]. Unfortunately, this strategy is not being used 
widely as it is a complex and expensive procedure that is difficult to implement in developing 
countries and is not without risk. Therefore, alternative immunotherapeutic approaches for 
restoring HBV-specific immunity are currently under investigation (Figure 4).
One approach is based on the observation that in CHB patients HBV-specific T cells are 
functionally exhausted and express inhibitory molecules such as PD-1, CTLA-4 and Tim-
3 which may impair T cell function upon ligation by their agonists on antigen presenting 
cells or infected hepatocytes [141-144]. Blocking these inhibitory receptors by monoclonal 
antibodies has been shown to enhance the function of HBV-specific T cells in vitro and 
therefore is considered as a viable approach to restore T cell function in CHB patients [145]. 
Another approach under investigation is restoration of virus-specific T cell immunity by 
adoptive T cell therapy. T cells from patients are genetically modified so that they express 
an HBV-specific T cell receptor (TCR) that can recognize and kill virus-infected cells [146-
148]. In vivo studies showed that adoptive transfer of such T cells can reduce HBV replication 
and HBsAg levels in a patient with HBV-related HCC [148, 149]. However, the disadvantage 
of this technique is that it depends on autologous T cells and can thus not be generically 
applied to all patients, which again prohibits its use in developmental countries.
Another opportunity currently exploited is to boost antiviral immune responses by the 
activation of Toll-like receptor 7 (TLR7). For this treatment TLR7 agonists are administrated 
that activate TLR7, which is predominantly expressed by pDCs and B cells, and thereby 
induce an endogenous type I IFN response that has direct antiviral activity and augments 
innate and adaptive immune responses. Recent studies have shown that administration of 
the TLR7 agonist GS-9620 in chronically HBV-infected chimpanzees and woodchuck hepatitis 
virus (WHV)-infected woodchucks (an animal model to study infection of hepadnaviruses) 
resulted in reduced HBV DNA levels [150, 151]. However, subsequent administration of a 
low dose of the TLR7 agonist in CHB patients did not induce clinically significant changes in 
HBsAg or HBV DNA levels [152]. Further research is required to determine the feasibility of 
this treatment in CHB patients.
Many studies have tried to boost HBV-specific immunity by therapeutic vaccination with 
nucleic acids encoding viral proteins  [135]. These studies showed that HBsAg-encoding DNA 
vaccines can stimulate immune responses and reduce HBV replication in some patients, but 
overall have limited virological and clinical efficacy [153, 154]. 
As CHB is associated with T cell hyporesponsiveness, and reduction of viral load by antiviral 
treatment has been shown to enhance HBV-specific T cell responses [155], administration 
of antiviral drugs prior to therapeutic vaccination was thus proposed to optimize the 
efficacy of immunotherapeutic strategies. Indeed, vigorous T cell response and sustained 
immunological control of chronic hepadnaviral infection was observed in woodchucks 
chronically infected with WHV that had received DNA prime-adenovirus boost vaccination 
and the nucleoside analogue entecavir [156]. Likewise, injection of DNA vaccines encoding 
multiple HBV proteins and IL-12 in combination with lamivudine treatment induced a 
virological response and vigorous HBV-specific memory T cell responses that persisted for 
40 weeks after vaccination in half of the treated patients [157]. 
Finally, efforts are made to exploit DCs to fight HBV. Mouse studies showed that DC-
stimulatory signals alone, i.e.  stimulation of intrahepatic DCs by TLR ligands or CD40L, 
already enhanced virus-specific CTL responses [158, 159]. Vaccination with HBsAg resulted 
in enhanced HBV-specific immune responses and lower HBV DNA titers in some patients 
[160-163]. In addition, clinical trials have been performed, in which HBV peptide-pulsed 
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DCs alone or combined with antiviral drugs were administered to patients [164-166]. This 
treatment resulted in suppression of virus replication and improved HBeAg seroconversion 
rates. 
Given the central role of DCs in immunity, these cells represent an attractive target for 
therapeutic vaccines. Therefore, protein/peptide vaccines are being developed that are 
based on in vivo (cross-)presentation by DCs [167]. These vaccines target DCs with HBV 
proteins or peptides in combination with proper stimulatory signals to boost DC activation 
and antigen presentation, resulting in induction of IFN responses as well as HBV-specific 
innate and adaptive immune responses. 
As BDCA3+ DCs possess excellent cross-presenting and IFN-λ-producing properties, delivery 
of TLR3 ligands combined with HBV peptide or antigen to these cells may lead to their 
activation and subsequent initiation of HBV-specific CTL responses and IFN-λ production. 
Targeting the BDCA3+ DCs in particular may thus be an interesting novel therapeutic strategy 
for HBV. For development of efficient DC-targeted vaccines against CHB however it is 
essential to know whether (BDCA3+) DCs are present in livers and peripheral blood of CHB 
patients and what the functional state of these cells is.
Figure 4. Therapeutic strategies for chronic hepatitis B.
Depicted are the various strategies for the treatment of chronic hepatitis B that are available or under investigation. 
These strategies include: A, inhibition of viral entry; B, cleavage of cccDNA upon activation of the lymphotoxin 
beta receptor (LTβR) and APOBEC3 proteins; C, cleavage of cccDNA upon activation of the CRISPR/Cas9 system; 
D, inhibition of HBsAg and HBcAg production by siRNAs; E, inhibition of HBV DNA replication by nucleot(s)ide 
analogs (NUCs); F, induction of ISGs and stimulation of immune response by PEG-IFN-λ or PEG-IFN-α; G, blocking 
of inhibitory T cell receptors by monoclonal antibodies; H, genetic modification of T cells by T cell receptor gene 
transfer; I, administration of TLR7 agonists; J, administration of DNA-based vaccines; K, administration of protein/
peptide-based vaccines.
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Aims and outline of the thesis
DCs are key players in induction of anti-viral immunity and therefore this thesis aims to 
better understand how DCs, and specifically BDCA3+ DCs, are affected by or may help to 
clear chronic HBV infection. 
In chapter 2, the different mechanisms employed by human DCs to facilitate MHC class I 
presentation of viral antigens and subsequent anti-viral CD8+ T cell induction are discussed. 
This overview shows that cross-presentation is a highly efficient mechanism to initiate virus-
specific immunity. 
Compared to other DC subsets, BDCA3+ DCs were discovered more recently and are less 
well studied. To get more insight into this cell type, chapter 3 provides a summary of the 
developmental, phenotypic and functional characteristics of BDCA3+ DCs. As the frequencies 
of BDCA3+ DCs in the body are very low, assessment of these cells is challenging. Therefore, 
we attempted to generate BDCA3+ DCs from CD34+ progenitor cells in vitro in chapter 4. 
Although we were able to generate CD34+-derived BDCA3+ DCs that produce high levels of 
IFN-λ, subsequent gene expression analysis revealed that they do not completely resemble 
BDCA3+CLEC9A+ DCs in vivo. Nevertheless, CD34+-derived BDCA3+ DCs represent a valuable 
model to study regulation of IFN-λ production and BDCA3 expression by DCs. 
BDCA3 is also (partly) expressed by other DC subsets than the typical BDCA3hiCLEC9A+ DCs, 
including BDCA1+ DCs. However, whether differences exist between BDCA3+ and BDCA3- 
cells within the BDCA1+ DC population remains unknown. In chapter 5, we therefore studied 
the difference between blood BDCA3+BDCA1+ DCs and BDCA3-BDCA1+ DCs, which indicated 
that BDCA3+BDCA1+ DCs have a more activated status and produce higher cytokine levels 
compared to BDCA1+ DCs. 
In contrast to regulation of type I IFN production, regulation of type III IFN production is 
poorly understood. Chapter 6 describes the study of regulation of IFN-λ production by the 
major IFN-λ-producing cells, BDCA3+ DCs, and reveals that this process involves the canonical 
NFκB pathway and the PI3K-PKB-mTOR pathway.
BDCA3+ DCs are considered to be important in regulating antiviral immune responses 
because of high IFN-λ production and efficient antiviral cytotoxic T cell induction. However, 
the presence and function of these cells in HBV-infected patients remains unknown. Chapter 
7 describes the frequency and function of BDCA3+ DCs in liver and blood of CHB patients and 
control individuals. The data show that BDCA3+ DCs are abundantly present in HBV-infected 
livers. However, blood BDCA3+ DCs from CHB patients are impaired in their capacity to mature 
and produce IFN-λ compared to controls. This impaired function may be caused by the virus 
or viral proteins since we show that HBsAg inhibits IFN-λ production by BDCA3+ DCs in vitro 
via its effect on other immune cells. One of the cell types of which the function is directly 
influenced by HBsAg are BDCA1+ DCs. The HBsAg receptors on BDCA1+ DCs that affect the 
function of these cells, however, are unknown. In chapter 8 the interaction between HBsAg 
and BDCA1+ DCs and its effect on BDCA1+ DC function was investigated, which demonstrated 
that BDCA1+ DCs are activated by HBsAg and that this activation depends on the presence 
of (soluble) CD14. 
A detailed discussion and interpretation of results is given in chapter 9.
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Abstract
Effective viral clearance requires the induction of virus-specific CD8+ cytotoxic T lymphocytes 
(CTL). Since dendritic cells (DC) have a central role in initiating and shaping virus-specific CTL 
responses, it is important to understand how DC initiate virus-specific CTL responses. Some 
viruses can directly infect DC, which theoretically allows direct presentation of viral antigens 
to CTL, but many viruses target other cells than DC and thus the host depends on the cross-
presentation of viral antigens by DC to activate virus-specific CTL.
Research in mouse models has highly enhanced our understanding of the mechanisms 
underlying cross-presentation and the DC subsets involved, however, these results cannot 
be readily translated towards the role of human DC in MHC class I antigen presentation of 
human viruses. Here, we summarize the insights gained in the past 20 years on MHC class I 
presentation of viral antigen by human DC and add to the current debate on the capacities 
of different human DC subsets herein. Furthermore, possible sources of viral antigens and 
essential DC characteristics for effective induction of virus-specific CTL are evaluated.
We conclude that cross-presentation is not only an efficient mechanism exploited by DC 
to initiate immunity to viruses that do not infect DC but also to viruses that do infect DC, 
because cross-presentation has many conceptual advantages and bypasses direct immune 
modulatory effects of the virus on its infected target cells.   
Since knowledge on the mechanism of viral antigen presentation and the preferred DC 
subsets is crucial for rational vaccine design, the obtained insights are very instrumental for 
the development of effective anti-viral immunotherapy. 
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Role of dendritic cells in the induction of anti-viral immunity
Immune responses to viral infections are a complex interplay between the virus, target cells 
and cells of the immune system. Effective viral clearance requires the induction of virus-
specific CD8+ cytotoxic T lymphocytes (CTL), which have the capacity to eradicate the virus 
by direct and indirect mechanisms [1]. Dendritic cells (DC), a low frequent population of 
white blood cells, play a central role in the induction of virus-specific CTL, since they are the 
most potent antigen presenting cells and unique for their capacity to activate naïve T cells 
[2]. DC are located at strategic positions at sites of pathogen entry, where they continuously 
sample the environment for invading pathogens. Capturing antigens in combination with 
encountering danger signals from pathogens induces maturation of DC and their migration 
to secondary lymphoid organs where they can activate naïve T cells. Activation of naïve CD8+ 
T cells and polarization towards effective CTL requires presentation of MHC class I-peptide 
complexes (signal 1) together with co-stimulation (signal 2) and the presence of cytokines 
(signal 3) such as IL-12 [3] and IFNα [4].
DC comprise a family of different subsets, diverging in ontogeny, localization and phenotype. 
Each DC subset has its own specialized immune functions with regard to the functional 
interactions with all kind of immune cells, including T cells, B cells and NK cells, due to 
differential expression of receptors and intrinsic differences in their ability to produce 
different cytokines and other membrane-bound and soluble immune modulatory molecules 
[5]. Human DC subsets present in blood, peripheral and lymphoid tissues can be classified 
in two main categories: plasmacytoid DC (pDC), and myeloid DC (mDC), which can be 
further divided into BDCA1+ (CD1c+) and BDCA3+ (CD141+) DC [6]. pDC are specialized in 
the production of high amounts of antiviral type I interferon (IFN; IFNα/β) upon activation 
[7], whereas BDCA1+ DC are known for their high production of IL-12 and their ability to 
induce T cell responses [5]. BDCA3+ DC, on the other hand, can produce high levels of type 
III IFN (IFNλ) [8], which possess direct antiviral activity, and induce Th-1 responses [9]. In 
the skin, two additional mDC subsets have been characterized, epidermal Langerhans cells 
(LC) and dermal interstitial DC [10]. Since DC represent a very rare population in the human 
body that hampers isolation of sufficient numbers, in vitro-generated DC differentiated from 
monocytes [11] or hematopoietic progenitor cells [12] are frequently used for functional 
studies on human DC. 
The notion that DC compared to other antigen presenting cells stand out in their capacity 
to induce strong virus-specific CTL goes back more than 20 years, when it was reported that 
human blood-derived DC exposed to HIV-1 or influenza virus could induce proliferation of 
autologous CTL [13,14]. At that time, it was not known whether the efficacy of DC reflected 
specialized antigen presentation pathways or that other factors were responsible for the 
efficacy of DC in virus-specific CTL cell induction. At least it was noted that only low numbers 
of DC were sufficient to induce influenza-specific T cells [14].
Now we know that DC, in addition to their broad expression of pathogen-recognition 
receptors (PRR) and excellent T cell stimulatory capacities, harbor unique specialized 
antigen presentation pathways, that are of major importance for their central role in the 
induction of virus-specific immunity; DC can efficiently facilitate MHC class I presentation of 
endogenously synthesized antigens, a process that is active in all nucleated cells, but also 
facilitate MHC class I presentation of antigen engulfed from exogenous sources, a process 
called cross-presentation [15]. DC are very efficient in capturing exogenous antigen, because 
they express a diverse repertoire of receptors and exploit various mechanisms to engulf 
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antigens, including endocytosis, phagocytosis and pinocytosis. The cross-presentation 
capacity of DC may be crucial for the induction of virus-specific CTL during infections with 
viruses that do not infect DC.  
Seminal mouse studies have demonstrated the importance of cross-presentation for the 
generation of virus-specific CTL responses [16–18]. In addition, mouse studies have provided 
important insights into the cell-biological mechanisms underlying cross-presentation by DC 
[19,20]. However, composition of the human DC compartment and susceptibility to viruses 
differ largely between mice and men. In addition, the mechanism of cross-presentation by 
human DC is less well understood. Therefore, research on MHC class I presentation of viral 
antigens by human DC is of great importance to understand the induction of virus-specific 
CTL in humans. 
The study into antigen presentation of viruses by subsets of human DC ex vivo has been 
facing several technical challenges, which has hampered the understanding of this process 
for many viruses. However, some recent technical advancements have become available 
that empowered this research. For example, the possibility to more efficiently isolate 
human DC subsets from peripheral blood and other organs and the development of a new 
generation of protocols to generate human DC subsets in vitro [21,22], as was previously 
shown for BDCA1+ monocyte-derived DC (moDC)[11] and CD34+ HPC-derived interstitial 
DC and Langerhans cells (LC), that resemble mDC found in mucosal tissues including skin 
[12,23]. These technical advancements have revived the scientific interest in the interactions 
between viruses and different human DC subsets. Since 2010, a significant body of literature 
has been published on presentation of viral antigens by different human DC subsets that 
facilitated this review, which is based for a large part on studies using human DC. 
In the present review, the different mechanisms employed by human DC to facilitate MHC 
class I presentation of viral antigens are discussed. For this purpose, possible sources of viral 
antigens, essential DC characteristics for optimal MHC class I presentation of viral antigens 
and host factors important for virus-specific CTL induction are defined. Furthermore, the 
roles of the various human DC subsets of human DC in these processes are evaluated. Since 
knowledge on mechanisms of virus-specific CTL induction by human DC subset is crucial for 
rational vaccine design, recommendations for development of effective anti-viral immune 
therapies will be provided based on the insights obtained in this review.
Sources of viral antigen for MHC class I presentation by DC
Virus-infected DC can use endogenously synthesized viral proteins as antigens for 
presentation in MHC class I, whereas non-infected DC need to actively engulf exogenous 
viral antigens for cross-presentation. Here, we discuss possible sources of viral antigen 
obtained from different viruses for MHC class I presentation by human DC.
Human moDC are permissive for quite a number of viruses including Measles Virus (MV), 
Human Cytomegalovirus (HCMV), Influenza A virus (IAV), Human T-cell Lymphotropic 
Virus Virus type 1 (HTLV-1), Dengue Virus (DV), Vaccinia virus (VV), Respiratory Syncytial 
Virus (RSV), Herpes Simplex Virus (HSV), and Human Metapneumovirus (hMPV) [24–36]. 
Although moDC can take up HIV-1, they are largely refractory to HIV-1 productive infection 
[37], whereas, productive infection of peripheral blood-derived BDCA1+ DC and pDC has 
been demonstrated [38]. In addition to moDC, RSV also infects BDCA1+ and BDCA3+ mDC 
[39] and IAV infects BDCA1+ mDC, but not pDC [40]. LC are permissive for MV, but only after 
MHC class I presentation of viral antigens by human DCs
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maturation [25]. Although LC can take up HIV-1, they are not permissive for HIV-1 replication 
and transmission, but rather prevent it by degradation [41]. Permissiveness to infection 
indicates that these viruses not only enter human DC, they also induce a certain level of 
protein neo-synthesis in DC that ranges from restricted synthesis of early viral proteins 
[33] to extensive synthesis of multiple viral proteins and secretion of viral progeny [26]. 
Intracellular synthesis of viral antigens by DC suggests that these infected DC may facilitate 
direct presentation of viral antigens in MHC class I and activation of virus-specific cytotoxic T 
cells (CTL). MHC class I presentation of viral antigens has been reported for DC infected with 
IAV, MV, HTLV-1, and HCMV, albeit sometimes with low efficiency [14,25,27,31,42].  
Nevertheless, it has been demonstrated in several independent studies, involving IAV, HIV-1 
and MV, that the efficiency of MHC class I antigen presentation of replication-incompetent 
virus was at least comparable to replication-competent virus [25,40,43–46]. These heat-or 
UV-treated replication-incompetent viruses have lost the capacity to induce synthesis of 
viral proteins, but still efficiently enter DC to act as exogenous sources of viral antigen. It was 
estimated that MHC class I presentation of replication-incompetent IAV by BDCA1+ mDC was 
300 times more efficient than MHC class I presentation of replication-competent IAV [40]. 
These studies clearly show that endogenous synthesis of viral antigens is not required for 
MHC class I presentation and that cross-presentation is an efficient mechanism to facilitate 
MHC class I presentation of viral antigens.  
Thus, cross-presentation is not only an efficient mechanism exploited by DC to initiate 
immunity to viruses that do not infect DC but also contributes to initiation of anti-viral 
immunity to viruses that do infect DC. In fact, cross-presentation seems a clever way 
to bypass direct immune modulatory effects of the virus on its infected target cells. For 
instance, interference with MHC class I presentation is commonly used by herpes viruses to 
evade immunity (reviewed by [47]) and is also exploited by IAV, as was elegantly shown by 
comparing CMV-specific CTL proliferation by CMV-antigen loaded IAV-infected and uninfected 
BDCA1+ mDC [40]. In addition, early during HIV infection, part of the DC compartment is 
depleted, which may contribute to decreased activation of adaptive immunity [48]. Virus-
induced cell death is also reported for RSV [34,39] and VV [33]. 
In addition to replication-incompetent viral particles, other sources of exogenous viral 
antigens for cross-presentation by human DC include virus-like particles (VLP), viral proteins 
and virus-infected cells (Figure 1). VLP morphologically and immunologically resemble 
infectious viral particles because they contain the natural viral envelop proteins, however, 
they are not infectious, because they do not contain the viral genome. Although some VLP 
naturally occur in vivo, they are often man-made, being used as surrogate viral particles 
to study virus-host interactions [49] or in the context of vaccine research [50,51]. VLP 
can be efficient sources of exogenous viral antigen for cross-presentation by DC, as was 
demonstrated for Hepatitis C virus (HCV) VLP [49], Human Papilloma Virus 16 (HPV16) VLP 
[50] and VLP composed of the coat protein of Papaya Mosaic Virus (PapMV) [51].
Recombinant proteins such as HCV-derived NS3 [52], HIV-1-derived Nef [53], HCMV-derived 
pp65 [9,54] and hepatitis B virus (HBV)-derived hepatitis B surface antigen (HBsAg) [55,56] 
are sources of exogenous antigens that are often used to study the mechanism of cross-
presentation by DC. Nevertheless, the efficiency of cross-presentation of these recombinant 
proteins is relatively low compared to other sources of viral antigens. Moreover, with the 
exception of HBsAg, which is secreted by human hepatocytes and can be measured in 
peripheral blood, most proteins are not naturally occurring as soluble proteins in vivo but 
are only present in/associated with infected cells.
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Cell-associated antigen, i.e. antigen associated to or present in infected target cells, 
represents another important source of viral antigens that can be encountered by DC. Albert 
and colleagues contributed the first evidence of this by showing that uptake of apoptotic 
IAV-infected monocytes by moDC leads to efficient activation of influenza-specific CTL [57]. 
After this study, a compelling number of studies have confirmed that virus-infected target 
cells can be efficient antigen sources for cross-presentation in many infections. For instance, 
VV-infected monocytes [45,58], HTLV-1 infected CD4+ T cells [31], MV-infected B cell lines 
[25], HCMV-infected fibroblasts [27,59] and  EBV-transformed B cells [60,61] are reported 
as efficient sources of viral antigens for cross-presentation by human DC. The latter study 
nicely illustrated the high efficiency of this mechanism by demonstrating activation of EBV-
specific CTL by DC cross-presenting EBV latency antigens that were expressed at low levels 
in EBV-transformed B cells [61].  
In the above-mentioned studies, apoptotic or necrotic virus-containing cells or cell remnants 
were used as sources of cell-associated antigens for cross-presentation. Transfer of viral 
peptides from infected cells to DC could represent an alternative efficient mechanism 
underlying cross-presentation of cell-associated viral antigens. Two different mechanisms 
facilitating peptide exchange between cells have been described, including transfer of 
antigenic peptides via intercellular communication channels, called gap junctions [62], and 
direct transfer of MHC class I/peptide complexes from infected cells to DC, named cross-
dressing [63,64]. The relevance of these pathways in presentation of viral antigens by human 
DC and induction of virus-specific T cell immunity should be further evaluated. 
In summary, for efficient viral antigen presentation to CD8+ T cells, DC can acquire viral 
antigens from various sources. Although direct presentation of endogenously generated 
antigen by virus-infected DC has been reported for some viruses, evidence to support an 
important role for this mechanism in the induction of virus-specific CTL is lacking. In contrast, 
there is compelling evidence that cross-presentation of exogenously acquired viral antigen 
is highly efficient and provides an excellent way for the host to bypass evasion mechanisms 
that several viruses employ to prevent direct MHC class I presentation in infected target 
cells. 
Endocytic receptors involved in uptake of viruses by DC
Being intracellular parasites, viruses use the host machinery for internalization, proliferation 
and transmission. DC are attractive target cells for viral entry because they express numerous 
receptors at their cell surface and they migrate through the body, which facilitates viral 
dissemination. Viruses can enter DC via docking with their viral envelop to endocytic 
receptors expressed at the cell membrane [43,44,46]. A commonly described receptor 
used by viruses to enter DC is DC-specific C-type lectin Dendritic Cell-Specific Intercellular 
adhesion molecule-3-Grabbing Non-integrin (DC-SIGN/CD209). DC-SIGN is involved in the 
infection of moDC by DV [32,65], HCMV [28], HSV [66], MV [67] and IAV [68] and also in 
DC-mediated transmission of HIV-1 [69] and HTLV-1 [70] to CD4+ T cells. DC-SIGN is part of 
the large family of C-type lectin receptors (CLR), comprising Ca2+-dependent receptors that 
each have unique functions but share the recognition of carbohydrate structures present on 
micro-organisms [71]. Other CLR family members involved in interaction with viruses include 
Langerin (CD207), involved in the interaction with MV and HIV-1 [25,41], DC immunoreceptor 
MHC class I presentation of viral antigens by human DCs
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(DCIR) [72], proposed as an alternative receptor for HIV-1 promoting infection in cis and 
trans and Macrophage Mannose Receptor (MMR/CD206), possibly involved in uptake of 
HBsAg by liver BDCA1+ DC [73]. Also non-CLR can be involved in the interaction with viruses 
or VLP. DC-specific heparin sulfate proteoglycan Syndecan-3 cooperates together with DC-
SIGN to facilitate infection of DC and transmission to CD4+ T cells [74] and is involved in 
the interaction with HPV VLP [75]. Since expression of endocytic receptors varies widely 
between DC subsets (Table 1), the different subsets will likely have specialized roles in the 
interaction with different viruses, determined by the combination of receptors expressed 
on each DC subset.
Figure 1: Overview of different 
pathways underlying MHC 
class I presentation of viral 
antigens by human DC. 
Although direct MHC class I 
presentation may contribute 
to virus-specific CTL induction 
(dashed arrow), cross-
presentation is an effective 
mechanism for MHC class I 
presentation of viruses that 
do not infect DC but also for 
those viruses that do infect DC. 
Sources of viral antigen that can 
be efficiently cross-presented by 
human DC include viral proteins, 
(infectious) viral particles, virus-
like particles (VLP) and virus-
infected cells, also referred 
to as cell-associated Ag. 
Endocytic receptors including 
C-type lectin receptors (CLR), 
Fc receptors (FcR) and other 
receptors (Table 1) play an 
important role in the uptake 
of Ag for cross-presentation. 
Cross-presentation can be 
enhanced by opsonization.
Two main pathways for cross-
presentation have been 
described that are also relevant 
for cross-presentation of 
viruses by human DC and are 
characterized by differences in 
the mechanism of protein degradation and differences in kinetics (black arrows). The slower cytosolic pathway, 
that relies on proteasomal degradation in the cytosol, facilitates cross-presentation of viral particles, infected cells 
and opsonized viral proteins (A). The relatively fast vacuolar pathway is independent of proteasomal degradation 
and facilitates cross-presentation of VLP (B), as well as other forms of viral antigen by pDC. Alternatively, DC can 
obtain viral peptides or MHC class I-peptide complexes by interaction with virus-infected cells. 
Abbreviations: EE: early endosome, LE: late endosome, PR: proteasome
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Are these CLRs only involved in supporting viruses to enter the host or did they evolve to 
support activation of the host’s immune system through antigen presentation? Langerin 
is an important receptor for interaction with pathogens in the skin and has been shown 
to support  antigen presentation in MHC class II, but its role in MHC class I-mediated 
antigen presentation is under debate [25]. Moris et al showed that blocking of DC-SIGN 
partly reduced MHC class I presentation of internalized HIV-1 by DC, arguing in favor of a 
role of DC-SIGN in cross-presentation of HIV-1 [76]. In contrast, Sabado et al showed that 
blocking of DC-SIGN, DEC-205 (CD205) or MR did not reduce MHC class I presentation of 
HIV-1 antigens [46] whereas Tjomsland and colleagues showed that blockade of MR even 
promoted cross-presentation of HIV-1 by DC [77]. Thus, the physiological role of DC-SIGN in 
cross-presentation of HIV-1 is thus far inconclusive, which may be explained by differences 
in experimental set-up such as the HIV-1 strain used. Antibody-mediated delivery of antigen 
to the CLRs MR, DEC-205 [78], DCIR [79], DC-SIGN [80] and CLEC9A [81] (Table 1) on human 
DCs facilitates efficient cross-presentation. These examples show that CLR can facilitate 
cross-presentation, however, the physiological role of these receptors in cross-presentation 
of viral antigens is still under debate. 
Whereas CLR can directly recognize viral envelop antigens, complement receptors and Fc 
receptors (FcR) selectively recognize viral antigens that are opsonized with complement and 
Immunoglobulins, respectively. Antigen immune complexes naturally exist and are formed 
when pre-existing antibodies bind to blood-borne antigens in the circulation, for example 
during HCMV re-infection [82]. Binding of immune complexes to Fcγ receptor (FcγR) on 
DC leads to efficient cross-presentation in MHC class I [82]. Strikingly, the observation that 
FcR-dependent uptake of HBsAg can enhance activation of HBV-specific CTL was made 
years before the concept of cross-presentation by DC was recognized [83], indicating that 
opsonization of viral antigens may be important for generating virus-specific CTL. Similarly, 
opsonization of antigen by complement can efficiently enhance cross-presentation, as was 
recently demonstrated for HIV-1 by targeting HIV-1 particles to CR3 [77]. In addition, although 
not classically referred to as opsonization, binding of high-density lipoprotein (HDL) to HCV 
VLP supported efficient Scavenger receptor B-mediated uptake and cross-presentation [84]. 
A similar role for extracellular heat-shock proteins (HSP) has been proposed (reviewed by 
[85], mainly based on mouse studies in the field of cancer immunotherapy. However, the 
role of HSP in cross-presentation of viral antigens by human DC remains to be investigated.
Although these results indicate that several endocytic receptors may be involved in 
facilitating cross-presentation, their exact role needs to be determined. Especially 
recognition of viral antigens by opsonins seems to be an effective way of natural antigen 
targeting to DC for cross-presentation. Increased knowledge on the receptors used by 
viruses for infection on the one hand and the receptors that facilitate cross-presentation 
on the other hand may be of great value for therapeutic interventions.
MHC class I presentation of viral antigens by human DCs
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Mechanisms underlying cross-presentation 
One of the intriguing aspects of cross-presentation is that processing of incoming antigen 
needs to be very efficient to compete with the vast amount of endogenous proteins for 
MHC class I binding. In addition, cross-presentation requires access of incoming antigen 
to the MHC class I pathway that is mechanistically separated from the uptake vesicles by 
membranes [86]. 
DC harbor unique pathways to facilitate these logistic and mechanistic challenges underlying 
cross-presentation. Based on research of numerous groups, two main models have been 
put together for the mechanisms underlying cross-presentation of exogenous antigens, 
referred to as the ‘cytosolic’ pathway and the ‘vacuolar’ pathway [20]. These pathways are 
not mutually exclusive and may operate together in one cell [87]. The most discriminative 
aspects between the two pathways are discussed below. 
In the cytosolic pathway, antigens are degraded by the proteasome, a large enzyme complex 
situated in the cytosol that makes this pathway sensitive to inhibitors of proteasomal 
degradation. Alternatively, in the vacuolar pathway, both antigen degradation and MHC class 
I presentation occur in the endocytic compartment. Involvement of this pathway can be 
experimentally addressed by confirming resistance to inhibition of proteasomal degradation 
and sensitivity to inhibition of lysosomal proteolysis. 
Lysosomal proteolysis has a detrimental role in the cytosolic cross-presentation pathway. 
It was experimentally demonstrated that limiting lysosomal proteolysis by chemically 
increasing the lysosomal pH favors cross-presentation of viral proteins HCV-derived NS3 
and HIV-derived Nef by preventing complete degradation of potential MHC class I binding 
epitopes [53]. Several different adaptations on the endocytic compartment, including a 
differential lysosomal protease activity, mechanisms to control the lysosomal pH and antigen 
storage compartments, together endow DC to facilitate cross-presentation via the cytosolic 
pathway [88–90]. Cross-presentation via the cytosolic pathway further requires export 
of internalized antigens from the endocytic compartment to the cytosol for proteasomal 
degradation, which is probably the rate-limiting step in this pathway, at least for protein 
antigen. Many enveloped viruses can enter the cytoplasm as part of their infection strategy 
that requires fusion of the viral envelope with the endosomal membrane to release the 
viral genome into the cytoplasm. This endosomal fusion capacity probably underlies the 
efficiency of cross-presentation of viral particles, at least for those particles that are able to 
enter the cytoplasm of DC. The mechanism of cytosolic delivery for other viral antigens and 
viruses that do not undergo endosomal fusion in human DC is largely unknown. Candidate 
proteins that may be involved in cytosolic delivery include heat-shock proteins and p97 and 
sec61, which belong to the endoplasmatic reticulum-associated protein degradation (ERAD) 
machinery [20], however, the role of these molecules in human DC is poorly studied.
Interestingly, the cytosolic and vacuolar pathway have totally different kinetics, which can 
be used to determine which pathway is involved [91]. Whereas cross-presentation via the 
vacuolar pathway is fast and can be detected after 20 minutes [92], cross-presentation via 
the cytosolic pathway is much slower and formation of MHC class I – peptide complexes 
via this pathway may take at least eight hours [88], probably because it relies on MHC 
class I neosynthesis [20]. In contrast, MHC class I loading in the vacuolar pathway occurs 
in the endocytic compartment and depends on recycling of MHC class I molecules that are 
constitutively internalized by a highly regulated process [93].
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Table 1. Summary of receptors that are involved in DC-virus interaction on different DC 
subsets. 
Family Name BDCA1+ 
mDC
BDCA3+
mDC
pDC Epidermal 
LC
Dermal 
intDC
moDC References
C-type lectin 
receptors
DEC205 
(CD205)
+ + + - + + [146]
[147]
DCIR + - + + + + [148]
[149]
[150]
[79]
MMR 
(CD206)
+/- + - - + + [78]
[146]
[149]
DC-SIGN
(CD209)
- - - - + + [151]
[146]
CLEC9A
(DNGR1)
- + - - - - [129]
Langerin
(CD207)
- - - + - - [151]
[146]
Toll-like 
receptors
1
2
3
4
5
6
7
8
9
10
+
+
+
+
+
+
-
+
-
+
+
+
+
-
-
+
-
+
-
+
+
-
-
-
-
+
+
-
+
+
+
+
+
-
-
+
+
+
-
-
+
+
+
+
+
+
+
+
-
-
+
+
+
+
+
+
-
+
-
+
[5]
[9]
[149]
Fcγreceptors FcγRI
(CD64)
+ - nf nf nf +/- [82]
FcγRIIA
(CD32)
+ + + nf nf + [82]
[132]
FcγRIII
(CD16)
- - - nf nf - [82]
Complement 
receptors
CR4, 
(CD11c)
+ + - + + + [146]
[149]
CR3, 
(CD11b)
+/- - - +/- + + [152]
[134]
[21]
Heparan 
sulfate 
proteoglycan
Syndecan 3 nf nf nf nf nf + [74]
Chemokine 
receptor
XCR1 - + - - - - [126]
[153]
pDC, plasmacytoid DC; LC, Langerhans cell; intDC, interstitial DC; moDC, monocyte-derived DC; nf, information 
not found
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The viral road to cross-presentation
The cytosolic and the vacuolar pathways were largely established based on model antigens 
and mouse studies. It important to assess if these models are applicable to cross-presentation 
of viral antigens by human DC. 
As discussed above, viral particles use receptors expressed on the plasma membrane to enter 
DC and uptake of viruses often involves endocytosis. After receptor-mediated endocytosis, 
the cargo is transported through the endocytic compartment, a highly regulated network 
of vesicles with different characteristics and functions [91]. An important function of the 
endocytic system is to sort internalized receptors and cargo to different locations for either 
degradation or recycling. Viruses use the endocytic system to exert their fusion capacity, 
however, at the same time DC use it to obtain viral antigen for cross-presentation. For 
example, when IAV reaches late endosomes, the low pH enforces conformational change, 
leading to hemagglutinin-mediated fusion of the endosomal and viral membranes and 
release of the viral RNA and proteins into the cytoplasm [94]. IAV is efficiently cross-
presented, at least when its fusogenic activity is intact [43,95]. The fusion dependence was 
also observed for HIV; cross-presentation of HIV-1 was completely absent when fusion-
incompetent HIV-1 mutants were used or fusion was inhibited chemically [44,46]. Cross-
presentation of HIV-1 viral particles is sensitive to proteasome inhibitors, but enhanced by 
inhibition of lysosomal proteolysis [46]. Taken together, the abovementioned work suggests 
a role for the cytosolic pathway in cross-presentation of fusion-competent viral particles, 
at least by myeloid DC. Interestingly, cross-presentation of IAV by pDC is not sensitive to 
proteasome inhibitors, but is sensitive to inhibition of endosomal processing. Together with 
fast MHC class I presentation this study suggests a role for the vacuolar pathway for cross-
presentation of IAV by pDC.
Evidence from different studies involving IAV-infected monocytes [96], HCMV-infected 
fibroblasts [27] and EBV-transformed B cells  [61] suggests that cross-presentation of cell-
associated antigen involves uptake by receptor-mediated phagocytosis and that antigen 
processing is dependent on the proteasome, but also sensitive to inhibition of lysosomal 
proteolysis [97]. Cross-presentation of Ag-Ig immune complexes also requires both 
proteasomal and endosomal antigen processing [82]. Taken together, these data indicate that 
although cross-presentation of both cell-associated antigen and Ag-Ig immune complexes 
require proteasomal degradation, they may need some degree of lysosomal proteolysis to 
facilitate translocation of antigens from lysosomes to cytoplasm. Since these sources of viral 
antigen do not have intrinsic fusogenic capacity, they rely on functional specializations of DC 
to export Ag of the endocytic compartment to the cytosol [91]. 
Interestingly, several lines of evidence suggest that virus-like particles follow a different 
pathway for cross-presentation. Cross-presentation of PapMV VLP, HCV VLP and HBV VLP 
was not affected by proteasome inhibitors but sensitive to reagents that inhibit lysosomal 
proteolysis [51,84,98]. Furthermore, it was shown that cross-presentation of HBV VLP by 
both mouse DC [98] and human DC (our own unpublished observations) is fast and TAP-
independent. Together, these studies suggest that cross-presentation of VLP occurs via the 
vacuolar pathway.
The differences in cross-presentation pathways between fusion-competent viruses and VLP 
suggest that different vesicles within the endocytic compartment are involved. Chatterjee 
et al showed that antigen targeting via MR or DEC-205 both lead to cross-presentation 
via different compartments [78]. Evidence for a process of sorting comes from an elegant 
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study by Lakadamyali et al, where it was shown that after endocytosis, IAV is sorted into a 
population of dynamic endosomes that rapidly becomes more acidic which is necessary for 
the virus to enter the cytoplasm [99]. In contrast, an alternative non-viral ligand, transferrin 
is sorted into a different population of static endosomes that facilitate recycling of antigen 
and receptors to the cell surface. 
Antigen targeting to DC-SIGN can result in trafficking to different cellular compartments, 
as was shown for HCV envelop protein and Lewis X uptake via DC-SIGN [100]. In addition, 
antibody-mediated antigen targeting to the neck region of DC-SIGN was dramatically more 
efficient with regard to cross-presentation of the targeted antigen compared to targeting to 
the carbohydrate-binding domain, and these differences were related to different endocytic 
trafficking [80]. Taken together, these studies suggest that endocytic sorting is important for 
the fate of antigens and that sorting occurs at the receptor level. The nature of the sorting 
signal and the role of endocytic receptors and their adaptor molecules in this process 
remains to be further elucidated. However, an indication that poly-ubiquitination may be 
involved in sorting and antigen translocation comes from a mouse study involving the MMR 
[101].
We conclude that both the cytosolic and the vacuolar pathways are applicable to cross-
presentation of viral antigen by human DC, depending on the type of viral antigen that is 
encountered by DC (Figure 1). The studies discussed above suggest that VLP preferentially 
traffic via the vacuolar pathway for cross-presentation, whereas protein antigen, fusion-
competent viral particles, cell-associated antigen and Ig-opsonized antigen preferentially 
traffic via the cytosolic pathway for cross-presentation, except in pDC that may preferentially 
facilitate the vacuolar pathway. Since the abovementioned studies together suggest that 
antigen is sorted into pathways with different efficiency of cross-presentation at the 
receptor level, it is of high importance to gain more knowledge on the receptors used for 
internalization of viral antigens and their exact role in the sorting of Ag to different pathways 
in order to fully understand the cross-presentation of viral antigens. Currently, besides VLP, 
no other viral antigens were found that utilize the vacuolar cross-presentation pathway 
in human myeloid DC, thus the physiological role of this pathway remains to be further 
understood. However, since this pathway is highly efficient, as was demonstrated in pDC 
[102], further understanding of the mechanisms underlying the vacuolar pathway may be 
of interest for therapeutic purposes.
DC maturation as a critical factor for CTL induction
Antigen presentation in MHC class I can lead to CTL priming or tolerance, depending on 
the context in which DC encounter the antigen [15]. Sensing of danger signals by pattern-
recognition receptors (PRR) on DC (Table 1) induce DC maturation, a differentiation process 
initiated after innate immune recognition that regulates key functions involved in CTL 
induction, including migration, antigen presentation, co-stimulation and production of 
cytokines. Co-stimulation lowers the threshold for antigen recognition by the T cell receptor 
and is important for proliferation, survival, effector function and memory formation of 
T cells. Changes in antigen presentation after DC maturation include upregulation of 
MHC class I molecules [42], enhanced proteasomal activity [103] and reduced lysosomal 
antigen degradation [104] due to lower expression of lysosomal proteases [95]. It is well 
accepted that matured human DC have an enhanced capacity to activate virus-specific CTL 
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[25,42,56,60,105,106]. Importantly, however, the experimental stimuli used for induction 
of DC maturation are often not representative for the type of danger signals that are 
encountered by DC during viral infection in vivo. 
Which danger signals can be naturally encountered by PRR on DC during viral infection? 
Viruses can display danger signals of various nature including viral nucleic acids, replication 
intermediates, carbohydrate structures and proteins on the envelop, that can be sensed 
by PRR on DC (Table 1). IAV and RSV, both ssRNA viruses, induce maturation of different 
human DC subsets including moDC, BDCA1+ mDC and pDC [34,39,42,107,108]. Also VLP 
have been shown to induce DC maturation [49,50,75], which is not dependent on TLR but 
may be mediated by a recently identified innate recognition mechanism [109]. In addition to 
virus-derived danger signals, virus-induced danger signals produced by the host in response 
to viral infection can induce DC maturation. Examples of such virus-induced host-derived 
maturation signals include cytokines such as IFNα/β and TNFα secreted by virus-infected 
cells [110] and damage-associated molecular patterns (DAMP) released by damaged or 
dying cells [111]. During interaction of DC with cell-associated Ag, DC can encounter both 
virus-derived danger signals and host-derived maturation signals [27,112,113] or host cell-
derived DAMP, such as TLR4 ligand high-mobility group box 1 (HMGB1) [114] or CLEC9A 
ligand F-actin [115]. 
The induction of DC maturation by virus-derived and virus-induced stimuli suggests that 
these factors also enhance CTL priming, however, direct experimental evidence on the 
contribution of virus-induced DC maturation on CTL induction by human DC is limited. IAV-
infection of DC is associated with strong DC maturation and efficient antigen-specific CTL 
proliferation [42,105]. Similarly, TLR agonist poly I:C that mimics viral double-stranded RNA 
(dsRNA) is a strong inducer of DC maturation and effectively enhances cross-presentation 
of recombinant viral antigen by several subsets of human DC [9,56,116,117]. Also TLR7/8 
agonists have been shown to enhance DC-induced CTL expansion and effector function in 
vitro [79]. In contrast, cross-presentation of cell-associated antigen was inhibited when poly 
I:C or IAV were present in the captured dead cells, suggesting that virus-derived danger 
signals may also have a detrimental effect on cross-presentation which may be specific for 
cross-presentation of cell-associated antigen [118]. IFNα, a widely  studied representative 
of virus-induced signals, can exert multiple effects on human DC that promote CTL cross-
priming (reviewed by [4]. For example, moDC differentiated in the presence of IFNα, so called 
IFNα-DC, have superior cross-presentation capacity compared to classical moDC [52,119]. In 
conclusion, although it is widely accepted that virus-derived and virus-induced stimulatory 
signals are required for effective cross-priming of virus-specific CTL, it has been difficult to 
experimentally address this hypothesis in the currently used in vitro models. Challenges 
include the low precursor frequency of naïve virus-specific CD8+ T cells and dissection of the 
separate contributions of DC maturation and antigen-presentation to CTL induction. 
Interference with DC maturation and thereby subverting the development of effective CTL 
induction is an important mechanism of immune evasion used by many viruses. Examples of 
viruses that interfere with DC maturation are MV [120], VV, via the production of cytokine 
receptor homologues [33], HSV, via destabilization of host mRNA [35,121] and HCMV, which 
prevents up-regulation of co-stimulatory molecules and production of cytokines [122] and 
induces TGFβ production by its target cells [112]. Furthermore, DC isolated from patients 
with chronic HIV, HBV and HCV infections showed functional impairments in the capacity 
to produce IL-12 or induce T cell activation, which may be a direct effect of the virus on 
DC and thereby the cause of the failing adaptive immune response, but could also be the 
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consequence of the chronic infection [123,124]. 
The connection between innate immune recognition of viruses by human DC and the 
induction of virus-specific CTL is an important subject for further study. In addition, the PRR 
and pathways underlying recognition of viruses by DC and the mechanisms by which viruses 
circumvent these pathways needs to be further explored. Novel molecular techniques such 
as the ability to knock down PRR in human DC will empower this type of research, which is 
important for the development of therapeutic interventions.
DC subsets involved in cross-presentation of viral antigen
Before 2010, the large majority of studies on cross-presentation of viral antigen by human 
DC were performed with in vitro-generated monocyte-derived DC (moDC), however, more 
recently a number of groups have succeeded in obtaining sufficient numbers of DC from 
blood or other organs to assess the ability and mechanism of cross-presentation of viral 
antigens by different human DC subsets.
BDCA3+ DC were initially recognized as a subset with superior cross-presentation capacity 
compared to other human DC subsets [9,21,125,126]. Comparison of transcriptional profiles 
revealed that BDCA3+ DC represent the human equivalent of murine CD8α+ and CD103+ 
DC [56,127], which have a superior intrinsic cross-presentation capacity compared to other 
DC subsets [128]. BDCA3+ DC were believed to have a superior capacity to cross-present 
cell-associated antigen based on the selective expression of CLEC9A [129], a receptor that 
senses dead cells [130] and has been shown to facilitate cross-presentation by mouse [131] 
and human DC [81]. Superior capacity to cross-present cell-associated antigen by BDCA3+ 
DC was demonstrated by several independent studies [9,21,90,125,126], however, not 
observed in all studies [106]. Also for other types of antigen, among human DC subsets, 
cross-presentation capacity is not restricted to the BDCA3+ DC subset. Cross-presentation 
of protein antigen was shown for peripheral blood and tissue-derived BDCA1+ DC [9,116], 
BDCA2+ pDC [90,116] and BDCA3+ DC [9,56,90,116,125], as well as for in vitro-generated 
CD34+-derived DC [90] and monocyte-derived DC, as discussed above. Although BDCA3+ 
DC are highly capable of cross-presenting cell-associated antigen, cross-presentation of 
cell-associated antigen has also been demonstrated for BDCA1+ DC [90], pDC [106,126] and 
moDC, as discussed above.
Both BDCA3+ and BDCA1+ DC share the specialized machinery that is associated with efficient 
cross-presentation capacity, i.e. high phagosomal pH, production of ROS within endocytic 
compartments and efficient transfer of exogenous antigens into the cytosol [90]. Both 
subsets have a similar efficiency of endogenous MHC class I presentation after transfection, 
a similar efficiency of cross-presentation of heat-inactivated IAV that can egress to the 
cytosol at low pH and a similar efficiency of cross-presentation of antigen that is selectively 
delivered to early endosomes [95]. Nevertheless, BDCA3+ DC were superior compared to 
BDCA1+ DC at cross-presentation of antigen that was artificially targeted to lysosomes by 
using antigen conjugated to DEC-205 targeting antibodies [95]. This suggests that although 
both DC subsets can efficiently cross-present Ag delivered to early endosomes, BDCA3+ DC 
may exhibit a specialized machinery to transfer Ag from late endosomes and lysosomes to 
the cytosol. This DC characteristic might explain the superior capacity to cross-present IgG 
opsonized antigen targeted to FcγR that could not be attributed to superior FcγR expression 
and/or antigen uptake in these cells [82]. 
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pDC contribute to antiviral immune responses by producing large amounts of IFNα/β, 
however, their role as professional antigen presenting cell in the initiation of virus-specific 
T cell responses was initially questioned based on controversial results in mice [132]. Direct 
comparison of intrinsic characteristics that can influence cross-presenting capacity, such 
as phagosomal pH and ROS production, between pDC and BDCA1+ and BDCA3+ mDC was 
hampered due to inconclusive data for pDC [90]. However, pDC express a broad repertoire 
of antigen-uptake receptors on their cell surface such as Fc receptors and CLR BDCA-2, 
DEC-205, DCIR that can facilitate the uptake and cross-presentation of viral antigens [104]
(Table 1). In addition, pDC can efficiently transfer exogenous Ag into the cytosol suggesting 
that they may be capable of cross-presenting antigen via the cytosolic pathway [90]. 
Numerous functional studies showed that human pDC can cross-present recombinant 
protein antigens, long peptide antigens, IAV-derived antigens and cell-associated antigens 
(Hoeffel et al., 2007; Tel et al., 2013a; Fonteneau et al., 2003b; Lui et al., 2009). In addition, 
it was also demonstrated that pDC can efficiently cross-present viral antigen via the vacuolar 
pathway, which may be facilitated by MHC class I storage in recycling endosomes [102]. 
Taken together, we conclude that human pDC can efficiently facilitate cross-presentation of 
a wide range of viral antigens. Direct comparison of cross-presentation efficiency between 
human pDC and mDC was thus far inconclusive, with one study showing a higher efficiency 
of cross-presentation by pDC [102], another study showing superior MHC class I-restricted 
IAV presentation by BDCA1+ mDC [40] and three studies concluding that pDC and BDCA1+ or 
BDCA3+ mDC have similar cross-presentation efficiencies [106,107,133].  
Although blood DC required DC maturation for efficient cross-presentation, skin or lymph 
node DC can cross-present under steady state conditions, which might be due to a more 
mature/activated status of these tissue DC compared to circulating DC [56,90,135]. In 
addition to BDCA1+ and BDCA3+ DC, skin contains Langerin+ Langerhans cells (LC) and 
dermal interstitial DC (intDC), often referred to as CD14+ DC. Comparison of CD14+ DC to 
other skin DC subsets indicated that this subset showed the least cross-presenting capacity 
among skin subsets [10,56], which may be related to the finding that these cells express 
Immunoglobulin-like transcript receptors that antagonize CTL development [136]. Cross-
presentation capacity of LC cells is under debate and may vary upon the source of LC and 
type of antigen used in experiments. Cross-presentation of recombinant protein antigen by 
in vitro-generated LC has been demonstrated in several independent studies [10,90,137], 
however, cross-presentation of replication- incompetent MV and MV-infected cells by skin-
derived LC was absent [25]. Sine LC are potentially interesting vaccine target cells, because 
of their presence at mucosal sites such as skin and higher respiratory tract [25], further 
studies on the cross-presentation capacity of primary LC are required.  
We conclude that essential mechanisms of cross-presentation are present among most 
human DC subsets, with the exception of CD14+ DC. Superiority of cross-presentation among 
DC subsets can be attributed to the repertoire of uptake receptors and adaptations in the 
endocytic compartment and may vary depending on the type of antigen.
 
Technical limitations and novel approaches
Although several technical advancements have potentiated the study of MHC class I antigen 
presentation by human DC, several important questions remain to be addressed. 
One of the current technical challenges is to measure antigen presentation at the level of 
Chapter 2
48
DC. The purest read-out would be to measure MHC class I-antigen complexes at the surface 
of DC (signal 1 only), however, tools are lacking [20]. The best current available method 
to quantify MHC class I antigen presentation is a read-out involving activation or in vitro 
induction of virus-specific T cells. However, it should be taken into account that activation 
of virus-specific T cells results from a combination of TCR ligation by MHC class I – peptide 
complexes (signal 1) and other stimuli provided by DC such as cytokines and co-stimulation 
(signal 2 and 3).
The study of induction of human CD8+ T cells by DC is also hampered by the extreme low 
frequency of naïve virus-specific T cells in peripheral blood. As discussed above, MHC 
class I presentation by human DC has been most frequently studied for IAV, HIV-1 and 
CMV. For these viruses, it has been possible to obtain sufficient numbers of “memory” 
T cells from peripheral blood and use T cell expansion and IFNγ production as read-outs 
for antigen presentation in an autologous setting [13,14,54]. Virus-specific T cell clones 
to other viruses can be obtained by several rounds of antigen-specific expansion in vitro. 
However, performance of such in vitro generated clones in cross-presentation studies is 
complicated due to their limited life span and the allogenic bias present in experiments 
because DC and T cells are not from the same donor. A novel promising approach for the 
study of cross-presentation of viruses by human DC is the use of T cell receptor transfer 
to generate autologous virus-specific T cells [138,139]. Such T cells are evaluated in the 
context of immunotherapy of patients but may also be exploited as tools to monitor antigen 
presentation by DC.
Recommendations and considerations for development of therapeutic vaccine 
strategies 
Chronic viral infections such as HIV, HBV and HCV are a big health burden and affect hundred 
millions of patients worldwide. Viral persistence is associated with a failure of the patient’s 
immune response to eradicate the virus [124]. In addition to chronic persistent infections, 
reactivation of latent infections including HCMV, EBV, and HPVis a major threat for immune 
compromised patients. In addition, a high proportion of these chronic and latent infections 
including HIV, HBV, HCV, EBV, HPV and HTLV is related to the development of malignancies 
later in life [140]. Immunotherapy represents an attractive therapeutic intervention to 
combat such infections and prevent virus-related malignancies by using the body’s own 
defense mechanisms. To accomplish this, immunotherapy is directed to improve virus-
specific immunity and eradicate the virus but also generate protective memory responses 
to prevent re-infections. Moreover, immunotherapy should overcome T cell exhaustion and 
anergy, often observed in patients with chronic infections [140]. 
Insights into the mechanisms underlying effective priming of virus-specific CTL by human 
DC are instrumental for the development of effective virus-specific immunotherapy. We 
identified cross-presentation as a crucial mechanism for the induction of virus-specific 
CTL and embrace the concept to utilize the effective cross-presentation mechanisms 
naturally present in DC for immunotherapy. In line with this concept, antibody-mediated 
antigen targeting to endocytic receptors is an emerging approach employed by numerous 
groups to target antigen to DC for cross-presentation. Endocytic receptors that efficiently 
facilitate cross-presentation by human DC include FcγRIIA, CLEC9A, DEC-205 and DCIR 
[79,81,82,104,141]. An advantage of antigen targeting to specific receptors is the possibility 
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to select receptors that are uniquely expressed by distinct subsets of DC (Table 1), such 
as proposed for XCR1 [142] or CLEC9A [81]. Selective targeting to DC prevents antigen 
consumption by irrelevant cells which may lead to reduced availability of antigen to DC and 
improper T cell activation. 
As discussed previously, DC maturation is crucial for virus-specific CTL induction. Although 
the endocytic receptors are very potent in internalizing antigen, their role in promoting DC 
maturation is less clear. Therefore, the combination of antigen targeting with adjuvants is an 
important field of study. FcγR have been shown to facilitate both efficient antigen uptake and 
DC maturation, at least in mice [143]. However, it was recently shown that FcγR-dependent 
DC maturation in human DC is less pronounced [82]. Other interesting approaches that 
combine antigen targeting to DC and DC maturation in one cargo include TLR-ligand-peptide 
conjugates [144] and nanoparticles that contain both antigen and adjuvant [104].
Since DC comprise a heterogeneous family of subsets that differ in location, frequency, 
receptor expression and functional specializations, it is important to design a therapeutic 
vaccine with the desired DC subset in mind. Based on accumulated evidence from in vitro 
studies on antigen presentation by human DC subsets, we conclude that most human DC 
subsets have the basic capacity to cross-present, as long as the antigen is efficiently targeted 
to an endocytic compartment that favors cross-presentation. Nevertheless, DC subsets do 
have unique functional characteristics, such as type of cytokine production, which can 
have high impact on the type of immune response induced. Moreover, DC subsets express 
different PRR (Table 1) and only adjuvants for a selected number of TLRs are currently 
available at clinical grade. 
In addition to antigen targeting to DC in vivo, recruiting of DC precursors may represent 
an attractive immunotherapeutic approach, as was recently proposed for monocytes, 
which can contain a natural reservoir of HBsAg that can be presented in MHC class I upon 
differentiation of these monocytes to moDC [145]. 
Concluding remarks and future perspectives
Based on two decades of research into MHC class I-restricted presentation of viral antigen 
by human DC, we conclude that cross-presentation of viral antigens is a highly efficient 
mechanism for defense against viruses. Furthermore, cross-presentation of viral antigens 
seems not only pivotal for defense against viruses that do not infect DC, but also for those 
that infect DC, as demonstrated by in vitro studies using replication-incompetent IAV, HIV-1 
and MV. However, although these studies were very convincing, these viruses only represent 
a small number of viruses that can productively infect human DC and, thus the contribution 
of direct presentation by human DC infected with other viruses in vivo cannot be completely 
ruled out. Nevertheless, as discussed in this review, cross-presentation has many conceptual 
advances compared to direct presentation by infected DC. 
So far, knowledge on the presentation of viral antigens by human DC is mainly derived 
from in vitro studies. Whether these studies faithfully represent the in vivo situation is of 
course difficult to predict. Several caveats from these in vitro studies include the use of 
in vitro generated DC, which may behave differently than their in vivo counterparts, the 
use of laboratory adapted virus strains and pseudo-typed viruses, which may have tropisms 
that may not represent the in vivo situation, and the use of recombinant viral proteins 
and TLR ligands that are not fully representative for antigens or danger signals that can 
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be encountered in vivo. Nevertheless, taking these limitations into account, together these 
studies have given us an important understanding of the mechanisms underlying MHC class 
I presentation of viral antigens by human DC. This knowledge is an important basis for the 
rational design of therapeutic vaccines for chronic viral infections. 
Interesting venues for further research include identification of DC receptors involved 
in viral infection and initiation of immune response, elucidation of the molecular signals 
underlying sorting of viral antigen to endocytic compartments that favor cross-presentation 
and the role of virus-derived danger signals and virus-induced maturation stimuli in cross-
presentation and CTL priming. 
A more detailed knowledge of these key factors in virus-host interaction will further 
empower the design of novel therapeutics for infectious diseases.      
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Abstract
Dendritic cells (DC) are the most potent antigen presenting cells (APC). They comprise a 
family of different subsets and play an essential role in the induction and regulation of 
immune responses. Recently, gene expression profiling identified BDCA3+CLEC9A+ DC as 
a separate human DC subset. This subset was identified in blood, where they represent 
the smallest population of human DC, as well as in lymphoid and peripheral tissues. 
This review summarizes the phenotypic, functional and developmental characteristics 
of BDCA3+CLEC9A+ DC in relation to their mouse equivalents CD8α+ DC and CD103+ DC 
and other human DC subsets. Apart from being potent antigen presenting cells, their 
specialized functional capacities compared to other human DC subsets, indicate that these 
BDCA3+CLEC9A+ DC cells are of major importance in the induction of anti-viral and anti-
tumor immunity. Further characterization of their functional properties, developmental 
pathways and underlying molecular mechanisms may identify target molecules to fully 
exploit the immune modulatory function of BDCA3+CLEC9A+ DC and potential use of these 
cells in immunotherapy. 
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BDCA3+CLEC9A+ DC as a unique human DC subset
DC represent a heterogeneous population of professional APC that are found in almost 
all tissues. Due to their unique ability to stimulate naive T cells, DC serve as a major link 
between innate and adaptive immunity [1, 2]. Additionally, they interact with other cells 
of the innate and adaptive immune system. DC comprise a family of different subsets that 
all share the capacity to activate naive T cell responses, but vary in ontogeny, localization, 
phenotype and specialized immune functions [3, 4]. 
Most of the present knowledge on DC has been obtained from studies of DC in mice. In 
mice, DC are divided into plasmacytoid DC (pDC), conventional lymphoid-resident DC and 
migratory DC. The lymphoid-resident DC can be further divided into CD8α+ and CD8α- DC, 
whereas migratory DC include CD103+ DC, CD11b+ DC and Langerhans cells [5-7]. CD8α+ 
lymphoid-resident DC are more efficient than CD8α- DC at cross-presentation of exogenous 
antigen (Ag) and priming of CD8+ T cells, due to different intrinsic molecular properties [7]. 
CD103+ migratory DC were identified as the equivalent of CD8α+ DC in peripheral tissues 
since they share a common gene signature, developmental pathway, functional capacities, 
and several phenotypic characteristics [7-11]. 
Direct correlation of human and mouse DC subsets has been hampered by a lack of common 
surface markers. Human DC, which are characterized by expression of HLA-DR and lack of 
lineage markers, can be divided into two main categories: pDC and myeloid DC (mDC). mDC, 
which in contrast to pDC express CD11c+, can be further divided into BDCA1+ DC and BDCA3+ 
DC [12]. Comparative genomic analysis indicated that the gene expression profile of human 
blood BDCA3+ DC is comparable to that of mouse CD8α+ and CD103+ DC, suggesting that 
BDCA3+ DC might also be functionally related to this lineage [13]. 
Phenotypic characteristics
The finding of the equivalence between CD8α+ and BDCA3+ DC was confirmed by the 
identification of markers that were expressed on both DC subsets, including CLEC9A (c-type 
lectin domain family 9A), also known as DNGR-1, XCR1 (XC chemokine receptor 1), Necl2 
(Nectin-like molecule 2), also known as CADM1 (cell adhesion molecule 1), and TLR3 (Toll-
like receptor 3) [14-21]. These markers will be discussed in more detail below.
BDCA3/CD141/Thrombomodulin
BDCA3 is a cell surface-expressed transmembrane glycoprotein, also known as 
Thrombomodulin (TM) or CD141. Together with BDCA1, BDCA2 and BDCA4, BDCA3 is 
generally used to classify human DC. However, BDCA3 expression is not restricted to the 
typical BDCA3+ DC subset as discussed here, since intermediate expression of BDCA3 has also 
been found on monocytes and other DC, such as blood pDC, pulmonary Langerhans-type and 
interstitial DC, and skin interstitial DC [11, 22-26]. In addition, in vitro maturation of blood 
DC is associated with upregulation of BDCA3 on pDC and BDCA1+ mDC [12]. In many studies 
which analyze the function of BDCA3+ DC, these DC were isolated by magnetic separation 
using MACS beads directed against BDCA3. The typical BDCA3+ DC subset expresses higher 
levels of BDCA3 than other DC, so optimal use of antibodies will result in enrichment of 
these BDCA3hi DC. However, since BDCA3 expression is not selectively expressed by the 
BDCA3hi DC subset, this type of isolation should be performed with caution, since it may 
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also result in isolation of a heterogeneous BDCA3+ cell population that includes other DC 
subtypes and/or monocytes, as mentioned above. Therefore, it is important to use BDCA3 in 
combination with discriminating markers that are unique to the BDCA3hi DC subset to assure 
selection of BDCA3+ DC that belong to the CD8α+-like lineage. 
The function of BDCA3 expression on DC is thus far unknown. Besides its expression on 
DC, BDCA3 is predominantly expressed on vascular endothelial cells, where it is generally 
denominated as TM and well known for its anticoagulant activity. By binding thrombin, 
which is a pro-coagulant playing an important role in the coagulation cascade, TM/BDCA3 
reduces thrombin’s pro-coagulant activity. However, the expression of TM/BDCA3 on 
other cells than endothelial cells suggests an additional function of TM/BDCA3. Indeed, 
more recently TM/BDCA3 was described to have also a potent anti-inflammatory function 
through several direct and indirect mechanisms, which are reviewed by Li et al. [8].  In 
brief, these mechanisms include blocking of the pro-inflammatory factors thrombin, 
lipopolysaccharide (LPS) and necrotic or inflammatory cell-derived high mobility group box 
1 (HMGB1) protein, activation of the anti-inflammatory proteins activated protein C (aPC) 
and activated thrombin-activatable fibrinolysis inhibitor (TAFI) and activation of inhibitors of 
the complement system [8].
Although high expression of this marker on BDCA3+ DC might suggests an anti-inflammatory 
function of this DC subset, the exact function of BDCA3 expression on these cells remains 
to be elucidated.
CLEC9A
Although low levels of CLEC9A are expressed on mouse pDC and a subset of human 
monocytes, high CLEC9A expression is restricted to mouse CD8α+ and CD103+ DC and 
human BDCA3hi DC, which share a common transcriptomic profile and set of phenotypic 
characteristics [15, 16, 27]. This indicates that CLEC9A, in combination with BDCA3, can be 
used as a distinctive marker to identify DC of this lineage and therefore, the human BDCA3hi 
DC subset will be further referred to as BDCA3+CLEC9A+ DC in the present review. CLEC9A 
is a damage-associated molecular pattern (DAMP) receptor that senses necrotic cells [27]. 
Ligation of CLEC9A does not activate DC, but regulates cross-presentation of necrotic cell-
associated Ag via recruitment and activation of the tyrosine kinase Syk [27, 28]. However, 
until recently the ligand for CLEC9A was not known. Two different research groups reported 
filamentous actin (F-actin), which is exposed on cells upon cellular damage or necrosis, as a 
CLEC9A ligand [29, 30]. 
XCR1
XCR1 is a chemokine receptor which binds to its unique ligand chemokine (C motif) ligand 1 
(XCL1), selectively expressed by CD8+ T cells, Th1 cells and NK cells [17]. In both human and 
mice, XCR1 was shown to play an important role in the interaction between XCL1-producing 
CD8+ T cells and XCR1+ DC and subsequent activation of CD8+ T cells [31-33]. Upon interaction 
with XCR1+ DC, CD8+ T cells secreted high levels of XCL1, which enhanced the survival and 
effector functions of CD8+ T cells [33]. 
XCR1 is selectively expressed on human BDCA3+ DC, mouse CD8α+ DC, mouse CD103+ DC, 
and sheep CD26+ DC. This selective expression was confirmed by the observation that 
BDCA3+CLEC9A+ DC were the only human DC subset that migrates to XCL1 [18]. Since low 
CLEC9A expression can also be found on other cells, whereas XCR1 expression is highly 
restricted to BDCA3+CLEC9A+ DC in human, XCR1 seems to be the ideal marker to identify 
BDCA3+CLEC9A+ DC function and development 
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DC belonging to the BDCA3+ CD8α+-like DC subset [17]. However, the specificity of currently 
available antibodies against human XCR1 is debatable, and therefore, thorough research on 
this marker has been hampered.
Necl2
Another marker which is characteristic for the CD8α+-like DC lineage is Necl2. Necl2 is a 
ubiquitously expressed adhesion molecule that is involved in wound healing and can also 
act as a tumor suppressor [34, 35]. Although Necl2 can be expressed by various celltypes, 
among blood leukocytes its expression is restricted to BDCA3+CLEC9A+ DC. Necl2 interacts 
with Class-I-restricted T-cell-associated molecule (CRTAM). Since CRTAM is primarily 
expressed on activated cytotoxic T lymphocytes (CTL), the Necl2-CRTAM pair seems to be 
involved in the cross-talk between DC and T cells [19]. However, the specific function of this 
adhesion molecule on BDCA3+CLEC9A+ DC thus far remains elusive.
TLR3
Toll-like receptor 3 is a pattern recognition receptor (PRR) that recognizes viral double-
stranded RNA (dsRNA) and induces production of anti-viral interferons (IFN) through 
activation of interferon regulatory factor 3 (IRF3) and pro-inflammatory cytokines through 
NFκB. Hence, TLR3 is thought to play an important role in anti-viral defense [36]. Although 
TLR3 is also expressed by many other non-hematopoietic as well as hematopoietic cells, 
expression is significantly higher in BDCA3+CLEC9A+ DC compared to BDCA1+ DC and 
monocyte-derived DC (moDC) [21]. Because of this high expression, TLR3 ligation by 
polyinosine-polycytidylic acid (polyI:C), which is a synthetic analog of dsRNA, is commonly 
used for in vitro stimulation of BDCA3+CLEC9A+ DC. 
Other markers expressed by BDCA3+CLEC9A+ DC are depicted in table 1. Elucidation of all 
phenotypic markers expressed by BDCA3+CLEC9A+ DC will be of great importance for the 
identification of this subset in different organs. In addition, knowledge of these phenotypic 
markers will help to obtain insight into the functional properties of this DC subset. Currently, 
the BDCA3+CLEC9A+ DC subset is widely denominated as the ‘BDCA3+ DC subset’. However, 
it will be essential to define a better designation for these cells which will distinguish this 
specific BDCA3hi subset from other DC expressing BDCA3. We conclude that CLEC9A is 
currently the optimal marker to use in combination with BDCA3 for identification of the 
BDCA3hi DC subset belonging to the CD8α+ DC lineage, due to its specific high-level expression 
on this subset and the feasibility of detection both at RNA and protein level.
 
 
Localization
BDCA3+CLEC9A+ DC were originally identified in blood. Compared to pDC and BDCA1+ 
DC, BDCA3+CLEC9A+ DC represent a very rare subset of circulating DC, comprising only 
about 0.04% of peripheral blood mononuclear cells (PBMC) [12]. In the following years, 
BDCA3+CLEC9A+ DC were discovered in various lymphoid and peripheral tissues, including 
tonsil, spleen, skin, lung, liver, and kidney [22, 37-43]. However, at that time BDCA3+CLEC9A+ 
DC were not yet identified as the homologue of lymphoid-resident CD8α+CLEC9A+ mouse 
DC. Therefore, it was unclear whether the BDCA3+ cells described in lymphoid tissues 
belong to this CLEC9A+ lineage. Jongbloed et al. and Poulin et al. were the first to show 
BDCA3+CLEC9A+ DC in blood, lymph nodes, tonsil, bone marrow and spleen and proved that 
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these cells belonged to the CLEC9A+ lineage by phenotypic and functional analysis [21, 44].
Next, mouse migratory CD103+ DC were identified as the major cross-presenting subset 
in peripheral tissues and found to be related to CD8α+ DC [8, 45-47]. This suggested the 
existence of a human homologue of cross-presenting CD103+ mouse DC in peripheral tissues 
[5]. Indeed, CLEC9A+BDCA3+ DC were discovered in peripheral tissues, including skin, liver 
and lung [24, 25, 48]. Gene expression analysis of different blood and skin DC subsets 
indicated that blood BDCA3+CLEC9A+ DC were most closely related to skin BDCA3+CLEC9A+. 
In addition, the transcriptional profile of skin BDCA3+CLEC9A+ DC appeared to be equivalent 
to that of mouse peripheral tissue CD103+ DC [24].
Table 1. Phenotypic markers of BDCA3+CLEC9A+ DC.
BDCA3+CLEC9A+ DC
Antigen Blood Lymphoid-tissue Peripheral-tissue References
CD4 + + [37, 108]
CD5 +/- [12]
CD11b (CR3) - + + (low) [24, 37]
CD11c (CR4) + + [37, 108]
CD16 (FcγRIII) - [4, 109]
CD18 + [12]
CD23 (FcεRI) - [109]
CD32a (FcγRIIa) + [4, 109]
CD32b (FcγRIIb) + [4, 109]
CD33 + [12]
CD36 +/- [12]
CD38 + [12]
CD40 + + [37, 108]
CD43 + [12]
CD44 + + [12, 37]
CD45RA + [37]
CD45RO + + [12, 37]
CD52 + [108]
CD54 + [12]
CD56 +/- [108]
CD58 + [12]
CD62L + [12]
CD64 (FcγRI) - [4, 109] 
CD80 - - + [24, 37]
CD83 - + [24, 109] 
CD85k (ILT3) + [108]
CD86 + + (low) + [24, 37, 108]
CD89 (FcαR) - [109]
CD98 + [12]
CD116 + [12]
CD162 + [19]
CD184 (CXCR4) - + [37]
CD197 (CCR7) - + [24]
CD205 (DEC205) + [108]
CD206 (MR) - -  [25, 26, 106] 
CD207 (Langerin) - [24]
CD209 (DC-SIGN) - - [26, 106]
CD274 (PDL1) - + [24]
CLA + [108]
CLEC9A + + + [15, 21, 24] 
HLA-A,B,C + + + [12, 24-26, 108] 
HLA-DR + + + [24, 37, 108]
HLA-DQ + [12]
Necl2 (CADM1) + + [19, 24]
TLR 1, 2, 3, 6, 8, 10 3 [21]
XCR1 + + + [18, 24]
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Quantitative analysis revealed that BDCA3+CLEC9A+ DC are more frequently present in 
peripheral tissues, including lung, skin and liver, than in blood [24, 48, 49]. Remarkably, 
liver and lungs contain comparable or even higher frequencies of BDCA3+CLEC9A+ DC than 
of BDCA1+ DC and pDC, suggesting a preferential role for BDCA3+CLEC9A+ DC in regulation 
of immunity in these organs [22, 40, 50]. The relative high frequency of BDCA3+CLEC9A+ DC 
seems to be organ-specific and has not been observed in lymphoid tissues [21]. 
Although in mice the phenotype of cross-presenting DC subsets clearly differs between 
lymphoid tissue DC and peripheral tissue DC, in human the distinction between peripheral 
blood DC, lymphoid tissue DC and peripheral tissue DC is less evident due to a lack of tissue-
discriminating markers. 
Compared to blood DC, peripheral tissue BDCA3+CLEC9A+ DC in skin express higher levels of 
C-C chemokine receptor 7 (CCR7), which regulates migration of DC from the periphery to 
lymph nodes, and lower levels of the skin-homing molecule cutaneous lymphocyte antigen 
(CLA) [24]. In addition, BDCA3+CLEC9A+ DC derived from both peripheral and lymphoid 
tissues, including lung, liver, skin, spleen, bone marrow and tonsil, express higher levels 
of activation markers such as CD40, CD80, CD83, CD86 and PD-L1 than those derived from 
blood, indicating that tissue DC have a more activated phenotype than blood DC [24, 48, 
49]. This is in line with the observation that blood BDCA3+CLEC9A+ DC require stimulation 
with TLR ligands, such as polyI:C, for the cross-presentation of Ag, whereas tissue-derived 
BDCA3+CLEC9A+ DC can cross-present Ag even in the absence of stimulation [24, 26]. A more 
in-depth analysis of blood and spleen BDCA3+CLEC9A+ DC showed comparable patterns of 
TLR and transcription factor expression, except for TLR3 expression, which was lower in 
spleen DC.  In line, the higher intrinsic cross-presenting capacity of blood BDCA3+CLEC9A+ 
DC compared to spleen DC was boosted by polyI:C, whereas spleen DC did not respond to 
polyI:C. The cytokine production upon stimulation with a cocktail of CD40L, IFNγ, IL-4 and 
GM-CSF was comparable between these blood and spleen DC [51].
Thus, BDCA3+CLEC9A+ DC are present in peripheral blood as well as in lymphoid and 
peripheral organs, where they, except for their activation status and expression of 
chemokine receptors, do not show major differences in phenotype or function. The 
increased frequencies of BDCA3+CLEC9A+ DC in peripheral tissues compared to blood 
indicate a preferential localization of BDCA3+CLEC9A+ DC to these tissues.
Developmental pathway 
Investigation of the developmental pathway of BDCA3+CLEC9A+ DC has been hampered 
by their low abundance in blood and tissues and hence difficult isolation. Therefore, 
the developmental pathway of BDCA3+CLEC9A+ DC is poorly defined. Nevertheless, 
transcriptional profiling and the possibility to generate BDCA3+CLEC9A+ DCs in vitro  have 
recently boosted research into the developmental pathways of this subset [44, 52-54]. 
In mice, all different types of DC subsets have a common origin, the common DC precursor 
(CDP). From that point differential transcription factor expression results in the differentiation 
of distinct DC subsets [55]. However, the equivalent of CDP has not yet been described in 
humans. Since BDCA3+CLEC9A+ and BDCA1+ DC cluster together in transcription profiling 
and hierarchical clustering analysis, these DC subsets were suggested to represent different 
maturational stages of the same cell type [12, 37]. However, comparative genome-wide 
expression profiling of mouse and human DC subsets revealed that BDCA3+CLEC9A+ DC have 
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a unique expression profile compared to the other DC subsets and, in contrast to BDCA1+ 
DC, resemble mouse CD8α+ DC [13, 52].
The differentiation of mouse CD8α+ and CD103+ DC is regulated by a conserved set 
of transcription factors, including Batf3, Irf8, Id2 and Nfil3 (nuclear factor interleukin 
3-regulated, also known as E4BP4) [56, 57].
 In line with this, development of human BDCA3+CLEC9A+ DC from cord blood-derived 
hematopoietic progenitor cells (HPC) in vitro is BATF3-dependent, as indicated by a significant 
decrease in BDCA3+CLEC9A+ DC frequencies upon BATF3 silencing [53]. However, this BATF3-
dependence could not be proven in vivo since silencing of BATF3 in humanized mice did 
not result in reduction of BDCA3+CLEC9A+ DC. Since bypassing of BATF3-dependence has 
previously been observed for CD8α+ DC development in mice, it might be that the same 
occurs for BDCA3+CLEC9A+ DC in humanized mice. In patients with IRF8 deficiency, a loss of 
peripheral blood BDCA3+CLEC9A+ DC was observed [58]. Since this loss was also observed 
for monocytes, pDC and BDCA1+ DC, this observation indicates that IRF8 might be essential 
for the development of a certain CDP that also gives rise to BDCA3+CLEC9A+ DC. However, 
further research is required to define the exact role of BATF3, IRF8 and other transcription 
factors in the development of BDCA3+CLEC9A+ DC.
An essential growth factor for the development of both murine and human DC in vitro 
and in vivo is Flt3L [59]. Since frequencies of peripheral blood BDCA3+CLEC9A+ DC, but not 
other DC subsets, were reported to be increased in malaria patients who contain elevated 
levels of Flt3L in their plasma, it seems that Flt3L has a direct effect on homeostasis of 
BDCA3+CLEC9A+ DC or can enhance proliferation of BDCA3+CLEC9A+ DC precursors [60]. In 
addition, BDCA3+CLEC9A+ DC frequencies were increased in blood of Flt3L-treated human 
subjects and in blood and spleen of Flt3L-treated humanized mice [19, 60, 61]. However, 
this effect of Flt3L was not specific to BDCA3+CLEC9A+ DC, since also BDCA1+ DC and pDC 
frequencies were increased in humanized mice, indicating that Flt3L can enhance the 
development of most DC subsets.  
In addition to these humanized mouse models, also in vitro systems have been described 
that generate DC of the CLEC9A+ lineage from HPC [44, 54]. In the system described by Poulin 
et al. human lineage-negative cord blood cells, including HPC, were cultured in the presence 
of stem cell factor (SCF), Flt3L, IL-3 and IL-6 and subsequently differentiated with Flt3L, GM-
CSF and IL-4, which resulted in the development of a small population of BDCA3+CLEC9A+ 
DC [44]. The system described by Proietto et al. on the other hand, generated CLEC9A+ DC, 
simultaneously with BDCA1+ DC and pDC, from CD34+ HSC of G-CSF-mobilized blood in the 
presence of Flt3L and thrombopoietin (TPO) [54]. However, these CLEC9A+ DC did not co-
express BDCA3. Of note, both culture systems generated relatively low numbers of DC. A 
third system, described by Thordardottir and colleagues, involved TPO, SCF, Flt3L, IL-6, and 
StemRegenin 1 (SR1) and yielded much higher numbers of BDCA3+CLEC9A+ DC. This system 
also simultaneously generated BDCA1+ DC and pDC [62]. Although these reported culture 
systems all involve Flt3L, the requirement of Flt3L in BDCA3+CLEC9A+ DC development and 
the underlying molecular mechanisms remain to be elucidated.  
Based on comparative gene expression analysis and previously published functional studies, 
Crozat et al. proposed that BDCA3+CLEC9A+ DC development is promoted by Flt3L, which 
activates signal transducer and activator of transcription 3 (STAT3) signaling and subsequent 
induction of IRF8 [52]. In the same model, the authors predicted that GM-CSF will inhibit 
BDCA3+CLEC9A+ DC development by activating STAT5, which on its turn will inhibit induction 
of IRF8 by STAT3 signaling. However, from our own studies we know that the level of STAT5 
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activation and its effect on DC development depends on the stage of DC development and 
could be either positive or negative [63]. Since GM-CSF is a cytokine involved in steady-state 
DC homeostasis and essential for development of peripheral-tissue DC, low levels of GM-
CSF may therefore even contribute to development of BDCA3+ DC [64-66]. This was indeed 
observed in the system described by Poulin et al., which contains both Flt3L and GM-CSF 
[44]. 
The generation of BDCA3+CLEC9A+ DC in vitro will be instrumental to further study the 
developmental pathways and to define the precursor cells of this specific DC subset. With 
regard to BDCA3+CLEC9A+ DC in vivo, it is likely that both peripheral tissue and lymphoid tissue 
BDCA3+CLEC9A+ DC derive from blood BDCA3+CLEC9A+ DC. This hypothesis is supported by 
several studies including (a) studies of Segura et al. and Nizzoli et al., which reported that 
blood BDCA3+CLEC9A+ DC still proliferate, as shown by expression of the proliferation marker 
Ki67, whereas the proliferation of lymphoid tissue BDCA3+CLEC9A+ DC was found to be very 
low [26, 49] and (b) the study of Haniffa et al. which demonstrated that in contrast to blood 
BDCA3+CLEC9A+ DC skin BDCA3+CLEC9A+ DC partially co-express BDCA1 and CD1a, and that 
blood BDCA3+CLEC9A+ DC upregulate CD1a and BDCA1 when added to skin preparations 
[24]. Together this indicates that blood BDCA3+CLEC9A+ DC are not fully differentiated and 
may represent the precursors of fully differentiated DC in tissue.
Thus, although roles for BATF3, IRF8 and Flt3L in development of BDCA3+CLEC9A+ DC 
have been indicated, their exact contribution in this process remains to be determined. 
Additionally, the nature of precursors of BDCA3+CLEC9A+ DC in human needs to be further 
characterized. Further analysis of these factors will help to elucidate the BDCA3+CLEC9A+ DC 
differentiation pathway during steady state and inflammation.
Specialized immune functions 
Although all DC share the unique capacity to initiate naive T cell responses, they possess 
different specialized immune functions [3, 4]. Here, we summarize the specialized functions 
that have been reported for BDCA3+CLEC9A+ DC.
IFNλ production
Type III IFN (IFNλ) are antiviral cytokines including three subtypes, IFNλ1 (IL-29), IFNλ2 
(IL-28A) and IFNλ3 (IL-28B). IFNλ signals through the heterodimeric IFNλ receptor which 
consists of an IL-28 receptor α (IL-28Rα) chain and IL-10Rβ chain and activates JAK-STAT and 
MAPK pathways that are involved in the regulation of immunity [67]. Expression of the IFNλ 
receptor is mainly found on hepatocytes, epithelial cells, B cells, pDC and macrophages, 
however, the expression of the IFNλ receptor on immune cells is still under debate since 
contradictory results were obtained between receptor expression on RNA level and protein 
level due to a lack of appropriate antibodies [68-71]. 
IFNλ has direct antiviral effects by inhibiting replication of multiple viruses, including influenza 
virus, hepatitis C virus (HCV), hepatitis B virus (HBV), human immunodeficiency virus (HIV), 
rotavirus, encephalomyocarditis virus, vesicular stomatitis virus (VSV), cytomegalovirus 
(CMV), West Nile virus (WNV) and herplex simplex virus (HSV) [72-80], but may also support 
the skewing towards Th1 responses by downregulating Th-2 cytokine production, that will 
favor clearance of virus-infected cells [81-83]. 
Like mouse CD8α+ DC, blood BDCA3+CLEC9A+ DC were found to be major producers of all 
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three IFNλ subtypes upon polyI:C stimulation [48, 84, 85]. The same results were reported 
for tonsil and liver-derived BDCA3+CLEC9A+ DC, indicating that production of high levels of 
IFNλ is a specific characteristic of BDCA3+CLEC9A+ DC in blood as well as in lymphoid and 
peripheral tissues [48, 49]. 
Although production of IFNλ is also observed for pDC upon ligation of TLR9 and for BDCA1+ 
DC and macrophages upon ligation of TLR3, IFNλ levels produced by BDCA3+CLEC9A+ DC are 
significantly higher [49, 71, 86]. However, it remains to be elucidated whether this superior 
IFNλ-producing capacity is fully restricted to BDCA3hi DC that belong to the CLEC9A+ lineage, 
or if it is also shared by other BDCA3-expressing immune cells.
As known for TLR3-induced type I IFN production by DC, polyI:C-induced IFNλ3 production 
by BDCA3+CLEC9A+ DC was shown to occur via a TLR3-TRIF-dependent pathway, as indicated 
by decreased IFNλ3 production upon inhibition of endosomal TLRs or TRIF. Although the 
mechanism of type I IFN production is well characterized, the regulation of IFNλ gene 
expression is incompletely understood. The IFNλ1, -2 and -3 promoters contain binding 
sites for IRFs and NFκB, indicating that these factors are involved in the induction of IFNλ 
expression [87-89]. Indeed, activation of NFκB and IRF3/7 was shown to induce gene 
transcription of IFNλ1, -2 and -3 in human embryonic kidney (HEK)293 cells [88]. Since 
stimulation of TLR3, MDA5, retinoic acid-inducible gene I (RIG-I), TLR7, TLR8 and TLR9 can 
all lead to activation of IRF3, IRF7 and even more receptors are known to trigger NFκB, 
these findings suggest that also other stimuli than polyI:C may induce IFNλ production by 
BDCA3+CLEC9A+ DC. However, BDCA3+CLEC9A+ DC lack expression of TLR7 and TLR9 and, 
although it is known that murine CD8α+ DC lack RIG-I expression, it is unknown whether 
BDCA3+CLEC9A+ DC express RIG-I or MDA5 [21]. BDCA3+CLEC9A+ DC do express TLR8, but 
to the best of our knowledge, no studies have been published in which IFNλ production 
by BDCA3+CLEC9A+ DC upon TLR8 ligation was analyzed. Stimulation with the TLR8 ligand 
R848 in combination with polyI:C did not enhance IFNλ production by BDCA3+CLEC9A+ DC 
compared to stimulation with polyI:C alone [49]. Thus, BDCA3+CLEC9A+ DC produce IFNλ 
upon stimulation of TLR3, but involvement of other pattern recognition receptors in the 
induction of IFNλ expression remains to be investigated. 
Since BDCA3+ DC produce high levels of anti-viral IFNλ in response to TLR3 ligation by viral 
dsRNA, these cells are likely to play an important role in the host defense against DNA and 
RNA viruses that produce dsRNA intermediates [48, 84]. The role of IFNλ in the host defense 
against HCV infection has drawn a lot of attention, since single-nucleotide polymorphisms 
(SNPs) near the IL-28B (IFNλ3) gene are associated with spontaneous and therapy-induced 
clearance of HCV infection [90-93]. Both blood and hepatic BDCA3+CLEC9A+ DC, of which 
frequencies were increased in HCV-infected livers, were shown to produce IFNλ3 in response 
to HCV [48, 85, 94]. Interestingly, blood BDCA3+CLEC9A+ DC from subjects with minor IL-28B 
genotype produced lower levels of IFNλ3 in response to HCV than those from subjects with 
major genotype [48]. Although the exact mechanism by which IL-28B SNPs affect the anti-
viral responses in HCV patients needs to be investigated, these findings indicate that IFNλ 
production by BDCA3+CLEC9A+ DC may play an important role.   
Production of other cytokines
One of the first studies on the function of BDCA3+CLEC9A+ indicated that blood 
BDCA3+CLEC9A+ DC are, like their murine counterpart, superior at the production of IL-12p70 
in response to stimulation with a cytokine cocktail of polyI:C, IFNγ, TNF, IFNα and IL-1β 
compared to BDCA1+ DC [21]. In line with this, Poulin et al. reported production of IL-12p70 
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by spleen BDCA3+CLEC9A+ DC upon stimulation with a cocktail containing TLR1-9 agonists, 
IL-4, IFNγ, and T cells [44]. In contrast, a recent paper identified tonsil and blood BDCA1+ DC, 
but not BDCA3+CLEC9A+ DC, as the most potent IL-12-producing DC upon stimulation with 
polyI:C [49]. Only in response to polyI:C together with R848 and IFNγ, BDCA3+CLEC9A+ DC 
produced low levels of IL-12p70, which corresponded to the levels detected by Jongbloed 
et al. and Poulin et al. [21, 44]. Superior IL-12p70 production by BDCA1+ DC compared to 
BDCA3+CLEC9A+ DC was also observed for spleen-derived DC upon stimulation with CD40L, 
IFNγ, IL-4 and granulocyte macrophage-colony stimulating factor (GM-CSF) [51]. Direct 
comparison of different skin DC subsets, including BDCA3+CLEC9A+ DC, indicated that 
moDC, but not any of the skin DC subsets, produced IL-12p70 in response to polyI:C alone 
or combined with a cocktail of TNFα, IL-1β, IFNα, IFNγ and LPS [24]. Together, these results 
indicate that BDCA3+CLEC9A+ DC are able to produce IL-12p70 upon combinational TLR 
stimulation, but in contrast to BDCA1+ DC, don’t exhibit strong IL-12-producing capacity.
In addition, blood-derived BDCA3+CLEC9A+ DC were shown to produce IFNα, IFNβ, IL-6, IL-8, 
TNFα and CXCL10 upon polyI:C stimulation [21, 95]. Skin-derived BDCA3+CLEC9A+ DC also 
produced TNFα, IL-8 and CXCL10 upon polyI:C stimulation, although CXCL10 levels were 
much lower than those produced by blood-derived BDCA3+CLEC9A+ DC, but no IL-6 or IL-1β 
were detected [24]. The production of CXCL10, together with XCR1 expression, is suggestive 
for interaction between BDCA3+CLEC9A+ DC and Th1 cells or NK cells, since Th1 cells and 
NK cells express the CXCL10 receptor CXCR3 and are major producers of XCL1 [33, 96]. 
However, to the best of our knowledge, no studies on the interaction between NK cells and 
BDCA3+CLEC9A+ DC have been published.
Whereas Chu et al. demonstrated that skin-derived BDCA3+ DC are potent producers of IL-
10, Haniffa et al. could not detect any IL-10 production by skin BDCA3+CLEC9A+ DC [24, 25]. 
Since the BDCA3+ cell population analyzed by Chu et al. co-expressed CD14, this population 
probably includes not only DC of the BDCA3+CLEC9A+ lineage but also IL-10-producing CD14+ 
DC.
Induction of Th1/Th2 responses
The production of IFNβ, CXCL10 and IL-12p70 by blood-derived BDCA3+CLEC9A+ DC upon 
stimulation suggests that these cells are potent inducers of Th1 responses, which together 
with type I and III IFN production, play a key role in anti-viral immune responses. Co-
culture of blood BDCA3+CLEC9A+ DC with allogeneic naïve CD4+ T cells indeed induced high 
production of the Th1 cytokines IFNγ and IL-2, whereas secretion of the Th2 cytokines IL-4, 
IL-5 or IL-10 was low or absent [21, 26]. Induction of Th17 or regulatory T cells could not be 
observed. Lymph node-derived BDCA3+CLEC9A+ DC on the other hand, induced production 
of both Th1 and Th2 cytokines [26]. Direct comparison of BDCA3+CLEC9A+ DC with BDCA1+ 
DC and pDC for their capacity to stimulate allogeneic naïve CD4+ T cell proliferation showed 
that, although no major differences were observed, BDCA3+CLEC9A+ DC induced the highest 
T cell proliferation levels [97].
The preferential polarization towards Th1 responses, suggests a contribution of 
BDCA3+CLEC9A+ DC to typical Th-1 mediated immunity seen in auto-immune diseases or 
transplant rejection. In contrast, Yerkovich et al. showed that BDCA3-expressing cells induced 
a Th2-skewed response upon co-culture with PBMC and that atopic asthmatic patients had 
higher frequencies of BDCA3+CLEC9A+ DC in peripheral blood [98]. However, DC-PBMC co-
culture was performed with BDCA3-expressing moDC instead of BDCA3+CLEC9A+ DC, which 
may have a different function. Several other studies showed that BDCA3 expression is 
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associated with a tolerogenic function of DC [25, 99, 100]. However, in these studies it is 
not clear whether BDCA3+CLEC9A+ DC or other BDCA3-expressing DC were used for analysis, 
which also illustrates the importance of using the combination of BDCA3 and CLEC9A to 
identify these cells. Thus, the plasticity of these BDCA3+CLEC9A+ DC with regard to Th2-
skewing  and regulatory capacities in addition to their Th1-promoting ability remains to 
be established. Like for other DC subsets, plasticity of DC function enables BDCA3+CLEC9A+ 
DC to respond to environmental factors and adjust their function in order to induce the 
appropriate immune response. Therefore, the role of BDCA3+CLEC9A+ DC may vary among 
different types of disease and should be studied for each setting.  
Cross-presentation
mDC are known for their ability to efficiently capture and present Ag to T cells. Activation 
of CD8+ T cells, which plays an essential role in the immune control of tumors and viral 
infections, occurs via presentation of Ag in major histocompatibility complex class I (MHC 
class I). Although the majority of Ag presented by DC in MHC class I derive from endogenously 
synthesized proteins, DC have also the capacity to cross-present exogenous-derived Ag in 
MHC class I molecules [101].
BDCA3+CLEC9A+ DC were initially described to be more efficient at cross-presentation of 
both soluble and cell-associated Ag in MHC class I than other DC subsets, such as BDCA1+ 
DC, moDC or pDC [4, 17, 18, 21, 44]. These findings suggested that BDCA3+CLEC9A+ DC 
exhibit a specialized cross-presenting capacity, as has previously been shown for mouse 
CD8α+ DC [7, 10, 102]. In contrast, recent papers showed that other DC are able to cross-
present soluble Ag as efficient as BDCA3+CLEC9A+ DC [26, 49, 51, 97, 103]. Additionally, 
features associated with efficient cross-presenting capacities, including high phagosomal 
pH, production of ROS within endocytic compartments, and efficient antigen transfer from 
endocytic compartments into the cytosol, which is required for entrance of exogenous-
derived proteins into the MHC class I pathway, were not significantly different between 
BDCA1+ and BDCA3+CLEC9A+ DC derived from blood and tonsil [97]. Therefore, it is not likely 
that BDCA3+CLEC9A+ DC are equipped with an intrinsic specialization for cross-presentation. 
In line, Cohn et al. found that BDCA1+ and BDCA3+CLEC9A+ DC had similar efficiency 
of cross-presentation of Ag delivered to early endosomes by antibody (Ab)-mediated 
targeting to CD40 and CD11c [104]. Furthermore, MHC class I presentation of endogenously 
generated Ag after transfection was comparable between the subsets, suggesting that the 
general efficiency of MHC class I presentation is similar. However, delivery of Ag to late 
endosomes and lysosomes by DEC205 targeting resulted in enhanced cross-presentation by 
BDCA3+CLEC9A+ DC compared to BDCA1+ DC. Although BDCA3+CLEC9A+ DC expressed higher 
levels of DEC205, enhanced cross-presentation was not due to increased Ag internalization. 
Together, these studies indicate that differences in cross-presentation of soluble antigen 
between DC subsets may not be dependent on intrinsic cross-presentation capacities, but 
are highly dependent on the type of Ag used in each experiment and differential expression 
of Ag receptors, which varies on each DC subset. Nevertheless, BDCA3+CLEC9A+ DC may 
exhibit a specialized machinery to transfer Ag from late endosomes and lysosomes to the 
cytosol [104].
Although conflicting results were reported regarding the superiority of BDCA3+CLEC9A+ DC 
at cross-presentation of soluble Ag, this was not the case for their superiority at the uptake 
and cross-presentation of necrotic cell-associated Ag [17, 21, 44, 97]. This enhanced capacity 
might be due to CLEC9A, which is selectively expressed by BDCA3hi DC and recognizes F-actin 
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exposed on necrotic cells [27, 29, 30]. CLEC9A was shown to mediate cross-presentation 
by coordinating the delivery of necrotic cell-associated Ag into early endosomes, which 
is associated with efficient cross-presentation [27, 28, 104, 105]. Indeed, Ag delivered to 
CLEC9A by anti-CLEC9A-coated nanoparticles were cross-presented by BDCA3+CLEC9A+ DC 
to CD8+ T cells [106]. Cross-presentation of dead cell-associated Ag might also be enhanced 
through stimulation of TLR3 by dsRNA released from infected dying cells or by other DAMPs. 
Moreover, as previously suggested by M. Dalod, CLEC9A and TLR3 may act together in the 
optimization of the cross-presentation capacity of BDCA3+CLEC9A+ DC, since CLEC9A may 
coordinate Ag into endosomes containing TLR3 [107]. However, the exact mechanism by 
which CLEC9A regulates the trafficking of internalized Ag and promotes cross-presentation 
remains to be elucidated.
In addition, enhanced activation of CD8+ T cells upon presentation of exogenous Ag in MHC 
class I by BDCA3+CLEC9A+ DC might be due to their unique expression of XCR1, which probably 
has no direct effect on the intracellular cross-presentation process, but can enhance cellular 
interaction with CD8+ T cells by the XCR1-XCL1 axis [17, 18]. If XCR1 indeed has this effect, 
also the capacity to activate CD8+ T cells via direct presentation of endogenously synthesized 
Ag in MHC class I may be enhanced for BDCA3+CLEC9A+ DC. However, no studies on direct 
Figure 1. Functional 
specializations of 
BDCA3+CLEC9A+ DC suggest 
a key role in virus-specific 
and tumor-specific immunity. 
BDCA3+CLEC9A+DC are superior 
at the uptake and cross-
presentation of dead cell-
associated Ag by CLEC9A. Cross-
presentation of Ag from tumor 
or virus-infected cells results 
in the induction of tumor- or 
virus-specific CTL, respectively. 
The XCR1-XCL1 receptor-ligand 
pair enhances survival and 
effector functions of CD8+ T and 
Th1 cells. Upon TLR3 ligation, 
BDCA3+CLEC9A+ DC produce 
high levels of IFN-λ, which can 
directly inhibit viral replication. 
In addition, BDCA3+CLEC9A+ DC 
produce IFN-β and IL-12p70 
upon activation, and thereby 
induce polarization toward Th1 
responses. Secretion of CXCL10, 
together with XCR1 expression, 
contributes to the interaction 
betweenBDCA3+CLEC9A+ DC 
and Th1 cells, which express the 
CXCL10 receptor CXCR3 and are 
major producers of XCL1.
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Ag presentation by BDCA3+CLEC9A+ DC could be found. To confirm the superior capacity of 
BDCA3+CLEC9A+ DC at cross-presentation of dead cell-associated Ag, further research on the 
intrinsic cellular processes that enable efficient cross-presentation, and the involvement of 
BDCA3+CLEC9A+ DC-specific receptors in these processes is required. 
In summary, BDCA3+CLEC9A+ DC produce high levels of IFNλ upon polyI:C stimulation, 
preferentially induce Th1 polarization of allogeneic naive CD4+ T cells, facilitate efficient 
cross-presentation of soluble Ag and exhibit superior capacity to cross-present dead cell-
associated Ag. Given these functional characteristics, BDCA3+CLEC9A+ DC are likely to play 
an important role in initiation of adaptive immunity, including CTL, which are essential in the 
host defense against viral infections and tumors (Figure 1). 
Concluding remarks
BDCA3+CLEC9A+ DC represent a unique DC subset with a gene expression profile distinct 
from other DC. So far, reliable, easily accessible tools are lacking to identify this DC subset 
based on a single marker, such as XCR1. Therefore, identification based on simultaneous 
expression of BDCA3 and CLEC9A is recommended since low-to-intermediate expression of 
these markers can also be found on other immune cells. An important area for future research 
on BDCA3+CLEC9A+ DC is the developmental pathway of these cells and its precursors. 
Development of BDCA3+CLEC9A+ DC seems to specifically depend on transcription factor 
BATF3, as was also previously shown for their CD8α+ murine counterpart, but signaling 
pathways, precursor cells and growth factors involved in the differentiation of these cells 
remain to be elucidated. Recent development of protocols to generate BDCA3+CLEC9A+ DC 
in vitro will contribute to elucidation of molecular mechanisms underlying BDCA3+CLEC9A+ 
DC development.
Although BDCA3+CLEC9A+ DC represent the smallest population of human DC subset in 
peripheral blood, a different distribution, including relatively higher BDCA3+CLEC9A+ DC 
frequencies, in peripheral tissues and lymphoid organs together with several unique functions 
indicate that BDCA3+CLEC9A+ DC play a significant role in the induction and regulation of 
immunity. BDCA3+CLEC9A+ DC have functional specializations that include the capacity to 
produce high levels of IFNλ, elicit Th1 responses and activate CTL by internalizing and cross-
presenting dead cell-associated Ag. These characteristics suggest that BDCA3+CLEC9A+ DC 
may be key players in the induction of anti-viral and anti-tumor immunity. Therefore, this DC 
subset might be a potential tool or target for immunotherapy against chronic viral infections 
or cancer. Nevertheless, a better phenotypical and functional characterization of these cells 
as well as the underlying molecular mechanisms are required to fully understand their role 
in immune regulation and to identify target molecules to  exploit the potential of these cells 
for immunotherapy. 
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Abstract
High BDCA3 expression is associated with a specific human IFN-λ-producing dendritic 
cell (DC) subset. However, BDCA3 has also been detected on other DC subsets. Thus far, 
development and function of BDCA3 expression on DCs remains poorly understood. Human 
Langerhans cells (LCs) and interstitial DCs (intDCs) can be generated in vitro by differentiation 
of CD34+ hematopoietic progenitors via distinct precursor DCs (preDCs), CD1a+ preDCs and 
CD14+ preDCs, respectively. Here, we identified BDCA3 expression in this well-known GM-
CSF/TNF-α-driven culture system and described the effect of IL-4 and/or TGF-β on induction 
of BDCA3 expression. 
In control or TGF-β cultures, BDCA3 was only detected on CD14+ preDC-derived intDCs. IL-4 
induced BDCA3 expression in both CD14+-derived and CD1a+-derived cultures. TGF-β and 
IL-4 together further increased CD14+-derived and CD1a+-derived BDCA3+ DC frequencies, 
which partly expressed CLEC9A, but were not identical to the BDCA3highCLEC9A+ DC subset in 
vivo. Importantly, BDCA3+ cells, but not BDCA3- cells, in this system produced high IFNλ levels 
upon polyI:C stimulation. This culture system, in which BDCA3 expression is preferentially 
associated with the intDC lineage and IFNλ-producing capacity, will greatly contribute to 
further research on the function and regulation of BDCA3 expression and IFN-λ production 
by DCs.
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Introduction
Dendritic cells (DCs) represent a heterogeneous population of professional antigen 
presenting cells that are found in almost all tissues [1]. Peripheral tissue DC that migrate to 
lymphoid organs are crucial to the initiation of immunity [2, 3]. These so-called migratory 
DCs include various subtypes with specialized (immune) functions [4]. In humans, the best 
described migratory DC subtypes are those localized in the skin, including epidermal Langerin+ 
Langerhans cells (LCs) and two types of dermal interstitial DCs (intDCs) [5]. Additionally, 
BDCA3+CLEC9A+ DCs, specialized in antiviral functions including cross-presentation and 
IFNλ production [6-8], were recently identified in human dermis [9]. BDCA3 (also known as 
Thrombomodulin or CD141) is widely used to identify the IFNλ-producing BDCA3+CLEC9A+ 
DC subset. However, intermediate levels of BDCA3 expression were also detected on 
monocytes [10] and other DCs, including blood pDCs [11], pulmonary intDCs and LCs [12], 
and skin intDCs [9, 13, 14], indicating that BDCA3 is not a discriminating marker for the 
BDCA3+CLEC9A+ DC subset [9, 13, 14]. BDCA3 is a cell surface-expressed transmembrane 
glycoprotein. Besides its expression on DCs, BDCA3 is predominantly expressed on vascular 
endothelial cells, where it is well known for its anticoagulant activity [15]. However, the 
exact function of BDCA3 expression on immune cells remains to be elucidated. In addition, 
it remains poorly understood under which conditions BDCA3 expression is induced and 
whether this is restricted to specific cell subsets. 
Due to the rarity and limited accessibility of human DCs and their precursors, studies on 
their functions and developmental pathways remain largely dependent on in vitro culture 
systems [6, 16, 17]. The possibility to simultaneously generate intDCs and LCs by culturing 
CD34+ hematopoietic progenitor cells (HPC) with GM-CSF and TNF-α has been of great 
value to their characterization [17-21]. In this culture system, HPCs differentiate via two 
different precursor cells, CD1a+CD14- precursor DCs (preDCs) and CD1a-CD14+ preDCs, 
into CD1a+Langerin+ LCs and CD1a+DC-SIGN+ intDCs, respectively [17, 19, 20]. It has been 
described that the differentiation of these cells can be manipulated by addition of TGF-β, 
polarizing towards LCs, and IL-4, polarizing towards intDCs [22]. In the present study, we 
investigated whether human DCs generated from CD34+ HPCs by this accepted culture 
method expressed BDCA3 and examined the effect of TGF-β and IL-4 on the development of 
these BDCA3-expressing DC and their function.
Upon differentiation of CD34+ HPCs in this GM-CSF/TNF-α-driven culture system we 
identified BDCA3 expression on DCs in this system. Without additional cytokine stimulation 
BDCA3 expression was specifically found on cells of the CD14+-derived intDC lineage. 
Addition of TGF-β enhanced BDCA3 expression in CD14+-derived cultures, whereas IL-4 
enhanced BDCA3 expression in both CD14+-derived and CD1a+-derived cultures. Addition 
of both TGF-β and IL-4 further increased the frequencies of BDCA3+ DCs. Importantly, in 
contrast to CD34+-derived BDCA3- cells, BDCA3+ cells, either CD14+- or CD1a+-derived 
and generated in the presence or absence of IL-4 and/or TGF-β, produced high levels of 
IFN-λ upon polyinosinic:polycytidylic acid (polyI:C) stimulation, irrespective of CLEC9A co-
expression. This indicates that IFN-λ production is a specific characteristic shared by the 
BDCA3+ DCs generated in this system. These findings demonstrate that this CD34+-derived 
culture system is valuable for future research into DC biology aiming at the identification of 
the cellular and molecular mechanisms underlying development of BDCA3-expressing DCs 
and their functional regulation.
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Materials and methods
Isolation of CD34+ hematopoietic progenitor cells and peripheral-blood DCs
CD34+ HPCs  were isolated from umbilical cord blood samples, obtained from healthy donors 
according to legal guidelines, as described previously [17, 19, 20]. In brief, CD34+ HPCs were 
isolated from mononuclear cell fractions by positive immunomagnetic selection using anti-
CD34-coated microbeads and MS separation columns according to the manufacturer’s 
protocol (Miltenyi Biotec, Bergish Gladbach, Germany). Isolated cells were cryopreserved in 
10% DMSO (Sigma-Aldrich, St. Louis, MO) diluted in RPMI 1640 medium (Invitrogen, Breda, 
The Netherlands) supplemented with 9% heat inactivated fetal bovine serum (FBS; Sigma-
Aldrich) and penicillin/streptomycin (Invitrogen). 
Peripheral blood DCs were isolated from leukocyte-enriched buffy coats obtained from 
healthy donors. First, mononuclear cells were isolated by Ficoll-Paque density gradient 
centrifugation. Subsequently, BDCA3+ DCs were isolated either by enrichment for DCs using 
a Dynabeads Human DC Enrichment kit (Invitrogen) followed by sorting of BDCA3+CLEC9A+ 
DCs using a FACSAria (BD Biosciences), or by immunomagnetic enrichment using PE-labeled 
BDCA3 antibody (Ab), anti-PE microbeads and MS separation columns (Miltenyi).   
In vitro generation of CD34+ HPC-derived myeloid DCs
After cryopreservation, CD34+ HPCs were cultured as described previously [17]. Cells 
were seeded in RPMI 1640 containing 9% heat inactivated FBS, penicillin/streptomycin, 
10 mM HEPES (Lonza, Walkersville, MD), 2 mM L-glutamine (Invitrogen) and 50 µM 
β-mercaptoethanol (Merck, Darmstadt, Germany; referred to as complete medium), 
supplemented from day 0-6 with 100 ng/ml Granulocyte Macrophage-Colony Stimulating 
Factor (GM-CSF, PeproTech, London, U.K.), 25 ng/ml Stem Cell Factor (SCF, PeproTech), 2.5 
ng/ml Tumor Necrosis Factor α (TNF-α, PeproTech) and  5% heat-inactivated AB+ pooled 
human serum (NHS-AB, Lonza). From day 6, cells were cultured in 100 ng/ml GM-CSF. 1 ng/
ml Transforming Growth Factor β (TGF-β, PeproTech) and/or 20 ng/ml Interleukin 4 (IL-4, 
eBioscience, San Diego, CA) were added where indicated. 
Flow cytometry
For phenotypic analysis, cells were washed with PBS containing 1% bovine serum albumin 
(BSA; Sigma-Aldrich), 1% heat inactivated human serum and 0.02% NaN3  (Merck, Darmstadt, 
Germany; referred to as FACS buffer) and subsequently labeled with fluorochrome-
conjugated Abs. Labeling was performed during 30 minutes of incubation on ice with Abs 
recognizing BDCA3/CD141 (AD5-14H12, Miltenyi); BDCA1/CD1c (AD5-8E7, Miltenyi); CD1a 
(HI149, eBioscience); CD11c (3.9, eBioscience); CD14 (61D3, eBioscience); HLA-DR (LN3, 
eBioscience); CD11b (ICRF44, BD Biosciences, Breda, the Netherlands); CD86 (Fun-1, BD 
Biosciences); DC-SIGN/CD209 (DCN47, BD Biosciences); CLEC9A (8F9, BioLegend, San 
Diego, CA) and Langerin/CD207 (DCFM4, Beckman Coulter, Woerden, the Netherlands). 
Fluorescence was measured using a FACS Canto II (BD Biosciences) and resulting data were 
analyzed using FlowJo software (Tree Star, Inc.). 
For sorting experiments, day 6 cultures were sorted based on CD1a and CD14 expression 
using a FACSAria (BD Biosciences). For some experiments, CD14+CD1a--, CD14-CD1a+- or 
CD1a+CD14+-derived cultures were sorted again at day 12 based on BDCA3 and Langerin 
expression or at day 14 based on BDCA3/CD141 and CLEC9A expression. Sorted cells were 
seeded in complete medium supplemented with GM-CSF, either with or without TGF-β and/
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or IL-4, or stimulated as described below.
RNA isolation and gene expression analysis 
RNA was extracted according to the manufacturer’s instructions using an RNAeasy Micro 
kit or a Nucleospin RNA II kit for samples containing <5x105 or >5x105 cells, respectively. 
For qPCR, OD260/280 ratios were measured to determine RNA concentration and purity 
prior to cDNA synthesis using a PrimeScript cDNA synthesis kit (Takara Bio, Tokyo, Japan). 
qPCR was performed using a MyiQ Real-Time PCR detection system and primers as shown in 
table 1. For gene expression profiling using Nanostring nCounter system, RNA concentration 
and integrity was assessed using a Bioanalyzer system (Agilent Technologies). Human 
immunology-related genes were profiled using the nCounter GX Human Immunology v2 
kit  Gene Expression CodeSet (Nanostring Technologies). Gene expression levels were 
normalized according to 15 housekeeping genes. Principal component analysis (PCA) was 
performed using MeV software. 
Cytokine secretion
DC were stimulated for 24 or 48 hours with PolyI:C (20 µg/ml, Invivogen, Toulouse, 
France). The levels of secreted human IFN-λ1 (IL-29, eBioscience), IFN-λ2 (IL-28A), 
IFN-λ3 (IL-28B), CXCL10 (R&D systems) and IL-12p70 (eBioscience) were measured using 
commercially available ELISA kits according to the manufacturer’s protocol. Detection 
limits were 8 pg/ml (IFN-λ1), 30 pg/ml (IFN-λ2/ IFN-λ3), 1.67 pg/ml (CXCL10) and 4 pg/ml 
(IL-12p70). 
Statistical analysis
Statistical analysis was performed using Graphpad Prism version 5.01 for Windows 
(GraphPad Software, San Diego, California USA). A paired Student’s t-test was used to 
determine the p-values.
Table 1. RT-PCR primers
CLEC9A Forward 5’-ATCCAACAAGAGAGGGCAC-3’ Reverse 5’-TTGTTTGGACAAGGACTGC-3’
XCR1 Forward 5’- CAAGACGCATGTAAAGAGG-3’Reverse 5’- CTGGCTCTGAAGGTCATAG-3’
TLR3 Forward 5’-AGTTGTCATCGAATCAAATTAAAGAG-3’Reverse 5’-AATCTTCCAATTGCGTGAAAA-3’
CADM1 Forward 5’- TGCCAGCTCTATACCGATC-3’Reverse 5’- AATCTCCTCACCTTCCACC-3’
BATF3 Forward 5’-ATGATGACAGGAAGGTCCG-3’ Reverse 5’-TTTCTTGCTCCAGGCTCTC-3’
IRF8 Forward 5’- TCCCAACTGGACATTTCCG-3’Reverse 5’- ACTTCATTCACGCAGCCAG-3’
GAPDH Forward 5’-TGCACCACCAACTGCTTAGC-3’Reverse 5’-GGCATGGACTGTGGTCATGAG-3’ 
Chapter 4
90
Results
CD34+-derived intDCs express BDCA3 
We first aimed to fully elucidate the known culture system that generates DCs from CD34+ 
HPCs under the influence of GM-CSF and TNF-α [17]. As previously described, this system 
generated a BDCA1+CD1a+ DC population comprising Langerin+ LCs and DC-SIGN+ intDCs 
(Figure 1A), which are known to differentiate through independent pathways via CD1a+CD14- 
preDCs and CD14+CD1a- preDCs, respectively [17, 19]. In addition, we observed that DC-
SIGN+ intDCs, but not Langerin+ LCs, partially co-expressed BDCA3 (Figure 1A). 
To determine the route of differentiation of these BDCA3+ DCs, day 6 CD14+ preDCs and CD1a+ 
preDCs shown in Figure 1A were sorted and cultured separately. Indeed, BDCA3 expression 
was particularly observed within the CD14+-derived cultures (Figure 1B,C). By day 6, CD14+ 
preDCs already included a BDCA3+ population, which increased in frequency (2±0.5-fold, 
p<0.05), absolute cell numbers and BDCA3 expression level upon further differentiation from 
day 10 until day 14 (Figure 1B, C). Comparison of BDCA3+ and BDCA3- CD14+-derived cells for 
several phenotypic markers revealed that both populations had a CD11c+HLA-DR+CD86-/low 
immature DC phenotype, expressed BDCA1 and CD1a, partially expressed CD11b and DC-
SIGN, but lacked CLEC9A (Figure 1B,D). Although the BDCA3- population included Langerin+ 
cells, hardly any co-expression of Langerin and BDCA3 was detected (Figure 1D).
Thus, BDCA3 expression was detected on CD34+-derived DCs generated in the presence of 
GM-CSF and TNF-α and particularly associated with the CD14+-derived intDC lineage. CD14+-
derived BDCA3+ DCs had an immature phenotype and did not differ much in the expression 
of BDCA1, CD1a, DC-SIGN and CD11b from their BDCA3- CD14+-derived counterparts.
IL-4 induces CD1a+-derived BDCA3+ DCs and, like TGFβ, increases CD14+-derived BDCA3+ 
DCs
TGF-β and IL-4 have been described to skew the differentiation of CD34+-derived DCs 
towards LCs and intDCs, respectively [22]. Indeed, addition of TGF-β from day 6 strongly 
enhanced expression of the LC marker Langerin at day 14, whereas IL-4 decreased Langerin 
expression and increased expression of the intDC marker DC-SIGN (Figure 2A). Additionally, 
IL-4 enhanced differentiation towards CD1a+BDCA1+ DCs and expression of CD11b (Figure 
2A). Although addition of TGF-β and IL-4 together decreased the upregulation of DC-SIGN 
compared with IL-4 alone, the combination of TGF-β and IL-4 mostly resembled the effect of 
IL-4 alone with respect to Langerin,  CD1a, BDCA1, and CD11b expression (Figure 2A). 
In addition, we investigated the effect of TGF-β and/or IL-4 on the induction of BDCA3 
expresion on DCs in this system. As shown in Figure 1, in the absence of TGF-β and/or IL-4, 
BDCA3 was particularly expressed by CD14+-derived intDCs. To investigate whether addition 
of TGF-β and/or IL-4 affected this preferential expression by intDCs, we sorted CD14+ and 
CD1a+ preDCs at day 6 and cultured the two populations separately with or without TGF-β 
and/or IL-4. TGF-β enhanced the frequencies of BDCA3-expressing CD14+-derived DCs, but 
was not able to induce BDCA3 expression on CD1a+-derived DCs (Figure 2B, C, D, E). Since 
we already observed that BDCA3 expression specifically developed within the CD14+ preDC 
population in control cultures without additional cytokines (Figure 1), it was not unexpected 
that IL-4, a cytokine known to accelerate intDC development from CD14+ preDCs, enhanced 
the frequency and absolute numbers of BDCA3+ DCs in CD14+-derived cultures (Figure 
2B, C, D, E). Interestingly, culture of CD1a+ preDCs in the presence of IL-4 also resulted in 
highly increased frequencies and absolute numbers of BDCA3+ DCs (Figure 2B, C, D, E). The 
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combination of TGF-β plus IL-4 induced the highest expression of BDCA3 and the highest 
frequency of BDCA3+ cells in both CD14+ and CD1a+ sorted cultures (Figure 2B, C, D, E).
Furthermore, in depth analysis of BDCA3 expression by cells in the different cytokine cultures 
revealed that in CD14+-derived control cultures without additional cytokines, BDCA3 was 
mainly expressed by DC-SIGN+ intDCs (Figure 2F). CD14+-derived cultures to which also 
TGF-β was added contained a LangerinhiBDCA3- DC population that most likely represents 
LCs. 
Very remarkable, however, is the finding that these TGF-β-induced cultures also included a 
Figure 1. CD34+-derived DC cultures contain a BDCA3+ DC subset in addition to intDCs and LCs.
(A) CD34+ cells were plated and cultured for 6 days in the presence of GM-CSF, TNF-α and SCF, followed by an 
8-day culture in the presence of GM-CSF alone. CD34+-derived cells were analyzed at day 6 for expression of CD1a 
and CD14, and at day 14 for BDCA1, CD1a, Langerin, DC-SIGN and BDCA3 by flow cytometry. (B and C) Day 6 cells 
were FACSorted into CD1a+CD14- and CD1a-CD14+ fractions, and cultured separately. At day 6, 10 and 14, cells 
were counted with trypan blue exclusion and BDCA3 expression of FSC/SSC-gated viable cells was analyzed by 
flow cytometry. Isotype controls were used to determine the positions of the gates at each timepoint. Absolute 
numbers of BDCA3+ DC were calculated and standardized to day 6 CD1a-CD14+ fractions. (B) Representative FACS 
plots and (C) mean ±SEM standardized absolute BDCA3+ cell numbers are shown (n=5). (C) Data are pooled from 
5 independent experiments, each performed with a different donor. *p<0.05, ***p<0.001, paired Student’s t-test. 
(D) Day 14 CD14+-derived DCs were analyzed for BDCA3, CD11c, HLA-DR, CD86, BDCA1, CD11b, DC-SIGN, Langerin 
and CLEC9A expression. (A-D) FACS plots are representative of five independent experiments, each performed with 
a different donor.
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BDCA3+ DC population with intermediate Langerin expression. In addition, BDCA3+Langerin- 
DCs were observed (Figure 2F). 
In IL-4-induced CD14+-derived cultures BDCA3 was expressed by DC-SIGN+ intDCs, whereas 
in CD1a+-derived cultures BDCA3 was expressed by DC-SIGN+ DCs as well as DC-SIGN- 
DCs (Figure 2F). CD14+-derived DCs generated in the presence of IL-4 and TGF-β almost 
all expressed BDCA3. 70% of these cells co-expressed DC-SIGN and a small Langerin+ cell 
population was observed within the DC-SIGN- population. Development of BDCA3+ DCs was 
boosted in CD1a+-derived cultures by IL-4 and TGF-β compared with IL-4 alone. Both Langerin-
expressing BDCA3+ DCs and more intDC-related DC-SIGN+ BDCA3+ DCs were observed and a 
Langerin+BDCA3- DC population remained present, which is likely to represent LCs.
Together, these data show that IL-4 as well as TGF-β induce BDCA3+ DCs within the cell 
population derived from CD14+ preDCs, known as precursors of intDCs (pre-intDCs). Only 
IL-4, a cytokine known to stimulate intDC development, induces BDCA3+ DC development 
in cultures of CD1a+ preDCs, known as precursors of Langerhans cells (pre-LCs). In the 
presence of both TGF-β and IL-4, almost all CD14+-derived DCs express BDCA3 and most 
CD1a+-derived DCs express BDCA3, but within this latter condition also a BDCA3-Langerin+ 
DC population is present which does not respond to skewing towards a more intDC related 
cell type.  
Phenotypic and functional characteristics of TGFβ/IL-4-induced BDCA3+CLEC9A+ DCs
Since high BDCA3 expression is known to be specific for a distinct human DC subset in vivo 
that can be further characterized by CLEC9A expression and IFN-λ production, we first 
investigated whether the BDCA3+ DCs induced in this in vitro culture system also expressed 
CLEC9A and exhibited other phenotypical and functional characteristics associated with 
this human DC subset. In contrast to other conditions, cultures containing both TGF-β and 
IL-4 included BDCA3+CLEC9A+ cells (Figure 3A). Highest frequencies and absolute numbers 
of BDCA3+CLEC9A+ DCs developed from CD1a+-preDCs (Figure 3A, B, C, D). Whereas the 
percentage and absolute numbers of CLEC9A+ cells within CD1a+ cultures did not further 
increase from day 10, the CLEC9A expression level significantly increased from day 10 till 
day 14 (Figure 3B). 
Next, day 6 CD14+ preDCs and CD1a+ preDCs were cultured together in the presence of 
TGF-β and IL-4, and the total population of BDCA3+CLEC9A+ DCs was FACSorted at day 
14. We investigated whether these in vitro-generated BDCA3+CLEC9A+ DCs resembled 
peripheral blood-derived BDCA3+CLEC9A+ DCs. Both DC types were profiled for expression 
of 579 immunology-related human genes (Supplemental Table 1). Principal component 
analysis (PCA) indicated that along the PC1 axis, the variance between the two DC types is 
larger than the variance between the replicates. However, the adjacent position of the two 
DC types along the PC2 and PC3 axis indicates partial analogy in gene expression profiles of 
in vitro-generated DCs and blood-derived DCs (Figure 4A). In addition, there is a significant 
correlation in gene expression between the two DC types (r=0.84, p<0.0001, Figure 4B). 43% 
of genes showed a ≤3-fold change between in vitro-generated DCs and blood-derived DCs 
(Supplemental Table 1). Several of these genes encode proteins that are involved in antigen 
processing and presentation, receptors, and IFN-λ-regulatory elements (Figure 4C). Genes 
showing a >3-fold change in expression levels between in vitro-generated DCs and blood-
derived DCs (57%) included genes that were previously identified as being highly expressed 
in in vivo BDCA3+CLEC9A+ DCs, i.e. IRF8, XCR1, IDO1, NFIL3 and TLR3 (Figure 4C, Supplemental 
Table 1) [6, 8, 23, 24]. The expression levels of these genes were higher in blood-derived 
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Figure 2. In contrast to 
TGF-β, IL-4 not only induces 
BDCA3+ DCs within CD14+-
derived cultures, but also 
within CD1a+-derived 
cultures.
CD34+ cells were plated 
and cultured for 6 days in 
the presence of GM-CSF, 
TNF-α and SCF, followed 
by a 6-day culture in the 
presence of GM-CSF, either 
with or without TGF-β, IL-4 
or TGF-β and IL-4. (A) CD1a, 
BDCA1, Langerin, DC-SIGN 
and CD11b expression was 
determined at day 14. FACS 
plots of FSC/SSC gated viable 
cells are representative of 3 
independent experiments, 
each performed with 
a different donor. The 
maximum level of isotype 
staining is indicated by the 
dashed lines. (B-E) Day 6 
cells were FACSorted into 
CD1a+CD14- and CD1a-
CD14+ fractions and cultured 
separately in the presence 
of GM-CSF with or without 
TGF-β, IL-4 or TGF-β and 
IL-4. At day 14, cells were 
counted with trypan blue 
exclusion and BDCA3 
expression of FSC/SSC-gated 
viable cells was analyzed by 
flow cytometry (n=4). (B) 
Representative FACS plots 
are depicted in which the 
dotted line represents the 
isotype control staining. (C) 
Percentage of BDCA3+ cells 
within the different cultures. 
(D) Absolute numbers of 
BDCA3+ DCs were calculated 
(continued on the following 
page)
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DCs than in in vitro-generated DCs. Additionally, many cytokine-receptor and chemokine-
receptor genes varied >3-fold between the two DC types (Figure 4C). These results indicate 
that in vitro-generated BDCA3+CLEC9A+ DCs are not identical to peripheral blood-derived 
BDCA3+CLEC9A+ DCs, which may be partially explained by differences between in vitro-
generated and in vivo-derived DC in general. 
To further investigate phenotypic and functional differences and similarities between in vitro-
generated BDCA3+CLEC9A+ DCs and their BDCA3+CLEC9A- and BDCA3
-CLEC9A- counterparts 
on one hand and to confirm differential gene expression between in vitro-generated and 
blood-derived BDCA3+CLEC9A+ DCs on the other hand, DC populations were analyzed for 
CLEC9A, XCR1, BATF3, CADM1 and IRF8 by qPCR (Supplemental Figure 1). CADM1, TLR3 
and BATF3 mRNA expression was observed for all three FACSorted in vitro-generated cell 
populations, although BDCA3+CLEC9A+ DCs expressed significantly higher levels of CADM1 
and BATF3 than the other populations. Neither XCR1 nor IRF8 mRNA expression could be 
detected for any of the in vitro-generated DC populations (Supplemental Figure 1). Functional 
analysis revealed that all three in vitro-generated DC populations produced CXCL10 (Figure 
4D). Interestingly, despite the similar TLR3 expression by BDCA3- and BDCA3+ cells, only 
BDCA3+ DCs produced high levels of IFN-λ1 upon polyI:C stimulation, irrespective of the 
expression of CLEC9A (Figure 4D, E). Although IFN-λ1 levels produced by in vitro-generated 
DCs were lower than those produced by blood-derived BDCA3+CLEC9A+ DCs, they were 
at least 18-fold higher than levels produced by polyI:C-stimulated blood-derived BDCA1+ 
DCs and 80-fold higher than CpG-A-stimulated blood-derived pDCs (Figure 4D). IL-12p70 
production in response to polyI:C stimulation could not be detected (data not shown). 
Together, these data show that the in vitro-generated  BDCA3+CLEC9A+ DCs are, based on 
the above-mentioned markers, not distinct from CLEC9A- DCs generated in this system. 
However, like in vivo BDCA3+CLEC9A+ DCs, in vitro-generated  BDCA3+ DCs specifically 
produce high levels of IFN-λ upon polyI:C stimulation, irrespective of CLEC9A expression.
IFN-λ1 production levels correlate with BDCA3+ DC development
The observation that high IFN-λ production was restricted to BDCA3+ DCs, prompted 
us to also investigate the IFN-λ-producing capacity of cells derived from control, TGF-β, 
IL-4 and TGF-β/IL-4-induced cultures, each containing different frequencies of BDCA3+ 
DCs. Functional analysis of polyI:C-stimulated cultures revealed that IFN-λ1 was not only 
produced by TGF-β/IL-4-induced DCs, but specifically by all cultures containing BDCA3+ 
DCs, i.e. all CD14+-derived cultures and CD1a+ preDC cultures containing IL-4 either with 
or without TGF-β, but not in control or TGF-β-treated CD1a+ preDC cultures (Figure 5A). 
Moreover, statistical analysis of the relation between the percentage of BDCA3+ DCs present 
in the cultures exposed to polyI:C and the level of IFN-λ produced by these cell cultures 
revealed a positive correlation between the percentage BDCA3+ cells and the level of IFN-λ1 
and standardized to day 14 CD14+derived control fractions. These relative values correspond with an average 
CD14+-derived BDCA3+ cell yield of 1.7*104 cells after 14 days of culture under standard culture conditions starting 
from 1.0*106 CD34+ HPCs. (E) Mean fluorescence intensity (MFI) of BDCA3 staining on the BDCA3+ population. (C-E) 
Data are shown as mean ±SEM (n=4). *p<0.05, **p<0.01, paired Student’s t-test. (F) Day 6 cells were FACSorted into 
CD1a+CD14- and CD1a-CD14+ fractions and cultured separately in the presence of GM-CSF with or without TGF-β, 
IL-4 or TGF-β and IL-4. At day 14, BDCA3, Langerin and DC-SIGN expression were determined by flow cytometry. 
Representative FACS plots of FSC/SSC gated viable cells are shown. (B-F) Data are pooled from four independent 
experiments, each performed with a different donor. 
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(Figure 5B), suggesting that IFN-λ1 is particularly produced by BDCA3+ DCs. In addition, 
assessment of IFN-λ2 and IFN-λ3 production resulted in a similar pattern. Both IFN-λ2 and 
IFN-λ3 were also specifically detected in supernatants derived from cell  populations which 
included BDCA3+ DCs, although levels produced by the IL-4-induced CD14+-derived cell 
population were very low (Figure 5C, D). Interestingly, IFN-λ2 and IFN-λ3 levels produced by 
TGF-β-differentiated CD14+-derived cells were remarkably higher compared with those of 
the other conditions. 
To investigate whether indeed the BDCA3+, but not the BDCA3- cells, were the major 
IFN-λ producers in these cultures and to investigate the high IFN-λ production by TGF-β-
induced CD14+-derived DCs in more detail, TGF-β-induced CD14+-derived BDCA3+ and 
BDCA3- cells were FACSorted and analyzed separately for IFN-λ production upon polyI:C 
stimulation. Furthermore, since TGF-β is known as a cytokine promoting development of 
CD14+-derived Langerin+ cells, previously considered as Langerhans-like cells [22] (Figure 
2F), and BDCA3 expression was observed on Langerin+ as well as Langerin- cells, cells were 
also FACSorted based on Langerin expression. Indeed, BDCA3+ DCs, but not BDCA3- DCs, 
Figure 3. TGF-β/IL-4-induced cultures contain CLEC9A+ cells.
CD34+ cells were plated and cultured for 6 days in the presence of GM-CSF, TNF-α and SCF. Day 6 cells were 
FACSorted into CD1a+CD14- and CD1a-CD14+ fractions and cultured separately in the presence of GM-CSF with 
TGF-β and IL-4. (A) At day 14, CLEC9A and BDCA3 expression were analysed by flow cytometry. Representative FACS 
plots of FSC/SSC gated viable cells show CLEC9A and BDCA3 expression (n=3). (B-D) Cells cultured in the presence 
of GM-CSF, TGF-β and IL-4 were counted with trypan blue exclusion and analyzed for CLEC9A and BDCA3 expression 
by flow cytometry at day 6, 10 and 14. (B) Representative FACS plots of FSC/SSC gated viable cells. (C) Data are 
shown as mean ±SEM percentages and (D) standardized absolute CLEC9A+ cell numbers (n=3). **p<0.01, paired 
Student’s t-test. (A-D) Data are pooled from three independent experiments, each performed with a different donor. 
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Figure 4. TGF-β and IL-4-induced CLEC9A+BDCA3+ DCs do not resemble blood-
derived BDCA3+CLEC9A+ DCs, but produce CXCL10 and IFN-λ upon polyI:C stimulation.
CD34+ cells were plated and cultured for 6 days in the presence of GM-CSF, TNF-α and SCF. At day 6, CD14+ 
and CD1a+ preDCs were sorted and cultured together in the presence of GM-CSF with TGF-β and IL-4. At day 
14, cells were FACSorted based on BDCA3 and CLEC9A expression. (A-C) mRNA was isolated from in vitro-
generated BDCA3+CLEC9A+ DCs (n=3) and FACSorted peripheral blood-derived BDCA3+CLEC9A+ DC (n=3). Gene 
expression levels were measured using the NanoString nCounter system. (A) PCA was performed using the MeV 
software, based on genes expressed in at least one of the two DC types (expression level >50). PC1 accounts 
for 80.1%, PC2 for 8.8%, and PC3 for 6.6% of the total variance. Each point represents a sample, classified by 
DC type. (B) The correlation between gene expression profiles of the two DC types with 3-fold change lines. (C) 
Genes >3-fold upregulated in blood-derived DCs (left circle), >3-fold upregulated in in vitro-generated DCs (right 
circle) and ≤3-fold changed between the two DC types (overlapping area) are shown. (D) In vitro-generated 
BDCA3+CLEC9A+, BDCA3+CLEC9A- and BDCA3-CLEC9A- fractions and FACSorted blood-derived BDCA3+CLEC9A+ 
DCs were cultured in the presence or absence of polyI:C for 24 hours. IFN-λ1 and CXCL10 concentrations were 
determined by ELISA. (E) mRNA was isolated from in vitro-generated BDCA3+CLEC9A+, BDCA3+CLEC9A- and 
BDCA3-CLEC9A- DC fractions and a MACS-enriched blood-derived BDCA3+ DC fraction. TLR3 mRNA levels were 
measured by qPCR and normalized to GAPDH expression levels. (D and E) Data are shown as mean ±SEM of (D) 
IFNλ1 and CXCL10 production or (E) normalized expression levels (n=3). (A-E) Data are pooled from 3 independent 
experiments, each performed with a different donor. ND, not detected. *p<0.05, paired Student’s t-test. 
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produced high levels of IFN-λ1, IFN-λ2 and IFN-λ3 upon polyI:C stimulation (Figure 5E, F, G). 
The high IFN-λ1 production by BDCA3+ DCs was irrespective of Langerin expression (Figure 
5E, F, G). By contrast, neither polyI:C nor LPS, R848 or CD40L induced IFN-λ production by 
TGF-β-differentiated BDCA3- cells (data not shown). Thus, BDCA3+ DCs, either Langerin+ or 
Langerin, that are generated in this in vitro culture system are potent producers of IFN-λ.
Discussion
The GM-CSF/TNF-α-driven culture system firstly described by Caux et al., is known 
to generate LCs and intDCs [17]. In the present study we report for the first time the 
development of BDCA3-expressing DCs in this system that specifically produced IFN-λ. By 
using IL-4 and TGF-β, cytokines which were previously described to skew the differentiation 
towards interstitial DCs and LCs respectively, we observed that BDCA3 expression was 
strongly associated with the intDC lineage. Furthermore, BDCA3+ DCs, but not BDCA3- DCs, 
from different conditions shared the capacity to produce high levels of IFN-λ upon polyI:C 
stimulation.
BDCA3 has proven a useful marker in the classification of human DCs, but phenotypic and 
functional heterogeneity between BDCA3+ DCs has been described. High BDCA3 expression 
identifies DCs belonging to the CLEC9A+ DC subset, but BDCA3 is also expressed by CD14+ 
dermal DCs which do not belong to this CLEC9A+ DC subset [9, 13]. Here, BDCA3 expression 
was particularly observed in CD14+ pre-intDC cultures, which could be further promoted by 
IL-4, TGF-β, or both. In contrast, only when the intDC-skewing cytokine IL-4 was added to 
CD1a+ preDC cultures, significant BDCA3 expression could be detected on DCs derived from 
these precursors, suggesting that BDCA3 expression is specifically associated with the intDC 
lineage. The link between BDCA3 expression and the intDC lineage corresponds to recent 
studies of dermal DCs, which described that co-expression of BDCA3 was only detected in 
the CD14+ intDC population [13, 14]. It is currently unknown what the function of BDCA3 
is on this DC subset and whether BDCA3+ and BDCA3- intDCs are functionally different. 
BDCA3 has been described to have an anti-inflammatory function through several direct 
and indirect mechanisms, reviewed by Li et al. [15]. Indeed, several studies suggested that 
BDCA3 expression on DCs is associated with a tolerogenic function of these cells [14, 25, 26]. 
On the other hand, BDCA3+CLEC9A+ DCs in peripheral tissues and blood, are often associated 
with cross-presentation and anti-viral immunity and described as potent immunogenic DCs 
[6-9, 27]. In the present study we found no clear differences between CD34+-derived BDCA3+ 
DCs and BDCA3- DCs in CXCL10 and IL-12p70 production. Furthermore, it does not seem 
that BDCA3 is expressed by more mature DCs since the percentage of CD86
+ cells was even 
lower in the BDCA3+ population than in the BDCA3- population in control cultures. However, 
a very interesting finding is that BDCA3 expression in this culture system is associated with 
polyI:C-induced IFN-λ production. This suggests an anti-viral function of BDCA3-expressing 
cells. However, the mechanisms underlying the relation between BDCA3 expression and 
IFN-λ production remain to be elucidated.
The superior IFN-λ2 and IFN-λ3 production as specifically observed for TGF-β-induced BDCA3+ 
DCs may indicate that these cells are functionally different or further differentiated. On the 
other hand, TGF-β might positively influence the signalling leading to IFN-λ production, 
whereas IL-4 might have a negative effect on this process. Further research is required to 
obtain insight into the exact cause of these differences in IFN-λ levels between the distinct 
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Figure 5. BDCA3+ DCs are potent producers of IFN-λ in response to polyI:C stimulation.
CD34+ cells were plated and cultured for 6 days in the presence of GM-CSF, TNF-α and SCF. (A-D) Day 6 cells 
were FACSorted into CD1a+CD14- and CD1a-CD14+ fractions and cultured separately in the presence of GM-CSF 
with TGF-β and/or IL-4. At day 14, cells were cultured in the presence or absence of polyI:C without additional 
cytokines for 24 hours. IFN-λ1, IFN-λ2 and IFN-λ3 concentrations were determined by ELISA. (A) Data are shown 
as mean ±SEM IFN-λ1 production (n=3) and are pooled from 3 independent experiments, each performed with a 
different donor. The correlation between the percentage of BDCA3+ cells and IFN-λ1 production was determined. 
(B) Data from one representative experiment of three independent experiments with similar results is depicted. 
(C and D) Data are shown as mean ±SEM of (C) IFN-λ2 and (D) IFN-λ3 production (n=3) and are pooled from 
3 independent experiments, each performed with a different donor. Statistical analysis was performed on 
IFN-λ1, IFN-λ2 and IFN-λ3 levels standardized to levels produced by TGF-β-induced CD14+-derived cells. (E-
G) CD14+CD1a- cells were FACSorted at day 6 and cultured in the presence of GM-SCF and TGF-β. At day 12, 
BDCA3+Langerin+, BDCA3+Langerin- and BDCA3-Langerin+ fractions were FACSorted and further cultured in the 
presence or absence of polyI:C without additional cytokines. After 2 days, supernatants of BDCA3+Langerin+, 
BDCA3+Langerin- and BDCA3-Langerin+ cells were harvested and IFN-λ1, IFN-λ2 and IFN-λ3 concentrations were 
determined by ELISA. Data are shown as mean ±SEM production of IFN-λ1 (n=5, E), IFN-λ2 (n=3, F) and IFN-λ3 (n=3, 
G) and are pooled from 5 independent experiments, each performed with a different donor. Statistical analysis 
was performed on IFN-λ1, IFN-λ2 and IFN-λ3 levels standardized to levels produced by TGF-β-induced CD14+-
derived cells. polyI:C-stimulated BDCA3+Langerin+ cells. *p<0.05, **p<0.01, ***p<0.001, paired Student’s t-test.
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cytokine conditions. 
So far, the IFN-λ-producing BDCA3+ DCs in vivo have been identified by co-expression of 
CLEC9A, which is involved in the sensing and presentation of necrotic cell-derived antigens 
[6, 8, 27-30]. Here, CLEC9A was partially expressed on BDCA3+ DCs induced by TGF-β and IL-
4, which suggests that these in vitro-generated DC belong to the CLEC9A+ lineage described 
in vivo by Poulin et al. [29]. 
However, transcriptional profiling showed that gene expression patterns of in vitro-generated 
BDCA3+CLEC9A+ DCs showed only partial analogy with blood-derived BDCA3+CLEC9A+ 
DCs. This is in line with the findings of Lundberg et al., who show that many of immune-
related genes differ across in vitro model DCs and ex vivo DCs and that in vitro model DCs 
are more similar to each other than to ex vivo DCs [31]. Nevertheless, BDCA3+CLEC9A+ DC-
characteristic genes, i.e. IRF8, XCR1, IDO1, TLR3 and NFIL3, were absent or lower expressed 
by our in vitro-generated BDCA3+CLEC9A+ DCs. Thus, although in vitro-generated and in vivo-
derived BDCA3+CLEC9A+ DC share several functional and phenotypic features, overall the 
immunology-related gene expression profiles indicate that in vitro-generated BDCA3+CLEC9A+ 
DCs are not identical to bona fide BDCA3+CLEC9A+ DCs present in vivo. This also suggests 
that not only BDCA3, but also CLEC9A, a marker commonly used for identification of DCs of 
the BDCA3+CLEC9A+XCR1+ lineage in human and mice, can be expressed by cells that do not 
belong to this DC lineage. Moreover, BDCA3 and CLEC9A may be induced on each precursor 
cell when stimulated appropriately, and the induction of BDCA3 may require different 
stimulatory signals than induction of CLEC9A.  Low CLEC9A expression was previously 
also detected on human B cells and murine pDC [32]. By what exact mechanism CLEC9A 
expression is induced remains to be further investigated. Given the expression of CLEC9A in 
this culture system under certain conditions, this system may contribute to assessment of 
pathways regulating CLEC9A expression. Of note, the combination of Flt3L and IL-4, which 
was used in a previously described in vitro culture system to generate BDCA3+CLEC9A+ DC 
[6], did not induce any CLEC9A+ cells in this system (data not shown). 
The increased expression of Langerin upon addition of TGF-β to the culture system confirms 
previous findings showing that exogenous TGF-β can induce Langerin expression and 
polarize differentiation of CD14+ preDCs towards Langerin+ LC-like cells [19, 22, 33]. 
However, previous studies reported that Birbeck granules were detected in only 30% of 
TGF-β-induced CD14+-derived Langerin+ cells [22], which may indicate that only part of 
these Langerin+ cells could be considered as real LCs. Here, TGF-β was shown to induce 
LangerinintBDCA3+ cells besides LangerinhiBDCA3- cells, of which the latter population 
showed a Langerin expression level comparable to that of CD1a+-derived LCs (Figure 2F). 
Functional analysis of these two DCs subtypes showed that in contrast to LangerinhiBDCA3- 
DCs, LangerinintBDCA3+ DCs produced high levels of IFN-λ upon polyI:C stimulation. These 
findings indicate that not all TGF-β-differentiated CD14+-derived Langerin+ cells represent 
LCs, but suggest the development of two distinct DC subsets, i.e. LangerinhiBDCA3- LC and 
IFN-λ-producing LangerinintBDCA3+ DCs. 
In conclusion, we identified BDCA3 expression in a culture system known to generate 
intDCs and LCs and provided insight into the influence of TGF-β and IL-4 on the induction of 
BDCA3 expression on DCs in this system. Importantly, we found that BDCA3 expression is 
preferentially associated with the intDC lineage and that BDCA3+ DCs, but not BDCA3- DCs, 
have the capacity to produce high levels of IFN-λ upon polyI:C stimulation. This system may 
be of great use to obtain insight into the function and regulation of BDCA3 expression on 
DCs. In addition, this system will enable investigation of the mechanisms that regulate IFN-λ 
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production and how this is linked in particular to BDCA3-expressing DCs. 
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Supplementary information
Supplemental figure 1. TGFβ and IL-4-induced CLEC9A+BDCA3+ DC are not distinct from CLEC9A- DC.
CD34+ cells were plated and cultured for 6 days in the presence of GM-CSF, TNFα and SCF. At day 6, CD14+ and CD1a+ 
preDC were sorted and cultured together in the presence of GM-CSF with TGFβ and IL-4. At day 14, cells were 
FACSorted based on BDCA3 and CLEC9A expression. mRNA was isolated from in vitro-generated BDCA3+CLEC9A+, 
BDCA3+CLEC9A- and BDCA3-CLEC9A- DC fractions and a MACS-enriched blood-derived BDCA3+CLEC9A+ DC fraction. 
CLEC9A, XCR1, CADM1, BATF3 and IRF8 mRNA levels were measured by qPCR and normalized to GAPDH expression 
levels. Mean±SEM normalized expression levels of 3 independent experiments with different donors are shown. 
ND, not detected. *p<0.05, **p<0.01, paired Student’s t-test.
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Supplementary table 1. Gene expression profiles of in vitro-generated and blood-
derived BDCA3+CLEC9A+ DC.  
Gene expression analysis was performed as described in Figure 4. Transcripts identified by 
expression level >50 in at least one of the two DC types are shown.
Genes with >3 fold-change in expression between 
blood and in vitro DC
Genes with ≤3 fold-change in expression between 
blood and in vitro DC
Name
In vitro  
BDCA3+CLEC9A+ 
DC
Blood 
BDCA3+CLEC9A+ 
DC Name
In vitro 
BDCA3+CLEC9A+ 
DC
Blood 
BDCA3+CLEC9A+ 
DC
IRF8 1 10,832 ILF3 1,533 4,555
SELL 1 2,197 HLA-A 9,152 25,481
BTLA 1 1,136 TAPBP 1,172 3,255
CD45RA 1 649 LTB4R 38 102
XCR1 2 602 TAP2 443 1,183
CTLA4 1 319 FCGRT 2,821 7,320
LILRA4 1 212 HLA-C 1,970 5,073
CD48 54 6,294 NCF4 142 363
CAMP 1 84 ATG12 29 74
TNFSF8 1 82 IKZF1 60 150
CD22 3 209 IRAK1 202 505
CSF3R 5 355 TAP1 314 773
SMAD3 4 273 MIF 1,026 2,510
ADA 6 401 BCL3 321 777
KIT 8 561 HLA-B 9,117 21,620
HLA-DOB 101 5,008 HLA-DQA1 23,609 55,140
ICAM2 2 91 PSMB10 601 1,381
DUSP4 129 4,496 ARHGDIB 3,167 7,016
TLR3 58 1,937 IFNGR1 2,016 4,175
LILRA5 8 273 CASP2 316 643
CD5 10 312 TRAF6 363 710
DPP4 41 1,242 HLA-DRA 81,673 156,657
NFKBIZ 54 1,374 PSMB7 2,185 4,142
FYN 77 1,884 HLA-DRB3 45,058 83,971
CD97 21 506 ICAM1 1,992 3,622
IDO1 324 7,536 HLA-DPA1 145,869 263,906
TNFAIP3 175 3,229 BCL2L11 212 382
MAP4K1 114 2,058 C14orf166 2,846 5,131
JAK3 18 299 IL1RL1 31 54
NLRP3 58 905 PECAM1 1,529 2,682
PTK2 103 1,589 CD86 617 1,075
NOD2 16 224 PTPN22 699 1,186
CD45RB 72 990 LGALS3 1,297 2,174
IRAK2 28 380 PTPRC_all 4,589 7,672
ITGAL 149 1,877 JAK1 918 1,499
CXCR4 1,891 22,089 TNFAIP6 63 102
MYD88 458 4,709 STAT2 944 1,515
NFKBIA 2,619 25,981 RELB 384 607
SLAMF7 205 1,931 CTSS 6,929 10,802
IL2RG 303 2,803 IFIH1 184 279
TNFRSF1B 22 199 SYK 2,823 4,275
MCL1 6,425 59,024 ITGA4 1,019 1,536
CD83 2,750 24,329 CLEC5A 65 95
NOTCH2 143 1,238 IFNAR2 1,280 1,870
S100A9 77 661 NFATC2 1,096 1,552
CFP 139 1,126 BCL10 1,787 2,524
BCL2 18 139 PSMB8 3,709 5,227
POU2F2 60 448 TNFSF13B 446 614
TRAF4 150 1,051 IRF7 171 226
NFIL3 402 2,631 XBP1 762 979
LILRA2 51 307 MALT1 883 1,131
IRF1 198 1,187 RELA 403 516
ICAM3 1,363 8,064 TYK2 753 958
IL16 506 2,967 IL18 282 359
MAPKAPK2 313 1,760 TP53 1,022 1,296
C5 14 74 TGFBI 6,598 8,017
CXCR3 130 652 CD74 157,532 190,388
MX1 210 1,052 ITGB2 5,936 7,090
HLA-DPB1 49,850 234,676 CXCL2 294 339
TGFB1 409 1,760 NFKB2 362 416
IL18R1 167 713 CIITA 1,850 2,115
GPR183 1,578 6,516 RUNX1 715 814
ABL1 366 1,510 MAP4K4 788 894
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Genes with >3 fold-change in expression between 
blood and in vitro DC
Genes with ≤3 fold-change in expression between 
blood and in vitro DC
Name
In vitro  
BDCA3+CLEC9A+ 
DC
Blood 
BDCA3+CLEC9A+ 
DC Name
In vitro 
BDCA3+CLEC9A+ 
DC
Blood 
BDCA3+CLEC9A+ 
DC
NT5E 31 120 PTPN6 1,949 2,148
SIGIRR 20 75 CFB 139 152
PTGER4 210 784 HLA-DMB 9,182 9,886
HLA-DMA 4,195 15,502 GPI 1,047 1,123
HLA-DRB1 15,369 55,543 PSMD7 3,238 3,466
CASP8 561 1,975 IL6R 634 668
BCL6 907 3,012 SOCS3 616 648
sCTLA4 81 262 CUL9 109 113
ATG16L1 244 788 CEBPB 136 140
LILRB2 42 134 PYCARD 463 470
C1QBP 1,750 5,544 NFKB1 695 699
IL32 121,206 381,165 TIGIT 77 76
PSMB9 1,647 5,142 TFRC 1,385 1,358
HLA-DQB1 7,806 24,339 UBE2L3 361 354
LTB4R2 30 93 NFATC3 740 714
ITGAE 161 495 B2M 161,096 153,262
TRAF5 40 121 STAT5B 830 770
ATG10 226 74 MBP 655 606
IKBKG 493 154 IL10RA 4,856 4,444
CD58 3,003 927 ENTPD1 88 79
IRF5 2,953 890 BST2 733 657
MAPK14 1,440 433 LCP2 980 828
CASP1 679 199 TICAM1 588 496
ITGAX 9,088 2,632 LTBR 1,000 841
CD45R0 6,370 1,829 CD164 5,779 4,847
IRF3 140 40 RAF1 1,146 945
GFI1 160 44 STAT6 1,950 1,607
IKBKB 486 134 TNFSF12 85 69
TGFBR1 1,133 290 TAGAP 234 186
CCR5 170 40 PLAUR 1,469 1,153
LY96 1,862 429 BTK 661 510
NFATC1 295 66 PSMC2 2,159 1,653
ETS1 202 45 CD46 2,664 2,033
TOLLIP 1,023 228 CCND3 698 522
TLR4 91 19 PTPN2 1,362 1,000
IGF2R 2,165 429 FCER1G 1,171 851
NOD1 220 43 AHR 8,004 5,721
CLEC7A 6,608 1,270 ICOSLG 939 658
NOTCH1 313 57 MAP4K2 517 362
IL4R 1,592 276 ATG5 684 475
ITGA5 1,518 259 CD4 2,701 1,863
CD59 15,947 2,713 STAT1 722 490
PTGS2 335 56 CHUK 951 646
CD81 14,546 2,396 SLC2A1 847 571
TRAF2 368 60 CD44 4,228 2,847
IFI16 6,377 909 PML 319 215
PSMB5 2,823 384 IKBKAP 128 85
TIRAP 58 8 SMAD5 303 200
SKI 1,423 189 CTNNB1 8,378 5,387
APP 8,951 1,166 HAVCR2 1,912 1,214
CCRL2 101 12 CCR6 215 136
IFNAR1 159 18 TRAF3 281 175
ATG7 535 60 CD99 5,823 3,631
CD53 14,726 1,614 PRKCD 509 309
CRADD 99 11 IRAK4 407 244
MR1 311 33 STAT3 1,601 948
TNF 3,320 349 TNFRSF14 1,112 652
CASP3 1,513 136 LILRB4 270 156
IL1R2 982 73 LITAF 3,584 2,072
CSF2RB 8,595 617 TRAF1 215 124
IRF4 9,572 632 IL6ST 979 563
FADD 81 4 IFI35 264 149
PPBP 1,688 72 TLR1 633 353
CD9 2,226 94 TMEM173 125 69
CD40 9,152 382 ZEB1 395 212
IL8 30,722 1,157 BAX 4,040 2,153
CXCR2 150 5 TBK1 825 439
CTSC 15,965 551 HRAS 96 49
CDKN1A 21,125 699 TCF4 779 391
CXCL1 7,859 231 TLR2 227 113
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Genes with >3 fold-change in expression between 
blood and in vitro DC
Genes with ≤3 fold-change in expression between 
blood and in vitro DC
Name
In vitro  
BDCA3+CLEC9A+ 
DC
Blood 
BDCA3+CLEC9A+ 
DC Name
In vitro 
BDCA3+CLEC9A+ 
DC
Blood 
BDCA3+CLEC9A+ 
DC
IL1RL2 185 5 SELPLG 149 71
IL13RA1 15,202 398 BATF3 7,262 3,367
CCL4 163 4 MAPK1 4,005 1,823
CARD9 1,441 28 TGFBR2 1,339 598
CD8A 422 8 PDCD2 278 121
LAMP3 1,119 17 SRC 898 374
PRDM1 3,543 53 FKBP5 2,270 898
CFI 1,305 18 TNFRSF11A 763 292
CD36 41,474 562 JAK2 3,039 1,114
CLEC4A 30,981 404 STAT5A 1,030 372
MAF 568 5 BCAP31 2,474 863
KCNJ2 697 6 ITGB1 5,641 1,913
IL1R1 675 5
CCR1 995 8
SPP1 198 2
LTA 554 4
IL1RN 174 1
GBP5 183 1
IL7R 190 1
CD80 907 4
IKZF2 204 1
PDGFB 247 1
FCER1A 27,731 97
SOCS1 1,786 6
SLAMF1 299 1
CXCL13 321 1
IL1RAP 6,977 21
C1QA 967 2
CD24 397 1
FCGR2A/C 2,552 6
CFH 477 1
CSF1 1,643 3
PTAFR 526 1
TAL1 3,998 7
CSF1R 553 1
BLNK 1,220 2
PLAU 4,983 8
CD274 895 1
FCGR2A 1,168 1
CCL22 1,285 1
CISH 1,295 1
PDCD1LG2 1,611 1
ITGAM 1,950 1
EGR2 2,545 1
MRC1 2,628 1
CD276 2,858 1
CD209 4,172 1
CCL13 7,478 1
C1QB 12,337 1
CD1A 58,820 1
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Abstract
Myeloid dendritic cells, which include BDCA1+ DCs and BDCA3hi DCs, play a pivotal role in 
the induction and regulation of immune responses. Interestingly, BDCA1+ DCs  also express 
low to intermediate levels of BDCA3. We have previously shown that BDCA3 expression on 
CD34+ progenitor cell-derived DCs is associated with an increased capacity to secrete IFN-λ, 
a hallmark of BDCA3hi DCs. This raised the question whether BDCA3+BDCA1+ DCs share also 
other traits with BDCA3hi DCs that are absent in BDCA3-BDCA1+ DCs or whether their higher 
capacity to secrete IFN-λ is a stand-alone observation.
Here, we used immunology-related gene expression analysis to determine divergence 
between BDCA3-expressing and BDCA3-negative BDCA1+ DCs and their relation to bona 
fide BDCA3hi DCs. Results showed that transcriptomic fingerprints of BDCA3+BDCA1+ DCs 
and BDCA3-BDCA1+ DCs are very similar, and clearly distinct from that of BDCA3
hi DCs. 
Differences in mRNA expression, however, were observed between BDCA3+BDCA1+ DCs and 
BDCA3-BDCA1+ DCs that pointed towards a more activated status of BDCA3
+BDCA1+ DCs. In 
line with this, higher maturation marker expression and inflammatory cytokine production 
by BDCA3+BDCA1+ DCs was observed. This dataset provides better insight into differences 
between myeloid DC populations and contributes to further study of DC immunobiology.
Comparison of BDCA3+ and BDCA3- dendritic cells
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Introduction
Dendritic cells (DCs) represent a family of professional antigen presenting cells (APC) that 
play a crucial role in the immune defense against infections and cancer. DCs are located 
in peripheral blood, lymphoid and non-lymphoid tissues, where they continuously sample 
the environment for invading pathogens. Recognition of foreign antigens by pathogen 
recognition receptors (PRR) induces activation of DCs and migration to secondary lymphoid 
organs where they activate naïve T cells. Activation of DCs induces upregulation of several 
surface receptors and production of  cytokines that enable DCs  to migrate and to interact 
with and instruct T cells and other immune cells [1]. 
The human DC family comprises several subsets diverging in ontogeny, localization 
and phenotype. Although all DC subsets share the functional capacity to induce T cell 
responses, they vary in their specialized immune functions. These DC subsets can be 
divided into BDCA2+BDCA4+ plasmacytoid DCs and myeloid DCs, which includes BDCA1+ 
DCs and BDCA3hiCLEC9A+XCR1+ DCs [2]. These markers, BDCA1, BDCA2, BDCA3 and BDCA4, 
are generally used to classify human DC. However, BDCA3 is not exclusively expressed by 
BDCA3hiCLEC9A+XCR1+ DCs (further referred to as BDCA3hi DCs), but also at intermediate 
levels by other DCs, such as BDCA1+ DCs in blood [3] (chapter 6), and even more so by 
BDCA1+ DCs in lymphoid tissues [4] and non-lymphoid tissues [5]. 
BDCA3, also known as CD141 or thrombomodulin, is a cell surface-expressed transmembrane 
glycoprotein. On vascular endothelial cells, BDCA3 is known for its anticoagulant activity, 
and has been described to have an anti-inflammatory function as it blocks pro-inflammatory 
proteins and activates anti-inflammatory proteins and inhibitors of the complement system 
[6, 7]. However, the exact function of BDCA3 expression on immune cells is not completely 
understood. Although BDCA1+ DCs have been shown to represent a subset that is distinct 
from BDCA3hi DCs [5, 8], we find that BDCA3+BDCA1+ DCs share a higher IFN-λ-producing 
capacity with BDCA3hi DCs, which is almost absent in BDCA3-BDCA1+ DCs. Here, we compared 
the immunology-related gene signature of BDCA3+BDCA1+ DCs, BDCA3-BDCA1+ DCs, and 
BDCA3hi DCs, and analyzed differences between BDCA3+ and BDCA3- DCs within the BDCA1+ 
DC population. Results showed that although BDCA3+BDCA1+ DCs and BDCA3-BDCA1+ DCs 
are highly comparable and distinct from bona fide BDCA3hi DCs, BDCA3-expressing BDCA1+ 
DCs have a more activated status than BDCA1+ DCs that do not express BDCA3, and as a 
result produce higher levels of cytokines. 
Materials and methods
Cell isolation
Peripheral blood mononuclear cells (PBMC) were isolated from heparinized peripheral 
blood samples or from buffy coats from healthy blood donors using Ficoll density gradient 
centrifugation. All healthy controls gave written informed consent before blood donation. 
Cells were enriched for DCs using Dynabeads (Thermo Fisher) and DC subsets were isolated 
based on BDCA1, BDCA3 and BDCA4 expression by FACSorting  using a FACSAria (BD 
Biosciences). 
Flow cytometric analysis
For phenotypic analysis, cells were washed with PBS containing 1% bovine serum albumin 
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(BSA; Sigma-Aldrich, St. Louis, MO), 1% heat inactivated human serum and 0.02% NaN3 
(Merck, Darmstadt, Germany; referred to as FACS buffer) and subsequently labeled with 
fluorochrome-conjugated antibodies (Abs). Labeling was performed during 30 minutes 
of incubation on ice with Abs recognizing BDCA3/CD141 (AD5-14H12, Miltenyi Biotec, 
Bergish Gladbach, Germany); BDCA1/CD1c (AD5-8E7, Miltenyi and L161, BioLegend) and 
BDCA4/CD304 (12C2, BioLegend). Fluorescence was measured using a FACS Canto II (BD 
Biosciences). 
Gene expression analysis using Nanostring nCounter system
RNA was extracted according to the manufacturer’s instructions using an RNAeasy Micro kit 
or a Nucleospin RNA II kit for samples containing <5x105 or >5x105 cells, respectively. RNA 
concentration and integrity was assessed using a Bioanalyzer system (Agilent Technologies). 
Human immunology-related genes were profiled using the nCounter GX Human Immunology 
v2 kit  Gene Expression CodeSet (Nanostring Technologies). Gene expression levels were 
normalized according to 15 housekeeping genes. Gene clustering analysis was performed 
using GENE-E software (http://www.broadinstitute.org/cancer/software/GENE-E/). Principal 
component analysis (PCA) was performed using MeV software. Geneset enrichment analysis 
was performed using GSEA software [9].
DC activation and cytokine secretion
FACSorted DCs were stimulated with or without polyI:C (20 µg/ml, Invivogen, Toulouse, 
France) for 24 hours at 37°C in the presence of 10 ng/ml GM-CSF. The levels of secreted 
human IL-1β, IL-6, IL8, and TNF-α were measured in the supernatant using a BD cytometric 
bead array human inflammatory cytokines kit (CBA, BD Biosciences) according to the 
manufacturer’s protocol. Detection limits were 7.2 pg/ml (IL-1β), 2.5 pg/ml (IL-6), 3.6 pg/ml 
(IL-8) and 3.7 pg/ml (TNFα).
Results
Immunology-related gene expression patterns of BDCA3+BDCA1+ DCs are similar to those 
of BDCA3-BDCA1+ DCs
To assess how BDCA3+BDCA1+ DCs relate to their BDCA3-negative counterpart, DC populations 
shown in Figure 1 were sorted and expression of immunology-related genes was analyzed 
(for complete list of gene expression values, see supplementary table 1). BDCA3 expression 
on BDCA1+ DCs was highly variable between donors and ranged from 41-85 % (Figure 1). 
Sample clustering and principal component analysis (PCA) revealed a high level of overlap 
between the immunology-related gene expression profile of BDCA3hi, BDCA3-BDCA1+ and 
BDCA3+BDCA1+ DC subtypes (Figure 2AB). BDCA1+BDCA3+ DCs and BDCA3-BDCA1+ DCs, 
however, appeared far more comparable to each other than to BDCA3hi DCs (Figure 2AB). 
Although BDCA1+ DCs and BDCA3+BDCA1+ DCs were found to be most similar, some minor 
differences in immunology-related gene expression levels were observed (Figure 2A). 
Comparison of BDCA3hi DCs and BDCA3+BDCA1+ DCs 
In total, 10 genes showed a trend towards differential expression between BDCA3+BDCA1+ 
DCs and BDCA3-BDCA1+ DCs by t-testing, but none survived multiple testing correction 
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(Table 1). Yet, we were interested to see whether these 10 genes were also higher expressed 
in bona fide BDCA3hi DCs. Interestingly, 9 genes were also differentially expressed between 
BDCA3-BDCA1+ DCs and BDCA3hi DCs (up in BDCA3hi DCs: SLAMF7, CD83, SRC, CXCR3, and 
down: CD99, STAT5A, PRKCD, CD4, IRF4), indicating that BDCA3 expression on BDCA1+ DCs 
is accompanied by a trend for higher expression of also other genes highly expressed on 
BDCA3hi DCs (Figure 3A). 
To further asses the overlap between genes differentially expressed between BDCA3hi DCs 
and BDCA3-BDCA1+ DCs, and those between BDCA3-expressing and BDCA3-lacking BDCA1+ 
DCs, we  used  Gene Set Enrichment Analysis (GSEA). First, two gene sets containing the top 
50 genes higher and lower expressed in BDCA3hi DCs were generated. For visual insight into 
the composition of the resulting gene sets, STRING network analysis was used (Figure 3BC). 
As expected, the BDCA3hi-overexpressed network contained the BDCA3hi DC hallmark genes 
TLR3, BATF3 and XCR1 [10], but also genes related to antigen (cross)-presentation (HLA 
genes, proteasome- and transporter-associated with antigen presentation subunits (TAP). 
The BDCA1+ DC network in contrast was centered around the pattern recognition receptor 
(PRR) TLR4 for bacterial recognition and ITGAM, the alpha subunit of the MAC-1 integrin 
heterodimer that facilitates phagocytosis [11-13]. 
Using GSEA we next analyzed and visualized how the genes in these BDCA3hi DC over-
expressed and lower-expressed gene sets are behaving in BDCA3+BDCA1+ DCs with respect 
Figure 1. Gating strategy of DC 
populations
(A) PBMC were isolated from healthy 
controls and enriched for DCs using 
a Dynabeads Human DC Enrichment 
kit. Duplicates were excluded based 
on size, and DC populations were 
subsequently identified as BDCA3hi 
cells, BDCA3+BDCA1+ cells and BDCA3-
BDCA1+ cells. Representative results 
of 3 different donors in 3 different 
experiments are shown.
Up Down
SLAMF7 CD99
CD83 TOLLIP
SRC STAT5A
IRF4 PRKCD
CXCR3
CD4
Table 1. Genes differentially  expressed in BDCA3+BDCA1+ DCs as compared to BDCA3-BDCA1+ DCs.
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to BDCA3-BDCA1+ DCs. Although GSEA showed that the majority of the BDCA3hi DC over-
expressed gene set was higher expressed in BDCA3+BDCA1+ DCs relative to BDCA1+ DCs 
lacking BDCA3, enrichment of the gene set was not high (NES 1,6; FDR q-value 0.285, Figure 
3D). Enrichment of the lower-expressed gene set in BDCA3-expressing BDCA1+ DCs was also 
present but even less apparent (FDR q-value 0.925, Figure 3E). 
Finally we assessed the expression of several established hallmark genes of either BDCA3hi 
DCs or BDCA1+ DCs. For these key genes, BDCA3-expressing BDCA1+ DCs behaved almost 
identical to their BDCA3-lacking counterparts and higher expression of BDCA3hi DC-
associated genes was not observed (Figure 3FG). In contrast, the BDCA1+ DC hallmark gene 
IRF4 was even higher expressed in BDCA3-expressing BDCA1+ DCs. Thus, although BDCA3hi 
DCs and BDCA3+BDCA1+ DCs are distinct populations, BDCA3+BDCA1+ DCs are slightly more 
similar to BDCA3hi DCs than their BDCA3- counterparts.
BDCA3+BDCA1+ DCs have a higher cytokine-producing capacity than BDCA3-BDCA1+ DCs
Enhanced expression of SLAMF7 [14], CD83, SRC [15], IRF4 [16], and CXCR3, as well as 
reduced expression of TOLLIP [17] suggest a more activated status and differential cytokine 
production by BDCA3+BDCA1+ DCs compared to BDCA3-BDCA1+ DCs. To further investigate 
this, the surface expression of activation markers by freshly isolated cells, and the cytokine-
producing capacity of the two cell types after in vitro TLR stimulation was assessed. Although 
CD83 and CD80 expression measured by flow cytometry was not significantly different 
between BDCA3-BDCA1+ DCs and BDCA3+BDCA1+ DCs, CD83 expression was consistently 
higher on BDCA3+BDCA1+ DCs (Figure 4A). However, CD40 and CD86 expression was 
significantly increased on BDCA3+BDCA1+ DCs, confirming a more activated status of these 
cells (Figure 4A). In addition, cytometric bead array analysis of cytokine production after 24 
hour polyI:C stimulation revealed that IL-6, IL-8, IL-1β and TNFα production was consistently 
Figure 2. Expression profiles of immunology-related genes 
mRNA isolated from sorted DC populations of 2-3 different donors was 
pooled per sample and gene expression levels were measured using the 
NanoString nCounter system. (A) Log2 expression levels of genes that were 
expressed in at least one of the three DC subtypes (expression level >50) are 
shown in a heatmap. Hierarchical clustering was performed using Pearson 
correlation. The black arrow indicates differential gene expression between 
BDCA3+BDCA1+ DCs and BDCA3-BDCA1+ DCs. (B) PCA was performed using 
the MeV software, based on genes expressed in at least one of the three DC 
subtypes (expression level >50). PC1 accounts for 52% and PC3 for 8% of the 
total variance. Each point represents a sample, classified by DC type. 
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Figure 3. Analysis of DC population gene signatures by GSEA
mRNA isolated from FACSorted DC populations of 2-3  different donors was pooled per sample. Gene expression 
levels were measured using the NanoString nCounter system. (A) The Venn diagram represents the number of 
genes significantly differentially expressed between the indicated DC populations (p<0.05 by unpaired t-test). (B-
C) String analysis of the top 50 genes that were significantly upregulated (B) or downregulated (C) in BDCA3hi DCs 
compared to BDCA3-BDCA1+ DCs (p<0.05 by unpaired t-test). (D-E) Enrichment plots of GSEA performed using 
the genesets shown in 3C and 3D, and a ranked list containing genes ranked by fold-change in expression values 
between BDCA3+BDCA1+ DCs compared to BDCA3-BDCA1+ DCs. The genesets were complemented by the curated 
C2 genesets published on software.broadinstitute.org to properly determine the normalized enrichment score 
(NES), nominal p-value (NOM p-val), and false discovery rate (FDR). (F-G) Normalized expression of hallmark genes 
of BDCA3hi DCs (F) or BDCA1+ DCs (G) by the different DC populations.
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higher for BDCA3+BDCA1+ DCs compared to BDCA3-BDCA1+ DCs (Figure 4B). TLR3 expression 
levels were not significantly different between BDCA3+BDCA1+ DCs and BDCA3-BDCA1+ DCs, 
indicating that a more abundant activation of TLR3 was likely not the underlying cause 
(Figure 3F). Together our data indicate that BDCA3+BDCA1+ DCs have an enhanced activation 
status, also reflected by a higher cytokine producing capacity as compared to their BDCA3- 
counterparts.
Discussion
Myeloid DCs include BDCA1+ DCs and BDCA3hi DCs. Since BDCA1+ DCs can co-express 
intermediate levels of BDCA3 in vivo, this study aimed to provide insight into the relation 
between BDCA3 expression and other immunology-related genes in BDCA1+ DCs, and whether 
this also endows these cells with a more BDCA3hi DC-like phenotype. Results confirmed that 
BDCA3-expressing BDCA1+ DCs are most similar to their BDCA3-lacking counterpart and 
are distinct from BDCA3hi DCs [5, 8]. BDCA3+BDCA1+ DCs are highly comparable to BDCA3-
BDCA1+ DCs, yet differences in gene expression and cytokine production that were observed 
suggested a more activated status of BDCA3+BDCA1+ DCs relative to BDCA3-BDCA1+ DCs. The 
more activated status of BDCA3-expressing BDCA1+ DCs was confirmed for several activation 
markers on cells directly after isolation, and also for inflammatory cytokines after further in 
vitro TLR activation. 
The association between BDCA3 expression in vivo and enhanced DC activation and 
Figure 4. BDCA3+BDCA1+ DCs produce higher 
cytokine levels than BDCA3-BDCA1+ DCs.
(A) Expression of the indicated markers by freshly 
isolated DC as measured by flow cytometry. Data 
of 2 independent experiments, performed with 
3 different donors are shown. *p<0.05, paired 
Student’s t-test. (B) BDCA3+BDCA1+ DCs and BDCA3-
BDCA1+ DCs were FACSorted from PBMCs enriched 
for DCs and stimulated for 24 hours with or without 
polyI:C. Mean±SEM cytokine levels as determined 
by CBA (n=5). Data are pooled from 5  independent 
experiments, each performed with a different 
donor. **p<0.01, paired Student’s t-test. 
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cytokine production is in line with an increase in BDCA3 expression on pDCs and BDCA1+ DCs 
upon maturation of these cells in vitro [18]. In addition, BDCA3 expression is upregulated 
on monocyte-like cells upon TNF-α and IL-1β stimulation [19], and also associated with 
increased IFN-λ-producing capacity by CD34+-derived DCs [20]. BDCA3 is also higher 
expressed on BDCA1+ DCs in peripheral tissues compared to BDCA1+ DCs in peripheral blood 
[5]. Previously, functional comparison of BDCA3+ and BDCA3- monocyte-derived DC (moDC) 
showed that BDCA3+ moDC induced a more strongly Th2-polarized response compared 
to BDCA3- moDC [21]. Since BDCA3 has been described to exhibit direct and indirect 
anti-inflammatory functions [6, 7, 22], it is tempting to speculate that although BDCA3 is 
expressed on more activated DCs, BDCA3 may play a role in dampening and/or balancing 
pro-inflammatory responses.
The gene expression dataset presented here is valuable for the study of DC immunobiology, 
as it provides useful information regarding phenotypic, functional and developmental 
characteristics of the different DC subpopulations and the relation of the marker BDCA3 to 
cell function. Nevertheless, further research is required to determine the exact function of 
BDCA3 expression on BDCA1+ DCs or other DC subsets.
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Supplementary table 1. Expression levels of immunology-related genes of DC 
subpopulations.
Name BDCA3
hi 
DCs
BDCA3hi 
DCs
BDCA3hi 
DCs
BDCA3+ 
BDCA1+ 
DCs
BDCA3+ 
BDCA1+ 
DCs
BDCA3+ 
BDCA1+ 
DCs
BDCA3-
BDCA1+ 
DCs
BDCA3-
BDCA1+ 
DCs
BDCA3-
BDCA1+ 
DCs
ABCB1 1 1 1 1 10 7 2 12 1
ABL1 1558 1484 1488 589 688 704 689 753 579
ADA 430 373 400 218 321 301 166 226 202
AHR 6451 6495 4216 2166 6662 4615 5716 7650 2256
AICDA 1 1 1 1 1 1 1 1 1
AIRE 27 28 21 30 24 1 16 14 17
APP 1031 1308 1158 1389 1389 1354 1225 1322 1515
ARG1 13 1 11 1 7 1 1 2 10
ARG2 1 1 1 1 1 1 1 1 1
ARHGDIB 6746 6822 7481 6681 6609 4972 6000 5630 7130
ATG10 81 63 79 71 61 108 81 65 103
ATG12 61 82 78 125 75 108 111 90 117
ATG16L1 784 878 702 417 405 682 473 523 450
ATG5 516 502 408 509 614 635 540 621 449
ATG7 96 27 57 112 116 259 147 215 196
ATM 18 1 1 1 1 1 3 8 1
B2M 149514 167143 143130 138462 142270 121460 158637 148017 127355
B3GAT1 3 1 1 1 3 1 1 4 1
BATF 8 1 1 3 7 15 28 31 34
BATF3 3470 2867 3763 738 758 369 704 619 601
BAX 1861 2322 2275 2816 2756 2072 2471 2512 2747
BCAP31 798 843 949 1106 947 811 947 872 1158
BCL10 2737 2489 2347 2077 2320 2289 2302 2698 1980
BCL2 121 137 161 199 328 215 222 280 207
BCL2L11 435 404 307 105 207 301 202 232 115
BCL3 869 749 713 645 1562 1180 1029 1493 870
BCL6 2617 2576 3842 1381 2613 1676 2213 2226 1113
BID 67 1 33 99 79 105 53 86 85
BLNK 4 1 1 40 53 49 50 61 69
BST1 51 9 28 282 249 454 487 425 715
BST2 652 604 713 588 584 494 539 530 601
BTK 529 426 575 752 814 718 615 637 820
BTLA 1394 949 1064 23 53 17 27 66 13
C14orf166 5415 5246 4731 4612 4475 4784 4422 5009 4045
C1QA 5 1 1 13 7 1 10 1 13
C1QB 1 1 1 11 19 17 26 25 5
C1QBP 5524 5369 5740 4754 3617 3289 4139 3700 4290
C1R 1 1 1 13 3 12 9 22 47
C1S 29 1 1 1 7 2 10 6 5
C2 9 1 1 1 10 1 1 11 6
C3 1 1 1 1 1 1 1 1 1
C4A/B 3 1 1 1 1 1 1 1 1
C4BPA 15 1 1 1 1 1 1 1 5
C5 105 50 66 52 94 110 44 67 54
C6 37 27 12 18 3 1 12 15 17
C7 1 1 1 1 1 1 1 1 1
C8A 37 38 11 1 1 1 11 8 1
C8B 1 1 1 1 1 1 2 1 3
C8G 1 1 1 1 1 1 1 1 2
C9 1 1 1 1 1 1 1 1 11
CAMP 113 74 64 1 7 7 27 11 58
CARD9 44 1 38 122 143 169 122 146 119
CASP1 265 223 108 4361 4223 4476 3556 4490 3961
CASP10 1 1 1 1 1 1 9 7 1
CASP2 702 565 663 344 324 347 372 428 330
CASP3 176 109 123 156 142 151 111 188 138
CASP8 2473 1905 1548 918 1580 3193 1879 2485 1148
CCBP2 1 1 1 1 1 1 1 2 1
CCL11 1 1 1 1 3 1 2 1 10
CCL13 1 1 1 1 1 1 1 1 1
CCL15 5 1 1 1 1 1 2 1 1
CCL16 1 1 1 1 1 1 1 1 1
CCL18 1 1 1 1 1 1 1 1 1
CCL19 9 1 1 1 1 1 26 2 11
CCL2 1 1 1 1 1 1 1 1 1
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Name BDCA3
hi 
DCs
BDCA3hi 
DCs
BDCA3hi 
DCs
BDCA3+ 
BDCA1+ 
DCs
BDCA3+ 
BDCA1+ 
DCs
BDCA3+ 
BDCA1+ 
DCs
BDCA3-
BDCA1+ 
DCs
BDCA3-
BDCA1+ 
DCs
BDCA3-
BDCA1+ 
DCs
CCL20 1 1 1 1 1 1 1 1 1
CCL22 1 1 1 1 1 5 11 2 1
CCL23 1 1 1 1 1 1 1 1 1
CCL24 1 1 1 1 9 1 1 6 1
CCL26 9 1 1 1 1 1 1 1 1
CCL3 1 1 1 33 1 5 13 1 25
CCL4 10 1 1 9 1 1 11 1 5
CCL5 1 1 1 64 31 20 93 48 115
CCL7 1 1 1 1 1 1 1 1 1
CCL8 1 1 1 1 1 1 1 1 1
CCND3 447 548 572 697 906 775 759 897 1433
CCR1 18 1 5 19 142 110 119 137 48
CCR10 30 1 4 6 5 1 3 11 19
CCR2 1 1 1 31 61 64 73 100 65
CCR5 66 33 20 117 328 147 223 383 106
CCR6 146 164 98 140 152 44 101 179 145
CCR7 1 1 1 1 3 1 1 12 1
CCR8 1 1 1 1 1 1 1 1 1
CCRL1 1 1 1 1 1 1 1 1 1
CCRL2 24 11 1 51 55 51 92 67 61
CD14 1 1 1 23 32 22 9 28 57
CD160 3 1 1 1 1 1 1 1 1
CD163 1 1 1 158 394 638 348 650 387
CD164 5979 4764 3796 4346 4960 5495 4673 5491 4280
CD19 5 1 1 7 12 1 18 64 18
CD1A 1 1 1 65 119 73 37 108 89
CD1D 117 1 15 920 1871 1661 1100 2374 1089
CD2 1 1 1 34 109 115 61 108 73
CD209 1 1 1 4 10 12 11 21 33
CD22 197 227 203 185 94 151 91 190 182
CD24 1 1 1 1 5 1 11 48 25
CD244 128 58 43 513 413 775 610 647 829
CD247 20 1 7 9 3 1 7 3 13
CD27 8 1 1 1 1 1 1 11 1
CD274 1 1 1 1 1 1 1 1 1
CD276 1 1 1 1 1 1 1 1 1
CD28 1 1 1 1 1 1 1 1 1
CD34 1 1 1 1 1 1 1 1 1
CD36 727 582 378 1889 1917 3037 2017 2736 2712
CD3D 1 1 1 1 1 1 1 1 1
CD3E 47 44 26 37 15 20 27 34 45
CD3EAP 1 1 1 1 1 1 1 1 2
CD4 1352 1894 2342 5544 5492 5033 4801 4220 4840
CD40 409 368 368 65 191 88 105 149 39
CD40LG 6 1 1 1 1 1 1 1 1
CD44 2833 2867 2840 4650 6250 6125 6072 5804 5016
CD45R0 2832 1358 1297 1626 2333 2612 1453 2830 1484
CD45RA 814 546 586 1385 1589 1510 1018 1511 906
CD45RB 1289 768 914 1557 2157 2043 1261 1893 1404
CD46 2581 1854 1666 1510 1918 2526 1635 2548 1434
CD48 5964 7929 4989 5967 5259 5285 6934 5178 5630
CD5 554 261 120 394 2316 376 177 732 183
CD53 2123 1312 1406 3128 4405 3838 2802 4291 2975
CD55 1 1 1 1 1 1 1 2 2
CD58 1071 861 850 940 1039 1109 921 1412 997
CD59 2489 2741 2909 810 806 494 989 790 627
CD6 1 1 1 7 26 1 8 12 7
CD7 1 1 1 1 1 1 1 1 1
CD70 1 1 1 1 1 1 1 1 5
CD74 153660 196746 220758 145198 151766 102750 119246 110752 119836
CD79A 38 39 45 1 1 12 163 489 173
CD79B 13 1 5 72 77 61 81 174 119
CD80 11 1 1 2 1 1 2 15 22
CD81 2049 2464 2674 917 944 955 1168 810 962
CD82 37 2 14 1 1 1 13 28 12
CD83 25752 25431 21803 12421 15918 14901 10599 10461 7169
CD86 1261 966 998 2091 2572 2463 1845 2753 2002
CD8A 19 2 2 1 2 1 6 8 2
CD8B 1 1 1 1 1 1 1 1 1
CD9 79 186 19 1 108 7 9 139 21
CD96 11 1 1 1 5 1 4 12 1
CD97 547 474 498 1301 1700 1481 1237 1642 1333
CD99 3409 4070 3415 4569 5003 4755 7748 6301 7539
CDH5 1 1 1 1 1 1 1 1 1
CDKN1A 878 927 294 2620 4868 6931 5363 5331 3340
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Name BDCA3
hi 
DCs
BDCA3hi 
DCs
BDCA3hi 
DCs
BDCA3+ 
BDCA1+ 
DCs
BDCA3+ 
BDCA1+ 
DCs
BDCA3+ 
BDCA1+ 
DCs
BDCA3-
BDCA1+ 
DCs
BDCA3-
BDCA1+ 
DCs
BDCA3-
BDCA1+ 
DCs
CEACAM1 61 17 25 2 14 7 24 15 3
CEACAM6 10 1 1 1 1 2 1 1 35
CEACAM8 1 1 1 1 1 1 3 1 30
CEBPB 171 154 94 1387 3142 3843 2468 3914 2092
CFB 167 172 116 36 41 42 63 47 24
CFD 46 8 42 164 49 49 66 64 308
CFH 1 1 1 1 1 1 6 2 1
CFI 28 24 2 17 2 1 18 8 18
CFP 1300 991 1086 4360 4607 5380 4585 4402 5625
CHUK 893 599 445 410 824 1253 686 1068 427
CIITA 2485 1606 2253 2069 2994 2433 2077 3201 2299
CISH 1 1 1 7 14 1 28 21 27
CLEC4A 462 382 369 3566 2727 3169 3051 2646 3433
CLEC4E 1 1 1 1 5 27 1 38 1
CLEC5A 79 107 98 59 68 32 82 59 68
CLEC6A 1 1 1 1 12 29 15 43 1
CLEC7A 1638 1306 867 313 369 645 401 497 158
CLU 6 1 1 1 1 1 1 2 1
CMKLR1 14 1 1 1 1 1 1 1 1
CR1 14 1 1 117 184 129 200 287 113
CR2 9 1 1 1 1 1 1 4 1
CRADD 22 1 10 1 12 5 1 7 14
CSF1 8 1 1 1 1 1 4 1 1
CSF1R 1 1 1 37 92 68 49 80 77
CSF2 1 1 1 1 1 1 1 1 1
CSF2RB 570 625 655 753 1128 1422 814 1166 902
CSF3R 376 373 316 1190 1538 2258 1878 2123 1871
CTLA4_all 492 390 74 96 312 120 101 179 30
CTLA4-TM 84 77 4 10 44 34 3 34 1
CTNNB1 6382 5592 4189 6239 8899 11969 8108 11142 6839
CTSC 575 475 604 1573 1295 1268 1263 1484 1810
CTSG 1 1 1 1 2 1 1 1 44
CTSS 11954 10241 10210 23564 20700 25608 20128 24279 24646
CUL9 138 82 118 110 154 137 133 171 118
CX3CL1 1 1 1 1 1 1 1 1 1
CX3CR1 8 1 1 96 121 88 91 172 96
CXCL1 244 278 171 114 90 73 104 90 74
CXCL10 1 1 1 1 1 1 12 1 1
CXCL11 15 8 24 9 5 22 10 19 20
CXCL12 1 1 1 1 1 1 1 1 1
CXCL13 1 1 1 1 1 1 1 1 1
CXCL2 525 403 90 88 367 208 166 307 90
CXCL9 63 231 31 1 7 7 36 21 1
CXCR1 1 1 1 1 1 1 1 1 1
CXCR2 14 1 1 1 1 2 7 1 1
CXCR3 613 768 576 37 65 49 31 22 25
CXCR4 26819 25941 13507 26600 37951 38474 27786 35839 20939
CXCR6 1 1 1 1 1 1 1 1 1
CYBB 32 16 10 1428 1731 2008 1516 1852 1541
DEFB1 1 1 1 1 1 1 1 1 1
DEFB103A 1 1 1 1 1 1 1 1 1
DEFB103B 1 1 1 1 1 1 1 1 1
DEFB4A 1 1 1 1 1 1 1 1 1
DPP4 1233 1179 1314 84 85 17 61 46 43
DUSP4 7852 4157 1478 332 2142 2047 620 892 116
EBI3 20 27 19 29 26 20 29 39 28
EDNRB 1 1 1 1 1 1 1 1 1
EGR1 1 1 1 10 1 1 11 1 1
EGR2 1 1 1 1 1 1 1 1 1
ENTPD1 105 46 87 158 138 200 110 153 94
EOMES 14 5 1 1 2 1 7 4 1
ETS1 74 17 45 21 26 15 47 138 49
FADD 5 6 1 8 1 10 2 3 5
FAS 1 1 1 1 1 10 13 2 1
FCAR 1 1 1 1 1 1 1 1 1
FCER1A 151 121 19 25017 28343 32749 25735 44590 39350
FCER1G 987 741 825 3275 3545 3056 2905 3084 3218
FCGR1A/B 1 1 1 1 1 1 1 1 1
FCGR2A 1 1 1 1075 1502 2067 913 2017 1365
FCGR2A/C 16 1 1 4669 3917 3293 4278 7397 4984
FCGR2B 1 1 1 4157 1782 2692 2010 2655 4491
FCGR3A/B 1 1 1 1 1 1 1 1 1
FCGRT 6269 7472 8221 7301 7233 6536 7192 6855 8421
FKBP5 1062 727 904 1108 1410 1556 1014 1681 1085
FN1 1 1 1 1 1 1 1 1 1
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Name BDCA3
hi 
DCs
BDCA3hi 
DCs
BDCA3hi 
DCs
BDCA3+ 
BDCA1+ 
DCs
BDCA3+ 
BDCA1+ 
DCs
BDCA3+ 
BDCA1+ 
DCs
BDCA3-
BDCA1+ 
DCs
BDCA3-
BDCA1+ 
DCs
BDCA3-
BDCA1+ 
DCs
FOXP3 1 1 1 1 1 1 1 1 1
FYN 2030 1718 1904 1762 1714 1771 1608 1778 1906
GATA3 9 1 1 1 1 1 1 1 1
GBP1 11 1 1 194 338 323 376 402 156
GBP5 1 1 1 5 67 2 32 75 24
GFI1 56 33 45 31 38 39 55 58 47
GNLY 3 1 1 1 1 1 1 1 1
GP1BB 4 1 1 1 1 1 1 14 4
GPI 1114 1127 1130 1513 1601 1371 1375 1259 1557
GPR183 10349 6357 2843 7805 13349 15774 9314 10392 5417
GZMA 4 1 1 1 1 1 3 1 1
GZMB 14 25 1 1 10 10 1 8 1
GZMK 1 1 1 1 1 1 1 1 1
HAMP 5 1 1 1 1 1 1 1 5
HAVCR2 1632 968 1042 580 969 943 527 908 605
HFE 5 1 1 2 17 2 11 15 6
HLA-A 18780 28794 28868 17638 14289 11654 20992 15981 17686
HLA-B 20021 27192 17648 9551 17368 12035 17598 15025 9247
HLA-C 5699 4766 4754 3537 5856 3528 3564 4813 3127
HLA-DMA 14537 15387 16582 15959 14247 10696 12779 12323 13919
HLA-DMB 10704 9118 9835 10063 9191 8835 8961 9793 9298
HLA-DOB 4727 4311 5986 1403 1087 264 706 646 603
HLA-DPA1 217309 271098 303311 255680 156521 94214 152174 128553 176598
HLA-DPB1 216975 235797 251256 229957 174910 114275 144279 140283 157198
HLA-DQA1 31227 87266 46926 53495 40859 621 86353 33012 39551
HLA-DQB1 13793 31082 28144 26612 13385 195 24451 9606 20868
HLA-DRA 137443 162190 170337 180409 139366 94438 130622 114661 123809
HLA-DRB1 32660 64174 69796 62116 18331 7882 50209 15201 47787
HLA-DRB3 66446 87790 97677 81474 58261 40853 58407 43727 60881
HRAS 69 36 42 42 46 73 47 55 55
ICAM1 3126 3861 3879 1874 2084 2319 2661 2234 1834
ICAM2 126 71 76 220 237 217 172 240 245
ICAM3 7860 7935 8397 6214 5047 5048 6247 4410 6850
ICAM4 57 25 27 20 65 2 29 41 61
ICAM5 1 1 1 1 1 1 1 1 1
ICOS 4 1 1 1 1 1 5 1 1
ICOSLG 851 452 673 260 754 926 424 793 314
IDO1 7955 8235 6418 133 265 34 90 73 21
IFI16 1318 640 769 469 732 809 542 964 464
IFI35 197 109 141 145 147 95 107 156 117
IFIH1 256 305 275 169 178 210 259 252 179
IFIT2 24 11 1 22 24 1 98 54 10
IFITM1 134 124 22 983 3248 941 2736 2537 680
IFNA1/13 3 1 1 1 1 1 1 1 1
IFNA2 1 1 1 1 1 1 1 1 1
IFNAR1 37 8 10 16 29 10 22 48 30
IFNAR2 2119 1490 2000 1594 2156 1928 1469 2277 1613
IFNB1 23 1 1 1 1 1 1 1 1
IFNG 1 1 1 1 2 1 1 1 1
IFNGR1 4695 3808 4023 4368 4398 6176 3354 5596 3773
IGF2R 412 444 430 93 174 100 126 187 73
IKBKAP 128 27 102 40 75 68 51 70 65
IKBKB 195 83 124 183 191 318 197 266 207
IKBKE 8 1 1 1 12 17 2 23 24
IKBKG 176 124 162 178 179 151 170 215 194
IKZF1 161 127 162 153 181 132 171 217 171
IKZF2 1 1 1 1 1 1 1 7 1
IKZF3 1 1 1 1 1 1 1 44 6
IL10 1 1 1 1 1 10 5 2 1
IL10RA 4208 4558 4564 4387 5047 4671 4985 5828 4813
IL11RA 11 1 1 1 3 7 5 11 2
IL12A 1 1 1 1 9 12 15 25 4
IL12B 5 1 1 3 1 1 1 3 6
IL12RB1 38 20 24 146 155 144 156 101 113
IL13 25 6 1 4 1 5 21 17 19
IL13RA1 473 444 277 5668 6201 6963 5918 7302 5629
IL15 10 6 1 1 26 27 24 52 10
IL16 3339 2513 3049 2991 2349 2006 1780 2006 2404
IL17A 11 1 1 1 1 1 1 1 1
IL17B 14 1 1 1 1 1 1 1 1
IL17F 1 1 1 1 1 1 1 1 1
IL18 414 345 318 779 739 1205 791 756 782
IL18R1 840 762 538 462 591 384 747 514 313
IL18RAP 36 19 17 9 20 15 11 14 12
IL19 1 1 1 1 1 1 1 1 1
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Name BDCA3
hi 
DCs
BDCA3hi 
DCs
BDCA3hi 
DCs
BDCA3+ 
BDCA1+ 
DCs
BDCA3+ 
BDCA1+ 
DCs
BDCA3+ 
BDCA1+ 
DCs
BDCA3-
BDCA1+ 
DCs
BDCA3-
BDCA1+ 
DCs
BDCA3-
BDCA1+ 
DCs
IL1A 1 1 1 1 1 1 1 1 1
IL1B 1 1 1 73 87 318 51 42 43
IL1R1 1 14 1 70 113 44 54 131 59
IL1R2 85 80 53 677 674 320 380 533 369
IL1RAP 57 5 2 61 138 330 102 174 127
IL1RL1 55 57 52 38 53 22 38 31 42
IL1RL2 10 1 4 1 12 1 1 1 1
IL1RN 1 1 1 91 90 164 114 138 226
IL2 1 1 1 1 1 1 4 1 4
IL20 1 1 1 1 1 1 1 1 1
IL21 1 1 1 1 1 1 1 1 1
IL21R 4 1 1 1 20 1 19 38 16
IL22 1 1 1 1 1 1 1 1 1
IL22RA2 1 1 1 1 1 1 1 1 1
IL23A 4 1 1 1 17 17 11 15 7
IL23R 1 1 1 1 1 1 1 1 2
IL26 5 1 1 1 2 1 10 1 1
IL27 1 1 1 1 1 1 1 1 1
IL28A 1 1 1 1 10 1 3 1 4
IL28A/B 1 1 1 1 1 1 1 1 1
IL29 1 1 1 1 1 1 1 1 1
IL2RA 1 1 1 1 1 1 1 1 1
IL2RB 18 1 1 19 3 1 12 21 36
IL2RG 2705 2502 3202 3403 4916 3039 3664 4151 3037
IL3 1 1 1 1 1 1 1 1 1
IL32 357660 481697 304138 119431 192060 168937 181585 105815 47647
IL4 20 1 1 1 1 1 11 4 5
IL4R 250 261 316 446 461 391 449 618 550
IL5 1 1 1 1 1 1 1 1 2
IL6 1 1 1 1 1 1 4 5 6
IL6R 658 560 785 819 739 784 777 806 1060
IL6ST 771 607 310 370 553 987 765 920 303
IL7 1 1 1 10 22 15 48 25 33
IL7R 1 1 1 1 1 1 1 1 1
IL8 1590 1566 317 1084 922 1517 831 495 510
IL9 1 1 1 1 1 1 1 1 1
ILF3 4650 4539 4475 3329 4521 5150 3758 4816 3217
IRAK1 468 532 515 500 628 479 545 535 527
IRAK2 307 456 375 69 48 49 54 67 66
IRAK3 5 3 1 270 372 398 289 526 321
IRAK4 244 253 234 247 321 364 272 376 278
IRF1 1308 1912 341 549 1458 2729 3203 1686 570
IRF3 60 3 57 41 46 17 32 51 47
IRF4 685 824 385 2814 5015 4513 1798 2506 1535
IRF5 766 950 954 645 522 601 795 576 718
IRF7 270 211 197 241 430 335 314 335 258
IRF8 13770 7243 11482 802 992 2099 1515 1172 855
IRGM 1 1 1 1 1 1 1 1 1
ITGA2B 23 1 15 1 5 1 1 11 7
ITGA4 1718 1523 1367 1500 1857 2157 1503 1722 1063
ITGA5 264 230 282 347 526 462 430 694 533
ITGA6 30 1 25 1 1 1 3 1 1
ITGAE 400 592 493 977 659 674 1144 701 1087
ITGAL 2022 1756 1852 1089 1171 1312 1235 903 1133
ITGAM 1 1 1 215 746 347 437 661 282
ITGAX 2103 2868 2926 6538 9143 6778 7320 8474 6308
ITGB1 2126 1842 1771 1196 1323 1669 1311 1552 1074
ITGB2 5846 6664 8761 10511 9860 6712 8529 8412 11010
ITLN1 1 1 1 1 1 1 1 1 2
ITLN2 1 1 1 1 1 1 1 1 1
JAK1 1547 1345 1605 1651 2053 1766 1522 1921 1457
JAK2 1383 994 966 1386 1627 1818 1715 2082 1351
JAK3 308 198 391 465 867 423 455 730 503
KCNJ2 15 1 1 1 14 1 20 20 6
KIR_Acti-
vating_Sub-
group_1
27 1 19 1 3 1 11 18 21
KIR_Acti-
vating_Sub-
group_2
3 1 1 1 9 1 2 1 1
KIR_Inhib-
iting_Sub-
group_1
1 1 1 1 1 1 1 1 1
Comparison of BDCA3+ and BDCA3- dendritic cells
5
125
Name BDCA3
hi 
DCs
BDCA3hi 
DCs
BDCA3hi 
DCs
BDCA3+ 
BDCA1+ 
DCs
BDCA3+ 
BDCA1+ 
DCs
BDCA3+ 
BDCA1+ 
DCs
BDCA3-
BDCA1+ 
DCs
BDCA3-
BDCA1+ 
DCs
BDCA3-
BDCA1+ 
DCs
KIR_Inhib-
iting_Sub-
group_2
1 1 1 1 1 1 1 1 1
KIR3DL1 1 1 1 1 1 1 1 3 1
KIR3DL2 1 1 1 1 1 1 1 1 1
KIR3DL3 1 1 1 1 1 1 1 1 1
KIT 556 491 637 260 164 95 127 116 97
KLRAP1 1 1 1 1 1 1 1 1 1
KLRB1 1 1 1 1 1 1 1 1 1
KLRC1 3 1 1 1 1 1 1 14 1
KLRC2 10 2 1 10 9 1 7 8 26
KLRC3 1 1 1 1 1 1 1 1 1
KLRC4 22 1 6 1 1 20 1 5 5
KLRD1 1 1 1 1 1 1 1 1 1
KLRF1 4 1 2 13 1 1 16 1 16
KLRF2 1 1 1 1 1 1 1 1 1
KLRG1 20 80 37 1 1 1 35 7 6
KLRG2 1 1 1 1 1 1 1 1 1
KLRK1 4 14 1 1 1 1 1 1 1
LAG3 25 38 9 10 2 12 13 9 33
LAIR1 13 16 1 120 133 169 93 107 69
LAMP3 23 14 14 80 41 12 78 114 12
LCK 1 1 1 1 1 1 1 1 1
LCP2 926 730 829 1334 1773 2270 2043 1987 1357
LEF1 1 1 1 1 1 1 1 1 1
LGALS3 2279 2368 1874 4595 3840 5114 4639 4504 5192
LIF 1 1 1 1 1 5 1 1 1
LILRA1 33 47 11 339 386 264 303 291 216
LILRA2 363 313 245 1202 942 828 1056 848 1129
LILRA3 1 1 1 17 41 34 36 59 44
LILRA4 235 172 229 59 75 7 2 22 27
LILRA5 458 247 113 1076 2364 1564 801 1895 997
LILRA6 36 9 6 23 55 37 82 97 45
LILRB1 13 25 19 487 611 364 322 454 328
LILRB2 157 138 105 803 1101 926 890 1004 870
LILRB3 28 1 6 835 1101 643 906 1426 836
LILRB4 188 183 99 1057 1628 1410 1539 1718 1373
LILRB5 1 1 1 1 1 1 1 1 6
LITAF 2587 1710 1919 3403 3917 3501 1812 3293 3329
LTA 9 1 1 1 1 1 1 5 1
LTB4R 98 94 115 168 253 213 152 213 214
LTB4R2 100 104 74 71 137 288 147 169 100
LTBR 897 729 897 1070 1074 1036 1025 1158 1222
LTF 16 6 12 1 1 1 7 1 81
LY96 463 393 431 648 628 750 740 725 678
MAF 14 1 1 1 1 1 2 5 1
MALT1 1580 1045 768 1853 3267 4119 2165 3380 1773
MAP4K1 1960 2141 2073 1961 2050 1674 2096 1903 2006
MAP4K2 332 368 385 284 306 247 291 350 305
MAP4K4 967 928 788 679 1166 826 802 1291 598
MAPK1 2020 1646 1805 1832 2023 1752 1458 2058 1876
MAPK11 8 16 2 1 26 1 6 23 9
MAPK14 595 301 403 346 592 792 396 897 450
MAPKAPK2 1800 2011 1469 1311 1755 2087 1886 1566 1379
MARCO 20 2 1 42 77 125 146 132 68
MASP1 1 1 1 1 1 1 1 1 1
MASP2 1 1 1 1 1 1 1 1 1
MBL2 1 1 1 1 1 1 1 1 2
MBP 729 434 653 637 715 332 292 654 594
MCL1 80775 55950 40348 32892 67842 66998 50769 66430 25839
MIF 2395 2848 2288 1858 1937 1412 1797 1437 1572
MME 1 1 1 1 1 1 1 1 1
MR1 53 20 26 75 68 86 84 97 73
MRC1 1 1 1 233 1000 166 391 1363 248
MS4A1 4 1 1 1 1 1 79 414 37
MSR1 20 1 1 213 422 516 39 366 73
MUC1 1 1 1 1 5 1 1 1 1
MX1 1387 1083 687 743 1285 1016 1084 1464 710
MYD88 5388 4480 4258 4548 5404 4083 3789 4428 4026
NCAM1 42 1 1 1 7 5 7 1 1
NCF4 384 307 399 327 213 442 292 286 419
NCR1 1 1 1 1 1 1 1 1 1
NFATC1 82 71 45 40 116 73 93 151 82
NFATC2 1794 1336 1527 787 1360 948 961 1144 670
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Name BDCA3
hi 
DCs
BDCA3hi 
DCs
BDCA3hi 
DCs
BDCA3+ 
BDCA1+ 
DCs
BDCA3+ 
BDCA1+ 
DCs
BDCA3+ 
BDCA1+ 
DCs
BDCA3-
BDCA1+ 
DCs
BDCA3-
BDCA1+ 
DCs
BDCA3-
BDCA1+ 
DCs
NFATC3 764 574 803 667 713 628 672 789 608
NFIL3 3319 2875 1701 2446 5417 7146 5989 6388 2649
NFKB1 741 847 509 532 956 1024 827 959 546
NFKB2 444 382 421 334 485 696 386 579 383
NFKBIA 16584 27076 34282 15057 12710 19998 19122 17645 18461
NFKBIZ 1304 1263 1556 1327 2197 2411 1354 2184 986
NLRP3 1102 1084 529 1306 2898 3435 2024 2901 1131
NOD1 30 33 67 59 87 81 78 67 49
NOD2 221 222 229 934 1214 1732 1419 1742 1388
NOS2 1 1 1 1 1 1 1 1 1
NOTCH1 63 25 82 32 106 271 70 84 71
NOTCH2 1311 1023 1381 1045 1500 1104 1169 1457 1020
NT5E 152 104 104 124 44 49 71 103 119
PAX5 1 1 1 1 1 1 7 54 1
PDCD1 1 1 1 1 1 1 1 2 1
PDCD1LG2 1 1 1 1 1 1 1 11 1
PDCD2 123 120 121 131 150 110 115 154 119
PDGFB 1 1 1 1 1 1 1 1 1
PDGFRB 1 1 1 1 1 1 1 1 1
PECAM1 2719 2527 2800 2454 2140 2504 2228 2504 2767
PIGR 1 1 1 22 1 15 1 1 16
PLA2G2A 19 1 9 1 1 1 1 1 1
PLA2G2E 46 44 41 32 17 10 45 28 40
PLAU 22 1 1 202 181 232 239 225 246
PLAUR 1605 1079 774 3424 4547 5294 3411 3954 3902
PML 245 222 177 171 321 310 326 336 218
POU2F2 478 409 456 493 742 650 762 815 526
PPARG 1 1 1 1 1 1 1 1 1
PPBP 5 96 115 189 67 1 81 118 199
PRDM1 69 72 17 254 459 1170 456 444 196
PRF1 5 1 1 1 3 1 6 3 13
PRKCD 324 278 326 575 568 594 678 682 830
PSMB10 1360 1342 1441 1562 1601 1200 1279 1232 1382
PSMB5 435 365 351 314 300 252 291 319 328
PSMB7 4225 4173 4029 4674 3951 4298 4318 4052 4632
PSMB8 5616 5170 4895 2985 2994 2873 3729 2926 3099
PSMB9 4981 4637 5809 2257 2099 1581 2194 1799 2071
PSMC2 1838 1630 1491 1374 1396 1715 1514 1518 1370
PSMD7 3566 3251 3580 3868 3620 3489 3801 4215 3918
PTAFR 1 1 1 71 111 44 53 133 61
PTGER4 879 719 754 994 1398 796 1052 763 616
PTGS2 113 39 15 784 1220 2211 928 894 469
PTK2 1879 1396 1494 178 416 191 299 386 179
PTPN2 1222 983 794 738 997 1065 792 1093 733
PTPN22 1610 991 956 559 541 845 511 714 416
PTPN6 2390 1803 2251 3148 2900 3120 2501 2879 3287
PTPRC_all 12026 5579 5411 7740 10833 13653 7079 13153 6217
PYCARD 454 445 512 444 411 298 358 355 439
RAF1 1144 807 883 730 946 1354 917 1277 819
RAG1 1 1 1 1 1 1 1 1 1
RAG2 41 19 6 10 1 1 1 12 3
RARRES3 65 69 47 390 394 237 382 317 317
RELA 463 562 523 570 645 669 618 656 576
RELB 552 618 652 479 637 594 682 596 543
RORC 1 1 1 1 1 1 4 1 1
RUNX1 926 839 678 541 939 1791 967 1196 735
S100A8 1 1 1 838 840 2211 1527 1721 3281
S100A9 669 702 613 3931 3328 9189 6357 6706 12534
S1PR1 5 1 1 1 12 7 1 11 5
sCTLA4 350 308 128 130 306 134 114 167 84
SELE 1 1 1 1 1 1 1 1 1
SELL 2270 1731 2591 2032 1726 2294 1942 1875 2990
SELPLG 105 38 71 34 48 5 26 48 44
SERPING1 27 27 21 55 79 86 112 118 86
SH2D1A 1 1 1 1 1 1 1 1 1
SIGIRR 70 79 77 133 196 171 206 201 201
SKI 209 170 187 188 544 606 426 696 338
SLAMF1 1 1 1 1 1 1 1 1 1
SLAMF6 1 1 1 1 1 1 1 1 1
SLAMF7 2309 1531 1953 245 234 161 77 108 88
SLC2A1 774 470 468 363 300 491 266 376 476
SMAD3 307 278 234 325 524 652 562 802 436
SMAD5 255 162 183 183 382 369 313 548 194
SOCS1 16 1 1 1 7 2 20 23 10
SOCS3 1023 573 348 1413 3098 2912 2418 2871 1551
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Name BDCA3
hi 
DCs
BDCA3hi 
DCs
BDCA3hi 
DCs
BDCA3+ 
BDCA1+ 
DCs
BDCA3+ 
BDCA1+ 
DCs
BDCA3+ 
BDCA1+ 
DCs
BDCA3-
BDCA1+ 
DCs
BDCA3-
BDCA1+ 
DCs
BDCA3-
BDCA1+ 
DCs
SPP1 3 1 1 1 1 1 1 1 1
SRC 415 329 379 240 374 271 184 153 90
STAT1 618 629 224 429 1087 1915 1483 1406 452
STAT2 1667 1317 1562 1033 1444 1490 1025 1441 1185
STAT3 1149 747 948 1842 2620 2385 1809 2847 1864
STAT4 76 33 41 30 63 88 39 92 35
STAT5A 420 326 370 541 502 557 584 581 583
STAT5B 851 689 769 830 814 753 736 824 796
STAT6 1715 1426 1681 1771 2082 2087 1558 1869 2159
SYK 4406 3643 4777 5104 4798 3496 4333 5313 5867
TAGAP 260 200 98 2404 1441 2350 2477 1832 1998
TAL1 8 1 14 1 1 1 1 2 1
TAP1 858 749 713 147 225 156 228 196 170
TAP2 1120 1153 1276 343 558 332 334 441 278
TAPBP 2820 3293 3650 1599 2410 1776 1989 1724 1559
TBK1 491 466 362 381 418 750 596 824 349
TBX21 1 1 2 9 10 2 25 28 20
TCF4 426 385 360 276 427 315 250 431 203
TCF7 5 3 1 1 1 1 4 11 4
TFRC 1535 1245 1296 660 787 1087 611 865 499
TGFB1 1609 1836 1834 2710 3449 2856 3578 3386 3284
TGFBI 7828 9009 7214 5929 5322 4823 5882 3870 5455
TGFBR1 345 274 251 490 362 432 326 478 528
TGFBR2 587 610 596 1159 1511 1217 1371 1443 955
THY1 19 1 1 1 1 1 10 4 1
TICAM1 411 529 547 204 369 286 408 284 246
TIGIT 85 60 82 59 36 12 73 53 64
TIRAP 22 1 1 5 20 1 21 36 19
TLR1 448 271 339 399 522 472 486 762 310
TLR2 121 123 97 325 405 694 509 643 391
TLR3 2318 1872 1621 252 143 457 359 139 175
TLR4 9 16 31 78 126 205 113 162 100
TLR5 18 17 15 79 53 46 69 90 79
TLR7 1 1 1 1 2 1 1 2 1
TLR8 25 88 51 127 56 100 152 78 86
TLR9 39 39 11 16 39 22 34 41 13
TMEM173 65 63 79 866 910 1148 1110 1147 1441
TNF 164 384 499 98 31 34 95 48 140
TNFAIP3 2063 3600 4023 1148 2507 3323 1807 2838 1232
TNFAIP6 109 98 99 76 26 32 50 46 72
TNFRSF10C 1 1 1 1 20 1 1 24 2
TNFRSF11A 359 256 261 1 14 2 12 13 1
TNFRSF13B 1 1 1 1 1 1 1 28 1
TNFRSF13C 16 44 17 1 7 1 44 206 44
TNFRSF14 655 675 627 656 765 572 638 593 506
TNFRSF17 10 1 1 1 1 1 1 1 1
TNFRSF1B 237 126 235 1477 1509 1901 931 1616 2087
TNFRSF4 1 1 1 1 1 1 1 1 1
TNFRSF8 1 1 1 1 1 1 1 1 6
TNFRSF9 1 1 1 1 3 5 1 21 9
TNFSF10 77 91 38 249 278 137 793 399 303
TNFSF11 1 1 1 1 2 17 1 15 8
TNFSF12 75 30 102 650 637 418 532 609 750
TNFSF13B 936 466 441 1169 1828 1850 1105 2309 1239
TNFSF15 5 1 1 1 5 1 10 8 1
TNFSF4 4 1 4 7 1 1 7 24 5
TNFSF8 93 74 81 81 111 120 75 98 86
TOLLIP 245 214 225 149 167 181 199 226 247
TP53 1489 1094 1304 1236 1473 1410 993 1203 1277
TRAF1 147 110 115 5 48 5 21 41 7
TRAF2 60 44 77 44 49 24 48 40 57
TRAF3 170 195 161 310 384 325 453 404 355
TRAF4 948 1221 985 648 628 601 610 531 538
TRAF5 140 65 159 58 73 51 53 105 55
TRAF6 750 738 643 358 618 787 616 705 323
TYK2 1072 809 992 595 1108 1126 717 1191 773
UBE2L3 433 334 295 286 422 374 281 396 305
VCAM1 20 41 233 1 1 1 1 7 1
VTN 15 3 5 3 1 1 1 1 11
XBP1 799 1087 1050 841 671 613 694 727 925
XCL1 23 1 1 1 1 1 1 1 1
XCR1 509 765 533 1 1 1 8 1 1
ZAP70 1 1 1 1 1 1 1 1 1
ZBTB16 1 1 1 1 1 1 1 2 1
ZEB1 268 146 223 46 87 59 13 51 9
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Abstract  
Interferons (IFNs) play a pivotal role in antiviral immunity. Type III IFN (IFN-λ) was most 
recently discovered, and the pathways regulating its production are still poorly understood. 
BDCA3hi dendritic cells (DCs), which are characterized by high BDCA3 expression, are 
excellent IFN-λ-producing cells. However, neither BDCA3 expression nor IFN-λ production is 
restricted to these cells since both have been described for other cell types. Here, a possible 
association of BDCA3 expression by immune cells with IFN-λ-producing capacity, and the 
signaling pathways regulating IFN-λ production were investigated.
Flow cytometric analysis revealed that BDCA3 is highly expressed by peripheral blood 
BDCA3hi DCs and at intermediate levels by a population of BDCA1+ DCs, plasmacytoid DCs 
(pDCs) and monocytes, but not other immune cells. All DC subsets, but not other immune 
cells, produced detectable levels of IFN-λ in response to TLR signaling, and highest IFN-λ 
levels were secreted by BDCA3hi DCs. Enhanced IFN-λ production was associated with 
increased BDCA3 expression on myeloid DCs (mDCs), but not pDCs, indicating expression of 
the two is not always linked.
In search of the signaling cascade leading to IFN-λ production by BDCA3hi DCs we 
demonstrated that intact PI3K-PKB-mTOR pathway signaling and canonical NFκB pathway 
signaling is required for IFN-λ production by BDCA3hi DCs.
Thus, IFN-λ is produced by all DC subsets, especially by BDCA3hi DCs. We show here for the 
first time that IFN-λ production by these cells is regulated via the canonical NFκB pathway 
and PI3K-PKB-mTOR pathway. Insight into the major IFN-λ-producing cells and their 
regulatory mechanisms underlying IFN-λ production may aid in the development of IFN-λ-
manipulating therapies.
Regulation of IFN-λ production in dendritic cells
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Introduction
Interferons (IFNs) play a crucial role in host defense against viral infections. IFNs act in two 
ways; they have direct antiviral activities inhibiting cell infection and virus replication as well 
as immunoregulatory functions [1]. IFNs can be distinguished into three subtypes; type I 
IFNs (IFN-α/β), type II IFNs (IFN-γ) and the most recently discovered type III IFNs (IFN-λ) [2, 
3]. The IFN-λ family consists of four members, including IFN-λ1 (IL-29), the 96% homologous 
isoforms IFN-λ2 (IL-28A) and IFN-λ3 (IL-28B), and IFN-λ4,  the latter being only expressed in 
individuals of a particular genotype [4-6]. All IFN-λ subtypes signal through the heterodimeric 
IFN-λ receptor, that has similar downstream effectors as the IFN-α receptor. Yet the IFN-λ 
and IFN-α receptor differ in expression kinetics and bioactivity [2, 7-9]. Like IFN-α/β, IFN-
λs have potent antiviral activity against a broad spectrum of viruses and  support skewing 
towards Th1 responses [10]. However, compared to type I and type II IFNs, knowledge on 
the function and regulation of IFN-λs is still very limited. We know that most cell types are 
able to express IFN-λ1-3 mRNA in response to viral infections, yet dendritic cells (DCs) seem 
to be superior IFN-λ-producing cells [11, 12]. 
DCs are professional antigen presenting cells (APC) that play a pivotal role in the induction 
and regulation of innate and adaptive immune responses. The DC family comprises different 
subsets, diverging in ontogeny, phenotype, localization and specialized immune functions 
[13, 14]. Three main categories of human DC subsets can be distinguished, including 
BDCA1+ myeloid DCs (mDCs), BDCA3hiCLEC9A+XCR1+ mDCs and plasmacytoid DCs (pDCs). 
BDCA3hiCLEC9A+XCR1+ DCs (further referred to as BDCA3hi DCs) have been described as 
the main producers of IFN-λ upon TLR3 stimulation. However, also BDCA1+ DCs and pDCs 
are able to produce IFN-λ upon TLR3 and TLR9 stimulation, respectively [12, 15-18]. The 
reason why BDCA3hi DCs are such excellent IFN-λ producers compared to other DC subsets 
is not known. We have previously shown that BDCA3 expression on CD34+ hematopoietic 
precursor cell (HPC)-derived DCs is associated with IFN-λ production [19]. Of course high 
BDCA3 surface expression is a specific characteristic of BDCA3hi DCs [20, 21], but expression 
of BDCA3 can also be detected in low levels on other cells, including BDCA1+ mDCs and pDCs 
[22-24],  which suggests that the level of BDCA3 expression may be associated with IFN-λ-
producing capacity by DCs. 
Although the molecular mechanisms regulating TLR ligand and/or virus-induced type I IFN 
production by DCs are well characterized, the pathways regulating type III IFN production 
are incompletely understood. TLR3 triggering leads to activation and translocation of NFκB 
and IRF3, resulting in production of type I IFNs and other pro-inflammatory cytokines. NFκB 
activation occurs via the TRIF-TRAF6-IKK-α/β cascade, whereas optimal IRF3 phosphorylation 
requires both TRIF-TRAF3-TBK1 signaling and PI3K-PKB-mTOR signaling [25-27]. So far, most 
studies on IFN-λ-regulating pathways have been performed in epithelial-like cells, such as 
hepatocytes, HEK293 cells, airway epithelial cells, and colon epithelial cells, and in vitro-
generated DCs [28-32]. Most of these studies used mRNA gene expression instead of protein 
secretion as a read-out for IFN-λ production. In the cell types analyzed thus far, it seems that 
regulation of type III IFN production is comparable to that of type I IFN production, since 
the promotor regions of IFNL1, IFNL2 and IFNL3 contain binding elements for transcription 
factors IRF3, IRF7 and NFκB, although type III IFN seems more dependent on NFκB than type 
I IFN [28-36]. 
The molecular mechanisms regulating IFN-λ production in BDCA3hi DCs, the most potent IFN-
λ-producing cells, however, remain to be elucidated. Here, we set out to directly compare 
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IFN-λ production by naturally occurring human DC subsets, the relation between BDCA3 
expression and IFN-λ production, and the signaling pathways involved in the regulation of 
IFN-λ production in human BDCA3hi DCs.
We confirm that although IFN-λ1 is produced by all DC subsets in response to TLR signaling, 
BDCA3hiCLEC9A+ DCs excel by far. IFN-λ correlated with BDCA3 expression on mDCs, but not 
pDCs. In BDCA3hiCLEC9A+ DCs, both the PI3K-PKB-mTOR and the canonical NFκB pathway 
are involved in the regulation of IFN-λ production, but their contribution is different for the 
IFN-λ subtypes. These findings provide insight into the molecular mechanisms underlying 
regulation of IFN-λ production in naturally occurring DC subsets and may thus contribute to 
the development of therapies aimed at the manipulation of IFN-λ secretion by these cells.
Materials and Methods
Cell isolation
Peripheral blood mononuclear cells (PBMC) were isolated from heparinized peripheral 
blood samples or from buffy coats from healthy blood donors using Ficoll density gradient 
centrifugation. All healthy controls gave written informed consent before blood donation. 
Cells were enriched for DCs using Dynabeads (Thermo Fisher), and DC subsets were 
subsequently isolated based on BDCA1, BDCA3 and BDCA4 expression by FACSorting using 
a FACSAria (BD Biosciences). 
Flow cytometric analysis
For phenotypic analysis, cells were washed with PBS containing 1% bovine serum albumin 
(BSA; Sigma-Aldrich, St. Louis, MO), 1% heat inactivated human serum and 0.02% NaN3 
(Merck, Darmstadt, Germany; referred to as FACS buffer) and subsequently labeled with 
fluorochrome-conjugated antibodies (Abs). Labeling was performed during 30 minutes of 
incubation on ice with Abs recognizing BDCA3/CD141 (AD5-14H12, Miltenyi Biotec, Bergish 
Gladbach, Germany); BDCA1/CD1c (AD5-8E7, Miltenyi and L161, BioLegend); BDCA4/CD304 
(12C2, BioLegend), CD3 (UCHT1, eBioscience, San Diego, CA), CD11c (3.9, eBioscience); 
CD14 (61D3, eBioscience); CD19 (HIB19, eBioscience), CD56 (MY31, BD Biosciences, Breda, 
the Netherlands), CD123 (AC145, Miltenyi), CLEC9A (8F9, BioLegend, San Diego, CA). 
Fluorescence was measured using a FACS Canto II (BD Biosciences). 
Cytokine secretion
Cells were resuspended in RPMI 1640 (Invitrogen, Breda, The Netherlands) supplemented 
with 9% heat-inactivated FCS (Sigma-Aldrich, St. Louis, MO) and penicillin/streptomycin 
(Invitrogen). Total PBMC were stimulated with polyI:C (20 µg/ml, Invivogen, Toulouse, 
France), CpG-2336 (class A, 10 μg/ml, Invivogen) or Loxoribin (0.4 mM, Invivogen) for 7 
hours at 37°C in the presence of Granulocyte Macrophage-Colony Stimulating Factor 
(GM-CSF, 10 ng/ml, PeproTech, London, U.K.). PI3K inhibitor LY294002 (10 μM, Biomol), 
PKB inhibitor VIII (3 μM, Calbiochem, San Diego, CA), mTOR inhibitor rapamycin (0.5 μM, 
Biomol, Hamburg, Germany), and canonical NFκB signaling pathway inhibitors CAPE (10 μg/
ml, Sigma-Aldrich), BAY 11-7082 (1 μM, Calbiochem) and AS602868 (AS, 1 μM, a kind gift 
from Dr. I. Adcock, Imperial College London, U.K.) were added where indicated. During the 
last 3 hours, the cells were incubated with 10 mg/ml Brefeldin A (Sigma-Aldrich). Cells were 
stained with DC-subset specific antibodies as described above, fixed with 2% formaldehyde, 
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permeabilized with 0.5% saponin and stained with antibodies against TNFα (eBioscience) 
and IFN-λ (kindly provided by BMS, Uxbridge, U.K.). The frequencies of cytokine-producing 
cells were determined by flow cytometry (FACS Canto II, BD Biosciences).
Isolated DCs were stimulated for 24 hours with the TLR ligands indicated above with 
or without signaling pathway inhibitors. The levels of secreted human IFN-λ1 (IL-29, 
eBioscience) and IFN-λ2 (IL-28A) (R&D systems) were measured in the supernatant using 
commercially available ELISA kits according to the manufacturer’s protocol. Detection limits 
were 8 pg/ml (IFNλ1) and 30 pg/ml (IFN-λ2).
Statistical analysis
Statistical analysis was performed using Graphpad Prism version 5.01 for Windows 
(GraphPad Software, San Diego, California USA). 
 
Results
IFN-λ1 is mainly produced by BDCA3-expressing myeloid DCs
To assess whether BDCA3 expression on immune cells derived from peripheral blood in 
general is associated with IFN-λ production, we first determined which immune cells express 
BDCA3. NK cells, T cells and B cells did not express any BDCA3 (Figure 1A, B). In contrast, 
detectable BDCA3 expression levels were found on CD14+ monocytes (61±5%), BDCA1+ 
DCs (73±3%) and BDCA2+ pDCs (77±2%) , although the expression level on these cells was 
lower than that on BDCA3hi DCs (Figure 1A, B, Supplementary figure 1). These data show 
that of the immune cells tested, BDCA3 is only expressed by monocytes and DCs. Next, we 
investigated the presence of correlation between IFN-λ production and BDCA3 expression. 
In line with a lack of BDCA3 expression, NK cells, T cells and B cells did not produce any IFN-λ1 
upon activation of these cells by commonly used cell-specific activation stimuli (Figure 2A). 
Although monocytes did express BDCA3, IFN-λ1 production could not be detected for these 
cells. IFN-λ1 was produced by polyI:C-stimulated BDCA3hi DCs, polyI:C-stimulated BDCA1+ 
DCs and CpG-A-stimulated pDCs. In line with previous studies, BDCA3hi DCs were superior 
Figure 1. BDCA3 co-expression and IFN-λ1 production by immune cell subsets.
(A-B) PBMC were isolated from healthy controls and BDCA3 expression was analyzed on B cells, T cells, NK cells, 
monocytes, BDCA1+ DCs, BDCA2+ pDCs and BDCA3hi DCs. Representative flow cytometry plots (A) and mean±SEM 
percentage of BDCA3-expressing cells (B) of 10 independent experiments with 15 different donors are shown.
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in IFN-λ1 production compared to the other DC subsets (Figure 2B, C, D). This difference 
in IFN-λ1-producing capacity was not due to a differential response to TLR stimulation, as 
indicated by comparable TNF-α production by all three DC subsets (Supplementary figure 2). 
To distinguish between BDCA3+ and BDCA3- DCs of the BDCA1+ DC and pDC population, cells 
were sorted as shown in supplementary figure 3.   Within the BDCA1+ DC population, but not 
within the pDC population, BDCA3-expressing DCs produced significantly more IFN-λ1 than 
BDCA3- DCs (Figure 2D). Together these results indicate that IFN-λ production by peripheral 
blood immune cells is restricted to DCs, preferably BDCA3hi DCs, and that BDCA3 expression 
on these different immune cells is not consistently predictive for IFN-λ-producing capacity.
Figure 2. IFN-λ1 is mainly produced by BDCA3-expressing myeloid DCs.
(A-C) PBMC were stimulated for 7 hours with or without IL-12 + IL-18, anti-CD3 + anti-CD28 + anti-CD49, PMA + 
ionomycin, CpG-B, R848, LPS, polyI:C, or CpG-A. Production of IFN-λ1 by the indicated immune cells was measured 
by ICS. (A) Representative flow cytometry plots of Aqua- viable NK cells, T cells, B cells and monocytes (n=3). (B) 
Representative flow cytometry plots of Aqua- viable BDCA3hi DCs, BDCA1+ DCs and pDCs (n=7). (C) Mean±SEM 
percentage IFN-λ1-producing cells (n=7) *p < 0.05, ***p<0.001, paired Student’s t-test. Note: the percentage of 
IFN-λ-producing BDCA3hi DCs upon polyI:C stimulation was significantly higher (***p<0.001) compared to all other 
conditions. (D) DC subsets were FACSorted and stimulated for 24 hours with or without polyI:C, LPS, R848 or CpG-A. 
IFN-λ1 concentrations were determined by ELISA. Data are shown as mean±SEM production of IFN-λ1 (n=2-8) and 
are pooled from 8 independent experiments, each performed with a different donor. *p < 0.05, **p<0.01, paired 
Student’s t-test.
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IFN-λ1 production by BDCA3hi DCs is regulated via the NFκB pathway 
Although BDCA3hi DCs are superior at production of IFN-λ, the pathways regulating IFN-λ 
production in these cells have not been clarified. We first investigated the role of the 
canonical NFκB signaling pathway in the production of the two major isoforms of IFN-λ by 
BDCA3hi DCs by intracellular cytokine staining (IFN-λ1) and ELISA (IFN-λ1 and IFN-λ2) [31, 
32]. Stimulation of PBMC in the presence of AS (IKK-β inhibitor) , BAY (inhibitor of IκBα 
phosphorylation) and CAPE (inhibitor of translocation of NFκB to the nucleus) showed that 
these factors of the NFκB pathway are required for IFN-λ1 production by BDCA3hi DCs, as 
the percentage of IFN-λ1+ BDCA3hi DCs was significantly reduced (Figure 3A). Although NFκB 
is known to be involved in cell survival, neither absolute numbers of BDCA3hi DCs, nor the 
percentage of early apoptotic or dead cells seemed to be affected by the NFκB inhibitors 
(Supplementary figure 4A, B). The inhibitors also diminished the secretion of IFN-λ1 into 
the culture supernatant by isolated BDCA3hi DCs (Figure 3B), and production of the second 
isoform, IFN-λ2, was even more diminished (Figure 3C). Due to high variation in IFN-λ 
production between experiments, however, the reduction was significant only for BAY on 
IFN-λ1 and AS on IFN-λ2. Together, these data  demonstrate that canonical NFκB signaling 
regulates both IFN-λ1 and IFN-λ2 production by BDCA3hi DCs. 
IFN-λ1 production by BDCA3hi DCs is regulated via the PI3K-PKB-mTOR pathway
NFκB inhibitors could only partially reduce IFN-λ1 production, suggesting also other signaling 
pathways may be involved. The PI3K-PKB-mTOR signaling pathway is a likely candidate, as it 
is known to regulate IFN-α production by pDCs and IFN-λ production by in vitro-generated 
monocyte-derived DCs [37, 38]. So far, the involvement of this pathway in the regulation 
of IFN-λ production has not been addressed in primary DCs. Stimulation of PBMCs in the 
presence of the PI3K inhibitor LY, PKB inhibitor VIII and mTOR inhibitor rapamycin significantly 
reduced the percentage of IFN-λ1-producing BDCA3hi cells (Figure 4A). Like NFκB, PI3K-PKB-
mTOR signaling is known to be involved in cell survival. VIII and rapamycin did not seem 
to affect cell death, however, LY induced apoptosis in polyI:C-stimulated cells, resulting in 
Figure 3. The NFκB pathway is involved in regulation of IFN-λ1 and IFN-λ2 production by BDCA3hi DCs.
(A) PBMC were isolated and stimulated for 7 hours with or without polyI:C in the presence or absence of the NFκB 
pathway inhibitors AS, BAY and CAPE. Production of IFN-λ1 was measured using ICS. Mean±SEM percentage IFN-
λ1-producing BDCA3hi DCs (n=10) are shown. Data are pooled from 8 independent experiments performed with 10 
different donors. *p < 0.05, **p<0.01, paired Student’s t-test. (B-C) FACSorted BDCA3hi DCs were stimulated for 24 
hours with or without polyI:C in the presence or absence of the NFκB pathway inhibitors CAPE, BAY and AS. IFN-λ1 
and IFN-λ2 concentrations were determined by ELISA. Data are shown as mean±SEM production of IFN-λ1 (n=4-5) 
and IFN-λ2 (n=3-4) and are pooled from 5 independent experiments, each performed with a different donor. *p < 
0.05, paired Student’s t-test. 
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a complete lack of BDCA3hi DCs in some of the experiments. Therefore, the reduction in 
IFN-λ production by LY is likely to be due to a decline in cell viability (Supplementary figure 
4C, D). Addition of these signaling inhibitors to cultures with purified BDCA3hi DCs almost 
completely abrogated the production of IFN-λ1, showing a crucial role for PI3K-PKB-mTOR 
signaling in the production of this cytokine (Figure 4B). Intriguingly, PI3K-PKB-mTOR pathway 
inhibition much less reduced IFN-λ2 secretion (Figure 4C). These results show that also the 
PI3K-PKB-mTOR pathway is involved in regulation of IFN-λ1 production in BDCA3hi DCs, but 
plays only a minor role in regulation of IFN-λ2 production. 
Discussion
BDCA3hi DCs are characterized by high BDCA3 expression and IFN-λ production. Thus far, 
the pathways regulating IFN-λ production in BDCA3hi DCs as well as the relation between 
BDCA3 expression and IFN-λ production were unknown. Here, we have shown that although 
BDCA3 was moderately expressed by BDCA1+ DCs, pDCs and monocytes, its expression level 
was only associated with a higher ability to produce IFN-λ in BDCA1+ DCs. Thus, BDCA3 
expression on immune cells in itself is not predictive for IFN-λ-producing capacity. Moreover, 
we have demonstrated that regulation of polyI:C-induced IFN-λ1 production by BDCA3hi 
DCs involved both the canonical NFκB pathway and PI3K-PKB-mTOR pathway, while IFN-λ2 
production involved mostly the NFκB pathway and seemed to depend less on the PI3K-PKB-
mTOR pathway (Figure 5).
Apart from the typical BDCA3hi DC subset, we confirm the expression of BDCA3 on other 
hematopoietic cells, including monocytes, pDCs and BDCA1+ DCs. IFN-λ production could 
be detected for the different DC subsets, but in contrast to previous studies, not for LPS-
stimulated monocytes [39]. This discrepancy may be due to the use of mRNA expression 
instead of protein secretion as read-out for IFN-λ production, which demonstrates the 
importance of IFN-λ detection at protein level as it reflects actual IFN-λ production. 
Figure 4. The PI3K-PKB-mTOR pathway is involved in regulation of IFN-λ1 production by BDCA3hi DCs.
(A) PBMC were isolated and stimulated for 7 hours with or without polyI:C in the presence or absence of the PI3K-
PKB-mTOR pathway inhibitors LY, inhibitor VIII (VIII) and rapamycin (rapa). Production of IFN-λ1 was measured using 
ICS. Mean±SEM percentage IFN-λ1-producing BDCA3hi DCs (n=12) are shown. Data are pooled from 10 independent 
experiments performed with 12 different donors. ***p<0.001, paired Student’s t-test. (B-C) FACSorted BDCA3hi DCs 
were stimulated for 24 hours with or without polyI:C in the presence or absence of the PI3K-PKB-mTOR pathway 
inhibitors LY, inhibitor VIII and rapamycin. IFN-λ1 and IFN-λ2 concentrations were determined by ELISA. Data are 
shown as mean±SEM production of IFN-λ1 (n=5) and IFN-λ2 (n=3) and are pooled from 5 independent experiments, 
each performed with a different donor. 
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The enhanced IFN-λ-producing capacity of BDCA3+BDCA1+ DCs compared to BDCA3-BDCA1+ 
DCs is in line with our previous work that showed a link between BDCA3 expression and 
IFN-λ production on CD34+ HPC-derived myeloid DCs [19]. This increased IFN-λ production 
may be due to a more activated status of BDCA3+BDCA1+ DCs, as suggested in chapter 
5. Nevertheless, the exact function of BDCA3 expression on immune cells remains to be 
determined.
In contrast to regulation of type I IFN production, regulation of type III IFN production 
remains poorly understood. Here, we provide for the first time insight into IFN-λ-regulating 
pathways in the most potent IFN-λ-producing cells, primary BDCA3hi DCs. To establish IFN-λ-
manipulating strategies for therapeutic purposes, it is crucial to understand why these cells 
excel in IFN-λ production and how viruses may interfere with their IFN-λ production. In the 
present study, inhibitors were used to demonstrate the involvement of NFκB and PI3K-PKB-
mTOR pathways in the production of IFN-λ. More solid proof on the involvement of these 
pathways would come from siRNA-mediated knockdown, but this is unfortunately not a 
feasible strategy for the very rare BDCA3hi DC subset. Nonetheless, as multiple inhibitors 
acting on the same pathway were used, and as these all affected IFN-λ production, it is 
highly likely that these pathways investigated play an important role. 
Both the NFκB and PI3K-PKB-mTOR pathway are known to be involved in regulation of 
DC development and survival. However, two of our previous studies showed that in vitro-
generated CD34+ HPC-derived DCs were rescued from NFκB inhibitor-induced apoptosis by 
simultaneous presence of activation signals, and that survival of fully differentiated CD34+-
derived DCs was unaffected by inhibition of PI3K-PKB-mTOR signaling [40, 41]. In line with 
this, no loss of BDCA3hi DCs or induction of apoptosis by NFκB and PI3K-PKB-mTOR pathway 
inhibitors, except LY, was observed, indicating again that the effect on IFN-λ production was 
specific and not due to cell death.
 In addition to IFN-λ production by BDCA3hi DCs, IFN-λ production by pDCs was also regulated 
by NFκB and PI3K signaling, as all inhibitors except rapamycin significantly reduced the 
percentage of IFN-λ-producing pDCs (data not shown). What makes BDCA3hi DCs such 
excellent IFN-λ-producing cells remains elusive. The activation of NFκB and the PI3K-PKB-
mTOR signaling pathway is not unique for BDCA3hi DCs. Other factors that specifically 
stimulate IFN-λ production may contribute to different IFN-λ-producing capacities, i.e. IRF3 
Figure 5. Regulation of IFN-λ production in BDCA3hi DCs.
Schematic representation of the involvement of the NFκB 
pathway and PI3K-PKB-mTOR pathway in polyI:C-induced 
IFN-λ1 and IFN-λ2 production.
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and IRF7, and Med23, which enhances IFN-λ1 transcription via interaction with IRF7. Also 
BLIMP1 and ZEB1 regulate IFN-λ production by repressing IFN-λ1 transcription via binding 
of the IFN-λ1 promotor [29-32, 34, 42]. Unfortunately, due to experimental limitations, 
especially the low amount of available BDCA3hi DCs and the lack of specific inhibitors for 
these molecules, we were not yet able to determine their role.
Differences in expression levels of pattern recognition receptors (PRR) as well as the 
combined downstream signaling in BDCA3hi DCs compared to other DC subsets may also 
contribute to differential IFN-λ production. As polyI:C is not only a ligand for TLR3, but also 
for the cytoplasmic receptors RIG-I and MDA-5, and as RIG-I signaling has been shown to 
induce IFN-λ production in other cell types, these pathways may also be involved in IFN-λ 
production [43]. Furthermore, the accessibility and/or availability of pivotal signaling 
molecules and/or transcription factors may be unique for BDCA3hi DCs, which requires 
further investigation. 
So far, the function and regulation of type I and type III IFNs appear very comparable, except 
for the cells they target. It is, however, striking that IFNλ production is clearly dependent on 
canonical NFκB signaling, as demonstrated here and also by others, while IFN-α production 
seems to depend much less on NFκB [29]. More insight into the pathways regulating type III 
IFNs will help to understand how type I and type III IFN, as well as subtypes of IFN-λ differ 
in the location and timing of their secretion, and thus how they each contribute to the final 
immune response. We showed here that inhibition of the PI3K-PKB-mTOR pathway affected 
IFN-λ1 more than IFN-λ2 production, whereas inhibition of the NFκB pathway had a more 
pronounced effect on IFN-λ2 production. Although highly speculative, the subtle difference 
in regulation of the two subtypes may reflect a different mode of action. Balancing the 
relative subtype levels may further fine-tune the IFN-λ immune response.
Taken together, we show that among immune cells, IFN-λ production is associated with 
DCs, in particular with BDCA3hi DCs, and is regulated via the PI3K-PKB-mTOR pathway and 
NFκB pathway. These data contribute to better understanding of BDCA3hi DC function and 
the signaling pathways underlying IFN-λ regulation. Insight into the molecular mechanisms 
that regulate IFN-λ production in these major IFN-λ-producing cells may help to better 
understand their role in diseases associated with disturbed IFN-λ production and may aid 
the development of IFN-λ-manipulating therapies.  
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Supplementary information
Supplementary figure 1. Gating strategy for analysis of immune cell subsets
PBMC were isolated from healthy controls. FSC/SSC-gated cells were distinguished into CD56+CD3- NK cells, 
CD3+CD56- T cells, CD19+ B cells, CD14+ monocytes and HLA-DR+Lineage- DCs, including BDCA1+ DCs, BDCA3hi DCs 
and BDCA2+ pDCs. Representative flow cytometry plots of 10 independent experiments with 15 different donors 
are shown.
Supplementary figure 2. TNF-α production by DC subsets
PBMC were stimulated for 7 hours with or without polyI:C, or CpG-A. Production of TNF-α by the indicated DC 
subsets was measured by ICS. Representative flow cytometry plots of Aqua- viable BDCA3hi DCs, BDCA1+ DCs and 
pDCs (n=7). 
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Supplementary figure 3. Sorting strategy for analysis of BDCA3+ and BDCA3- DCs.
PBMC were isolated from healthy controls and enriched for DCs using a Dynabeads Human DC Enrichment kit. 
Duplicates were excluded based on size, and DC populations were subsequently identified as BDCA3hi cells, 
BDCA3+BDCA1+ cells and BDCA3-BDCA1+ cells. Representative FACS plots are shown.
Supplementary figure 4. Effect of inhibitors on cell survival
PBMC were isolated and stimulated for 7 hours with or without polyI:C in the presence or absence of the NFκB 
pathway inhibitors AS, BAY and CAPE and PI3K-PKB-mTOR inhibitors LY, VIII and mTOR. Mean±SEM percentage 
of BDCA3hi DCs (A, C; n=2), and  the mean percentage of viable cells (Annexin-7AAD-), early apoptotic cells 
(Annexin+7AAD-) and late apoptotic/dead cells (Annexin+7AAD+) within the BDCA3hi DC population are shown (B, D; 
n=2). Data are pooled from 1 experiment performed with 2 different donors.
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Abstract 
Chronic hepatitis B virus (HBV) infection results from inadequate HBV-specific immunity. 
BDCA3+ dendritic cells (DCs) are professional antigen presenting cells considered to be im-
portant for antiviral responses because of specific characteristics, including high interfer-
on-λ production. BDCA3+ DCs may thus also have a role in the immune response against 
HBV, and immunotherapeutic strategies aiming to activate DCs, including BDCA3+ DCs, in pa-
tient livers may represent an interesting treatment option for chronic HBV. However, neither 
the effect of chronic hepatitis B (CHB) infection on the frequency and function of BDCA3+ 
DCs in liver and blood, nor the effect of the viral surface protein (HBsAg) that is abundantly 
present in blood of infected individuals are known. Here, we provide an overview of BDCA3+ 
DC frequency and functional capacity in CHB patients. We find that intrahepatic BDCA3+ DC 
numbers are increased in CHB patients. BDCA3+ DCs from patient blood are not more ma-
ture at steady state, but display an impaired capacity to mature and to produce interferon-λ 
upon polyI:C stimulation. Furthermore, in vitro experiments exposing blood and intrahe-
patic BDCA3+ DCs to the viral envelope protein HBsAg demonstrate that HBsAg does not 
directly induce phenotypical maturation of BDCA3+ DCs, but may reduce IFN-λ production 
via an indirect unknown mechanism.
These results suggest that BDCA3+ DCs are available in the blood and on site in HBV infected 
livers, but measures may need to be taken to revive their function for DC-targeted therapy.
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Introduction
Hepatitis B virus (HBV) specifically infects hepatocytes and can cause chronic liver infection, 
often leading to severe liver diseases [1]. Chronic viral infection results from inadequate 
antiviral immunity, however, the mechanisms underlying ineffective HBV-specific immuni-
ty remain poorly understood [2, 3]. Effective viral immunity includes induction of antiviral 
cytokines such as interferons (IFNs) and virus-specific CD8+ cytotoxic T lymphocytes (CTL). 
Dendritic cells (DCs) play a crucial role in this process because they can, uniquely, activate 
virus-specific naïve T cells and produce high type I and type III IFN levels [4, 5]. The DC fam-
ily comprises several subsets, including plasmacytoid DCs (pDC) and the myeloid DC (mDC) 
subsets BDCA1+ DCs and BDCA3hiCLEC9A+ DCs [6-8]. These DC subsets differ in ontogeny, 
localization, phenotype and  function. 
We and others have previously characterized the frequency and function of BDCA1+ DCs 
and pDCs in peripheral blood of chronic HBV patients [9]. We demonstrated that although 
DC frequencies in blood were unaffected, blood BDCA1+ DCs were impaired in their capac-
ity to mature, to produce pro-inflammatory cytokines and to stimulate T cells, and that 
pDCs were impaired in IFNα-producing capacity [10, 11]. More recently, BDCA3hiCLEC9A+ 
DCs (further referred to as BDCA3+ DCs) were identified and shown to excel over other DC 
subsets in cross-presentation of cell-associated antigens (Ag) to CD8+ T cells [12-15]. In mice, 
the equivalents of BDCA3+ DCs (CD8α+ and CD103+ DCs) have been shown to be crucial for 
generating optimal virus-specific CD8+ T cell responses to influenza virus and West Nile virus 
[16, 17]. In addition, BDCA3+ DCs are the most potent producers of IFN-λ in response to vi-
ruses that induce TLR3 signaling, or in response to the synthetic RNA polyI:C [18-22]. IFN-λ 
is an important antiviral cytokine that supports T cell skewing towards Th1 responses and 
has antiviral activity against multiple viruses, including HBV [23, 24]. Although the effect of 
IFN-λ on HBV replication in in vitro and mouse studies was debatable [25, 26], a recent clini-
cal trial showed that in HBeAg-positive patients, PEG-IFN-λ induced a clear reduction in HBV 
DNA and viral surface antigen (HBsAg) levels, indicating that this cytokine may be valuable 
to fight CHB, and we envision that this cytokine could be even more effective when secreted 
on site [27]. BDCA3+ DCs may thus be a viable target to induce an effective immune response 
against HBV. BDCA3+ DCs are known to be present in human liver [21, 28, 29], however, it is 
unknown whether this is altered upon HBV-infection. Furthermore, the actual localization of 
BDCA3+ DCs within healthy and diseased liver tissue, as well as their functional state in HBV 
patients, and their response to the abundantly circulating HBsAg remains elusive. 
We here assessed the presence of BDCA3+ DCs in liver and blood of HBV-infected patients, 
as well as the effect of chronic HBV infection and HBsAg on BDCA3+ DC phenotype and 
function in vitro and ex vivo. We found that although BDCA3+ DCs are present in the liver 
immune infiltrate of chronic HBV (CHB) patients, their function may be compromised.  
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Materials and Methods
Patients and controls
Heparinized peripheral blood samples were obtained from CHB patients and control 
subjects of which the clinical characteristics are listed in Table 1. CHB patients and 
control subjects used for functional characterization of DCs were matched for age, 
gender and race. Liver tissue was obtained from HBV-infected livers and non-HBV-
infected livers, i.e. donor livers that were used for transplantation, donor livers that 
were rejected for transplantation, or non-cancerous peri-tumor tissue of donors who 
had not received chemotherapy in at least three months prior to tissue donation. The 
clinical characteristics of donors are summarized in Table 2. All patients were negative 
for antibodies (Abs) against hepatitis C, hepatitis D and human immunodeficiency virus. 
Patients did not receive antiviral therapy at time of blood or tissue donation. The study 
was approved by the medical ethical committee of the Erasmus MC University Medical 
Center and donors gave written informed consent before blood or tissue donation. 
Table 1. Characteristics of donors used for peripheral blood DC quantification and functional 
characterization.
 
Table 2. Characteristics of donors used for intrahepatic DC quantification. 
Cell isolation and stimulation
Peripheral blood mononuclear cells (PBMC) were isolated from heparinized peripheral 
blood samples or buffy coats from healthy blood donors using Ficoll density gradient 
centrifugation. PBMC were enriched for DCs using Dynabeads that deplete T cells, B cells, 
monocytes/macrophages, NK cells, erythrocytes and most granulocytes (Life Technologies), 
Characteristics Quantification Functional characterization
Number 19 18
ALT (IU/L) mean (range) 49 (12-164) 37 (12-78)
HBV DNA (log10 IU/ml) mean (range) 3.9 (1.3-8.6) 3.5 (1.3-8.6)
HBeAg+/HBeAg- 2/17 0/18
Characteristics Flow cytometry Immunohistochemistry
Number 11 14
ALT (IU/L) mean (range) 73 (32-164) 91 (12-370)
HBV DNA (log10 IU/ml) mean (range) 3.8 (1.3-8.6) 4.6 (1.3-9.5)
HBeAg+/HBeAg- 3/8 10/4
Fibrosis
F0 1 3a
F1 6 6
F2 2 2
F3 2 2
a Fibrosis status of one patient is unkown.
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and DC subsets were sorted based on BDCA3 expression using a FACSAria (BD Biosciences). 
Liver tissue (>1 cm3) was digested to obtain a single cell suspension. Briefly, liver tissue was 
cut into small pieces and digested with 0.5 mg mL-1 collagenase (Sigma-Aldrich) and 0.1 mg 
ml-1 DNase (Roche) for 30 minutes at 37°C. The digested material was subsequently filtered 
through a cell strainer and mononuclear cells were obtained by Ficoll density gradient 
centrifugation. Core needle-biopsies (14-gauge needle) were only filtered through a cell 
strainer to obtain a single cell suspension. 
 
Flow cytometric analysis
For phenotypic analysis, cells were labelled with Abs recognizing CD11c (3.9), CD40 (5C3), 
CD45 (HI30), CD83 (HB15e), HLA-DR (LN3, all eBioscience), BDCA1/CD1c (AD5-8E7, Miltenyi 
Biotec), BDCA3/CD141 (AD5-14H12, Miltenyi Biotec), CD86 (2331, BD Horizon), CLEC9A 
(8F9, BioLegend), HBsAg (Acris), a lineage cocktail including CD3 (UCHT1, eBioscience), 
CD14 (61D3, eBioscience), CD19 (HIB19, eBioscience) and CD56 (MY31, BD Biosciences), 
and the live/dead marker Aqua (LifeTechnologies). Fluorescence was measured using a FACS 
Canto II (BD Biosciences). 
Cytokine production
1*106 PBMC were stimulated with polyI:C (20 µg ml-1, Invivogen) in 250 μl in 96-wells 
plates (Greiner Bio-one, Alphen aan den Rijn, Netherlands) for 5 or 7 hours at 37°C in 
RPMI 1640 (Invitrogen) supplemented with 9% heat-inactivated FCS (Sigma-Aldrich) and 
penicillin/streptomycin (Invitrogen). During the last 3 hours, cells were incubated with 10 
μg ml-1 Brefeldin A (Sigma-Aldrich). Subsequently, cells were stained for BDCA3 and CD11c, 
fixed with 2% formaldehyde, permeabilized with 0.5% saponin and stained for tumor 
necrosis factor α (TNF-α) (eBioscience), IFN-λ1 (kindly provided by Bristol-Myers Squibb 
and commercial Ab from R&D systems) or polyclonal goat IgG (R&D systems). Cytokine-
producing cell frequencies were determined by flow cytometry.
Isolated DCs were stimulated for 24 hours with 20 μg ml-1 polyI:C in the presence of 10 ng 
ml-1 GM-CSF. Levels of secreted human IFN-λ1 (interleukin 29; IL-29) were measured using 
a commercially available ELISA kit (eBioscience) and IL-1β, IL-6, IL-8 and TNFα levels were 
measured using a BD cytometric bead array (CBA, BD Biosciences). Detection limits were 8 
pg ml-1 (IFN-λ1), 7.2 pg ml-1 (IL-1β), 2.5 pg ml-1 (IL-6), 3.6 pg ml-1 (IL-8), 3.7 pg ml-1 (TNF-α).
HBsAg uptake/binding and stimulation with HBsAg in vitro
For analysis of HBsAg binding/uptake, PBMC were incubated with 1 µg ml-1 fluorochrome-
labeled HBsAg isolated from pooled serum of patients (pHBsAg; subtype ay; American 
Research Products, ARP) in 250 μl for 2 hours at 4°C or 37°C. Cells were fixed with 2% 
formaldehyde and analysed by flow cytometry. For analysis of the effect of HBsAg on 
BDCA3+ DC function, cells were stimulated with 20 μg ml-1 polyI:C in the presence or absence 
of 5 μg ml-1 patient-derived pHBsAg or 5 μg ml-1 recombinant CHO-derived HBsAg (rHBsAg; 
Prospec; determined to be endotoxin free by Endolisa; Hyglos GmbH). Depletion of rHBsAg 
was performed by immunoprecipitation using protein G sepharose beads (GE Healthcare) 
that were bound to human anti-HBsAg Abs (Biotest Pharma), as described previously [30]. 
Immunohistochemistry
Formalin-fixed paraffin-embedded (FFPE) sections (5 μm) of 14 CHB livers and 6 donor livers 
(Table 2) were deparaffinized and boiled for 10 minutes in citrate buffer (pH 6) for antigen 
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retrieval. Sections were incubated with 3% H2O2, 10% human serum, and Abs against CLEC9A 
(polyclonal sheep, R&D systems) or non-specific polyclonal sheep Abs (R&D systems) for 1 
hour at 37°C. CLEC9A Ab was subsequently bound by horseradish peroxidase (HRP)-labeled 
donkey(Fab)-anti-sheep Ab (Life Technologies) and the signal was amplified using tyramide-
FITC, followed by mouse-anti-FITC (Jackson ImmunoResearch) and DyLight488-labeled goat-
anti-mouse (BioLegend). CLEC9A+ cells were manually counted in 5-9 microscopic fields 
(200x magnification) containing portal tracts and the mean number of cells per microscopic 
field was calculated. 
Statistical analysis
Statistical analysis was performed using Graphpad Prism version 5.01 for Windows 
(GraphPad Software). 
Results
BDCA3+ DCs are prominently present in HBV-infected livers
The frequency and function of BDCA3+ DCs in HBV-infected livers is currently unknown. 
Therefore, we set out to quantify BDCA3+ DCs in biopsies from HBV-infected livers and 
control livers from non-HBV infected individuals. The latter included healthy donor livers 
accepted or rejected for transplantation, as well as non-cancerous peri-tumor tissue. First, 
to distinguish immune cells from hepatocytes, we used the hematopoietic lineage marker 
CD45 (Fig 1A). As may be expected in a state of ongoing inflammation, the frequency of total 
CD45+ immune cells and DCs was significantly higher in livers of HBV-infected individuals 
compared to those of controls, indicating extensive immune cell infiltration (Fig 1B). Of these 
CD45+ immune cells, BDCA3+ DCs represented 0.18±0.15% both in control livers and HBV-
infected livers, which is in line with previous reports (S1 Fig) [29]. In line with an increase 
of immune cells in the liver, the percentage of BDCA3+ DCs of total liver cells seemed to be 
higher in HBV-infected livers, however, this increase was not significant. 
In addition to flow cytometry, immunohistochemical (IHC) stainings were used to accurately 
study BDCA3+ DC frequencies in the liver. This analysis demonstrated that numbers of 
CLEC9A+ DCs were indeed higher in HBV-infected livers than in control livers (Figs 1C and 
1D). The marker CLEC9A, that was used to identify BDCA3+CLEC9A+ DCs by IHC, was  uniquely 
expressed by CD45+HLA-DR+Lineage-BDCA3hi DCs in the liver (S2 Fig).  BDCA3+ DCs were 
predominantly located in portal tracts with immune infiltration. Interestingly, BDCA3+ DC 
numbers in the liver positively correlated with HBV DNA levels (Spearman r=0.782, p=0.001). 
However, no difference in BDCA3+ DC numbers could be detected between patients with 
high or low fibrosis or liver damage, as measured by alanine transaminase (ALT) (Fig 1D), 
suggesting that mostly active viral replication, and possibly consecutive local production 
of inflammatory cytokines/chemokines, rather than liver damage induces infiltration of 
BDCA3+ DCs into the liver. Unfortunately, any association between BDCA3+ DC numbers with 
HBsAg levels could not be determined as HBsAg levels at the timepoint of biopsy collection 
were not available for all donors. 
Together, these data show that during CHB infection, intrahepatic BDCA3+ DCs are present 
at a similar frequency with respect to other immune cells as in control livers. The absolute 
number of BDCA3+ DCs, however, is increased in HBV-infected livers due to the increased 
inflammatory infiltrate. 
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The capacity of blood BDCA3+ DCs to mature and produce IFN-λ is reduced in chronic HBV 
patients
Investigation of the functional state of intrahepatic BDCA3+ DCs in CHB patients was not 
feasible due to the limited amount of biopsy material. Therefore, the possible effects that 
HBV infection may have on the function of BDCA3+ DCs were assessed on BDCA3+ DCs from 
peripheral blood of CHB patients and healthy controls. BDCA3+ DCs were equally present in 
blood of HBV patients and healthy controls (both 0.04%, Figs 2A and 2B). Blood BDCA3+ DCs 
of both HBV patients and controls were largely immature, as indicated by low expression 
Fig 1. Quantification of intrahepatic 
BDCA3+ DCs from HBV patients and 
controls.
(A-B) Liver cells were isolated 
from HBV patients and controls. 
The DC population was identified 
as CD45+Lineage-HLA-DR+ 
mononuclear cells, within which 
BDCA3+CLEC9A+ DCs were detected. 
(A) Representative flow cytometry 
plots and (B) the percentage CD45+ 
cells of total cells (control n=4, 
HBV n=9), percentage DCs of total 
cells (control n=4, HBV n=9) and 
percentage BDCA3+ DCs of total 
cells (control n=5, HBV n=11) in 
livers of controls and HBV patients. 
Indicated are the mean percentage 
and SEM. Open dots represent cells 
from donor livers and filled dots 
represent cells from peri-tumor 
liver tissue. **p < 0.01 by Mann-
Whitney test. (C-D) FFPE sections 
of HBV-infected and control livers 
were stained with anti-CLEC9A Abs 
or non-specific sheep polyclonal 
Abs (green) and quantified (see 
methods). Nuclei were visualized 
using DAPI (blue). Magnification 
200x. (C) Representative pictures of 
an HBV-infected liver with high ALT 
(defined as > 60 IU L-1) and high viral 
load (>10,000 IU ml-1) and a control 
liver (healthy donor liver accepted 
for transplantation). White arrows 
indicate CLEC9A+ DCs. (D) Number 
of CLEC9A+ DCs per microscopic 
field in control livers (n=6) and total 
HBV-infected livers with different 
levels of viral load (low n=8, high 
n=6), ALT (low n=8, high n=6), and 
fibrosis (F0 – F0-1 n=6, F1 – F4 n=7) 
(mean±SEM). *p < 0.05, **p <0.01 
by Mann-Whitney test.
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of the maturation markers CD40, CD83 and CD86 (Figs 2C and 2D). Subsequent in vitro 
maturation by polyI:C induced upregulation of maturation markers both in healthy control 
DCs and DCs from HBV patients, however, this was much less pronounced in BDCA3+ DCs 
from HBV patients (Fig 2D and S3 Fig). Assessment of cytokine secretion showed that 
blood-derived BDCA3+ DCs produced TNF-α and IFN-λ1, but no IFN-α or IFN-β, upon polyI:C 
stimulation (Figs 2E and 2F, S4A Fig, data not shown). Most IFN-λ-producing BDCA3+ DCs 
co-produced TNF-α, and IFN-λ production correlated with TNF-α production (S4B and S4C 
Figs). However, only the secretion of IFN-λ1 by blood BDCA3+ DCs from HBV patients was 
significantly impaired (Figs 2E and 2F). The frequency of IFN-λ1-producing BDCA3+ DCs did 
neither correlate with serum HBV DNA or serum ALT levels nor age (Fig 2G, data not shown). 
Together, these results indicate that, although BDCA3+ DCs are not matured by chronic HBV 
infection, the capacity of CHB patient-derived blood BDCA3+ DCs to mature and produce 
IFN-λ1 upon TLR activation is impaired. 
HBsAg can affect BDCA3+ DC function via an indirect effect 
HBsAg, an HBV-derived protein which is abundantly present in patient’s circulation, has 
previously been shown to functionally impair pDC function [11, 31]. We therefore investigated 
whether HBsAg affected BDCA3+ DC function by incubating BDCA3+ DCs with HBsAg in vitro. 
Using fluorochrome-labeled patient-derived HBsAg (pHBsAg) we observed that BDCA3+ 
DCs readily internalized HBsAg via active endocytosis (Fig 3A). As we used a concentration 
comparable to that found in vivo, these results indicate that a direct interaction between 
BDCA3+ DCs and HBsAg is also likely to occur in vivo. 
Incubation of PBMCs with either pHBsAg or recombinant HBsAg (rHBsAg) for 6 hours 
increased CD40, CD83 and CD86 expression on BDCA3+ DCs, showing that under these 
circumstances the viral antigen can induce maturation (Fig 3B). Contamination of endotoxins 
in the HBsAg preparations, which might affect BDCA3+ DC function, was excluded by Endolisa, 
a specific and sensitive method to detect endotoxins (data not shown). Next, we investigated 
whether HBsAg affected polyI:C-induced cytokine production. IFN-λ1-producing capacity, 
but not TNF-α-producing capacity, of both peripheral blood and intrahepatic BDCA3+ DCs 
upon polyI:C stimulation of PBMCs or liver cells, respectively, was significantly decreased by 
rHBsAg (Figs 3C-3E, data not shown). This effect was diminished upon depletion of rHBsAg by 
immunoprecipitation using anti-HBsAg-coated beads, and restored upon addition of rHBsAg 
to the depleted fraction (S5A Fig), indicating that the effect is HBsAg-specific. In addition, 
patient-derived HBsAg (pHBsAg) also reduced IFN-λ1 production by peripheral blood 
BDCA3+ DCs (S5B Fig). The HBsAg-induced maturation and functional impairment of BDCA3+ 
DCs, however, was only observed when these cells were exposed to HBsAg in the presence 
of other PBMCs. Incubation of isolated BDCA3+ DCs alone with rHBsAg neither induced DC 
maturation, nor affected polyI:C or TNFα and IL-1β-induced maturation, suggesting that 
HBsAg acts on BDCA3+ DCs only via other immune cells (Fig 4A). In addition, rHBsAg did not 
affect polyI:C-induced production of IL-1β, IL-6, IL-8, TNFα and IFN-λ by isolated BDCA3+ 
DCs and also had no effect on the viability of BDCA3+ DCs (Figs 4B and 4C, data not shown). 
Addition of PBMC to isolated BDCA3+ DCs increased the production of IFN-λ, which was 
reduced by rHBsAg, confirming that rHBsAg affected BDCA3+ DCs only indirectly (Fig 4C).
Together, these results demonstrate that HBsAg does not directly mature or impair  BDCA3+ 
DC function, but may have an indirect effect via other immune cells.
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Fig 2. Blood BDCA3+ DCs from CHB patients are impaired in their capacity to mature and produce IFN-λ.
PBMC were isolated from CHB patients and healthy controls. (A-B) The DC population was identified as Lineage-
HLA-DR+ mononuclear cells, within which BDCA3+CLEC9A+ DCs were detected. (A) Representative flow cytometry 
plots and (B) the percentage of BDCA3+ DCs of CD45+ mononuclear cells (control n=22, HBV n=19; mean±SEM). 
PBMCs were stimulated for 5 hours with or without polyI:C. Expression of the maturation markers CD40, CD83 and 
CD86, and cytokine production by BDCA3+ DCs was measured by flow cytometry. (C) Representative histograms 
of maturation marker expression by BDCA3+ DCs. (D) Collected expression data (MFI) for each marker after 
isolation at t=0 (Unstimulated), and  relative upregulation after stimulation compared to the medium control at 
t=5 (TLR-stimulated) (control n=15, HBV n=8) (mean±SEM). (E) Representative flow cytometry plots of TNFα and 
IFN-λ1 production by FSC/SSC gated viable BDCA3+ DC. (F) Collected percentages of TNFα-producing and IFN-λ1-
producing BDCA3+ DCs in controls (n=18) and HBV patients (n=18) (mean±SEM). *p < 0.05 by Mann-Whitney test. 
(G) Spearman’s correlation between the frequency of IFN-λ1-producing BDCA3+ DCs from HBV patients and serum 
HBV DNA or serum ALT levels (n=18). 
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Discussion
BDCA3+ DCs are professional APCs that excel in IFN-λ production. In this study, we report 
on the intrahepatic presence and localization of BDCA3+ DCs in healthy and HBV-infected 
livers. We showed that BDCA3+ DCs reside in inflamed portal tracts and that their numbers 
are increased in HBV-infected livers compared to controls. In addition, blood BDCA3+ 
DCs of CHB patients displayed an impaired maturation and IFN-λ1 response upon ex vivo 
stimulation compared to controls. Furthermore, we demonstrated that the most prominent 
HBV protein, HBsAg, does neither directly induce BDCA3+ DC maturation, nor affects their 
function, but may exert an effect indirectly via an unknown mechanism.
Previous studies have shown that absolute numbers of BDCA1+ DCs and pDCs are increased 
in HBV-infected livers [32]. A result we here confirm and complement by demonstrating that 
Fig 3. HBsAg diminishes IFN-λ1 production by BDCA3+ DCs.
(A) PBMC from healthy subjects were incubated with or without fluorescently-labeled HBsAg for 2 hours at indicated 
temparatures and HBsAg binding/uptake by BDCA3+ DCs was measured by flow cytometry. Representative plots of 
3 independent experiments and donors are shown. (B) PBMC from healthy subjects were stimulated for 6 hours 
with or without rHBsAg, pHBsAg or polyI:C and maturation marker-expression on BDCA3+ DCs was analyzed by 
flow cytometry (n=3; mean±SEM; * p<0.05 by paired Student’s t-test). (C-D) PBMC from healthy subjects were 
stimulated for 7 hours with polyI:C in the presence or absence of rHBsAg and the production of IFN-λ1 by BDCA3+ 
DCs was measured by ICS. Representative flow cytometry plots (C) and the summarized percentage of IFN-λ1-
producing BDCA3+ DCs (D; n=7; mean±SEM) are shown. To determine the percentage of IFN-λ-producing BDCA3+ 
DCs in blood, a minimum threshold of 70 BDCA3+ DCs was used. **p < 0.01 by paired Student’s t-test. (E) Liver 
cells from peri-tumor liver tissue were stimulated for 5 hours with or without polyI:C in the presence or absence 
of rHBsAg and the production of IFN-λ1 by BDCA3+ DCs was measured by ICS. The percentage of IFN-λ1-producing 
BDCA3+ DCs is shown (n=3; mean±SEM). **p < 0.01 by paired Student’s t-test.
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also BDCA3+ DC numbers are increased in the liver upon HBV infection. IHC stainings showed 
that intrahepatic BDCA3+ DCs predominantly reside in portal tracts, and especially in those 
with high immune infiltration. Since these areas accommodate many other immune cells, 
including T cells, this suggests that BDCA3+ DCs may regulate immunity not only in the liver 
draining lymph nodes, but can also do so locally.
The impaired functional capacity of BDCA3+ DCs from CHB patients adds up to our previous 
findings for pDCs and mDCs, which demonstrated that the function of these DC subsets is 
also diminished in CHB patients [10, 11]. The reduced maturation capacity of BDCA3+ DCs 
together with a reduced IFN-λ production may impair T cell activation or skewing in these 
patients, and may thus affect the induction of effective adaptive immune responses [23].
We here find HBsAg was able to reduce IFN-λ production in vitro via an indirect mechanism. 
Therefore HBsAg may have a systemic effect that can contribute to the impaired IFN-λ 
production we observed in BDCA3+ DCs ex vivo, possibly via a monocyte-mediated 
mechanism [11, 33].
In contrast to the reduced maturation we observed for CHB patient-derived BDCA3+ DCs 
in response to polyI:C, maturation of BDCA3+ DCs in vitro was rather enhanced by HBsAg, 
suggesting the presence of alternative mechanisms and/or viral components that act 
on BDCa3+ DCs in these patients. Although BDCA3+ DCs may have become refractory to 
maturation as a result of continued HBsAg exposure, it is likely that the state of chronic 
inflammation itself plays a major role in reduction of BDCA3+ DC function as well. The exact 
contribution of viral proteins/particles or chronic inflammation in the impairment of BDCA3+ 
DC function during CHB remains to be determined. 
Fig 4. HBsAg does not have a direct effect on BDCA3+ DC function.
(A) Isolated BDCA3+ DCs from healthy subjects were stimulated for 6 hours with or without polyI:C or TNFα and 
IL-1β in the presence or absence of rHBsAg or pHBsAg. Mean±SEM percentages of maturation marker-expressing 
BDCA3+ DCs are shown (n=2-3). (B) Isolated BDCA3+ DCs from healthy subjects were stimulated for 24 hours 
with polyI:C in the presence or absence of rHBsAg. Data are shown as mean±SEM cytokine levels determined by 
CBA (n=5). (C) Isolated blood BDCA3+ DCs from healthy subjects were stimulated for 24 hours with polyI:C in the 
presence (n=6) or absence (n=7) of PMBC and/or rHBsAg, and cytokine levels in the culture supernatant were 
determined by ELISA (mean±SEM). *p < 0.05 by paired Student’s t-test.  
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Like blood BDCA3+ DCs, we and others showed that intrahepatic BDCA3+ DCs are able to 
produce IFN-λ [21]. In case of HCV infection, high IFN-λ levels have been detected in the 
liver, which may in part derive from BDCA3+ DCs [34]. CHB livers in contrast hardly contained 
IFN-λ transcripts [34]. Furthermore, IFN-λ levels in serum of CHB patients are comparable 
to those of controls [34-37]. One explanation may be that HBV by itself does not induce an 
effective IFN-λ response during its natural course of infection. However, our finding that IFN-
λ1-producing capacity of BDCA3+ DCs is impaired in HBV patients, together with recent data 
showing the inhibition of IFN-λ production in infected hepatocytes by HBV virions, also open 
up the possibility that HBV may actively diminish IFN-λ1-production [38, 39]. These latter 
studies demonstrated that in hepatocytes, HBV can induce but concurrently suppress host 
innate responses, in particular the TLR3/RIG-I/MDA5-induced response, and that it does so 
by factors present in the viral inoculum and via pgRNA [38]. We here already demonstrate 
that HBsAg has an indirect effect on IFN-λ production by BDCA3+ DCs, but more research 
is required to find out how it does so and whether other viral factors and/or the state of 
chronic inflammation may also contribute to the defect observed in patients’ blood BDCA3+ 
DCs. A pressing remaining question now is whether in HBV-infected livers also intrahepatic 
BDCA3+ DCs show a reduced IFN-λ-producing capacity. Unfortunately, the scarceness of 
BDCA3+ DCs in the liver makes the functional experiments on biopsy BDCA3+ DCs extremely 
challenging. In addition, the availability of liver biopsies for such studies is limited, especially 
since implementation of the fibroscan to determine fibrosis stage. Therefore, performing 
such studies is at this moment beyond our possibility.
In conclusion, we demonstrate for the first time that BDCA3+ DCs are increased in  HBV-
infected livers and that the function of BDCA3+ DCs of HBV patients is impaired. These 
results suggest that BDCA3+ DCs are available on site to be exploited to improve/redirect 
HBV-specific immune responses. For example, by targeting local BDCA3+ DCs with TLR3 
ligands to achieve local IFN-λ production, possibly even in combination with HBV antigens 
for simultaneous cross-presentation of viral antigens. To achieve optimal effect however, our 
study suggests that measures may need to be taken to overcome the impaired maturation 
and IFN-λ-producing capacity of BDCA3+ DCs in CHB patients. 
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Supplementary information 
S1 Fig. Quantification of intrahepatic BDCA3+ DCs from HBV patients and controls.
Liver cells were isolated from HBV patients and controls. The percentage BDCA3+ DCs of CD45+ cells (control n=20, 
HBV n=14) in livers of controls and HBV patients were determined. Indicated are the mean percentage and SEM. 
Open dots represent cells from donor livers and filled dots represent cells from peri-tumor liver tissue. 
S2 Fig. Specific expression of CLEC9A on BDCA3+ DC.
Representative flow cytometry plots of CLEC9A expression on lineage-CD45+HLA-DR+BDCA3hi liver cells. 
S3 Fig. Upregulation of maturation markers upon stimulation.
PBMC were isolated from CHB patients and healthy controls and stimulated for 5 hours with or without polyI:C. 
Expression of the maturation markers CD40, CD83 and CD86 by BDCA3+ DCs was measured by flow cytometry. 
Collected expression data (MFI) for each marker after isolation at t=0 and stimulation at t=5 is shown (control n=15, 
HBV n=8) (mean±SEM). *p<0.05, **p<0.01, ***p<0.001 by Wilcoxon signed rank test. 
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S4 Fig. Correlation between IFN-λ and TNF-α production.
PBMCs of CHB patients and healthy controls were stimulated for 5 hours with or without polyI:C. (A) 
Representative histogram including the isotype control of IFN-λ1 production by FSC/SSC-gated viable BDCA3+ DCs. 
(B) Representative flow cytometry plots of TNF-α and IFN-λ1 production by FSC/SSC-gated viable BDCA3+ DC. (C) 
Pearson’s correlation between TNF-α and IFN-λ1 production by BDCA3+ DCs from controls (open dots) and HBV 
patients (filled dots) (n=28).
S5 Fig. Inhibition of IFN-λ production by pHBsAg and rHBsAg
(A) PBMCs of healthy controls were stimulated for 7 hours with polyI:C in the presence or absence of rHBsAg 
(HBsAg), a fraction from which rHBsAg was depleted (α-HBs-Ig treated), or a HBsAg-depleted fraction to which (5 
μg ml-1) rHBsAg was added (α-HBs-Ig treated + HBsAg). The mean ±SEM percentage of IFN-λ1-producing BDCA3+ 
DCs is shown. * p<0.05 by paired Student’s t-test (B) PBMC of healthy controls were stimulated for 7 hours with 
or without polyI:C in the presence or absence of pHBsAg. The production of IFN-λ1 by BDCA3+ DCs was measured 
by ICS. The mean±SEM percentage of IFN-λ1 BDCA3+ DCs from 5 different donors is shown. * p<0.05 by paired 
Student’s t-test.
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Abstract
Hepatitis B virus (HBV) infection can cause chronic liver disease which is associated with 
increased risk of liver cirrhosis, liver failure and liver cancer. Clearance of HBV infection 
requires effective HBV-specific immunity, however the immunological mechanisms that 
determine the development of effective HBV-specific immunity are poorly understood. 
Dendritic cells (DC) play a pivotal role in the regulation of anti-viral immunity. Here, we 
investigated the interaction between HBV surface antigen (HBsAg), the main envelop 
glycoprotein of HBV, and BDCA1+ myeloid dendritic cells (mDC).  
Exposure of peripheral blood-derived BDCA1+ mDC to HBsAg resulted in strong DC 
maturation, cytokine production and enhanced capacity to activate antigen-specific CTL. By 
using neutralizing antibodies, crucial roles for CD14 and TLR4 in HBsAg-mediated BDCA1+ 
mDC maturation were identified. Concordantly, HBsAg-mediated DC maturation required 
FCS or human plasma, naturally containing soluble CD14 (sCD14). Intriguingly, HBsAg-
induced DC maturation was significantly reduced in umbilical cord blood-plasma that 
contained less sCD14 than adult plasma, indicating that sCD14 is an important host factor 
for recognition of HBsAg by DC and subsequent DC activation. A direct interaction between 
sCD14 and HBsAg was demonstrated by using ELISA. Moreover, sCD14-HBsAg complexes 
were detected both in vitro and in serum of HBV-infected patients. Abundance of sCD14-
HBsAg complexes varied between chronic HBV disease stages and correlated with activation 
of BDCA1+ mDC in vivo.
We conclude that HBsAg activates BDCA1+ DC via a sCD14-dependent mechanism. These 
findings provide important novel insights into initiation of HBV-specific immunity and 
facilitate development of effective immunotherapeutic interventions for HBV.
Importance
 
Hepatitis B virus (HBV) infection is a significant health problem as it causes progressive liver 
injury and liver cancer in patients with chronic HBV infection, which affects approximately 
250 million individuals worldwide. Part of adults and the majority of neonates fail to mount 
an effective immune response and consequently develop chronic infection. The viral and 
host factors involved in the initiation of effective HBV-specific immune responses remain 
poorly understood. Here we identified CD14 and TLR4 as receptors for HBsAg, the main 
HBV envelop antigen. HBsAg induced strong maturation of dendritic cells (DC), which have 
a central role in regulation of virus-specific immunity. These results provide essential novel 
insights into the mechanisms underlying initiation of HBV-specific immunity. Intriguingly, 
since neonates have naturally low sCD14, the finding that serum-derived sCD14 is a crucial 
host factor for recognition of HBsAg by DC may have implications for immunity of neonates 
to HBV infection.
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Introduction
Hepatitis B virus (HBV) is a dsDNA virus that is transmitted via blood and specifically 
infects hepatocytes. It can cause chronic liver disease and progressive liver injury leading 
to increased risk of liver cirrhosis, liver failure and liver cancer [1]. The current estimated 
prevalence of HBV infection is 248 million individuals globally [2]. Although the initiation 
of an effective anti-viral immune response is paramount for resolving HBV infection [3], the 
early steps in the recognition of the virus by immune cells and the functional consequences 
of this interaction remain to be resolved.
A pivotal role for dendritic cells (DC) is anticipated, because these cells play a central role in 
the orchestration of anti-viral immunity due to the expression of a wide variety of different 
pathogen-recognition receptors and their unique capacity to initiate virus-specific cytotoxic 
T cell (CTL) responses [4,5]. Among the different DC subsets, BDCA1+ myeloid DC (mDC) are 
of particular interest for HBV-specific immunity, since Hepatitis B surface antigen (HBsAg) 
positive mDC were detected in liver [6] and peripheral blood [7] of HBV patients. This suggests 
that interaction between BDCA1+ mDC and HBsAg, the main envelop glycoprotein present 
on HBV infectious particles and sub-viral particles, occurs in vivo. Although initially it was 
suggested that HBsAg has immune-regulating capacities (reviewed in [8]), more recently, also 
immune-stimulatory effects of HBsAg on myeloid cells including monocytes [9], monocyte-
derived DC [10] and Kupffer cells [11] have been reported. Nevertheless, whether HBsAg is 
able to directly activate mDC and which receptor(s) are involved is currently unknown. 
In the present study we investigated the interaction of HBsAg with BDCA1+ myeloid DC and 
its functional consequences. We demonstrated that HBsAg can induce maturation/activation 
and cytokine production in these mDC. By using neutralizing antibodies, we showed that 
HBsAg-dependent maturation of DC, but not uptake of HBsAg, is dependent on CD14 and 
TLR4. Since DC hardly express membrane-bound CD14, we postulated that HBsAg-induced 
DC maturation is mediated via serum component soluble CD14 (sCD14). Interestingly, by 
using serum from umbilical cord blood that naturally contains low sCD14, we showed that 
sCD14 concentration is associated with the strength of HBsAg-mediated DC maturation. In 
conclusion, we identified CD14 and TLR4 as PRR for HBsAg and sCD14 as important host 
factor for activation of BDCA1+ DC by HBsAg.
Materials and Methods 
Isolation of monocytes and BDCA1+ myeloid DC
Monocytes and BDCA1+ myeloid DC (mDC) were isolated from buffy coats of healthy 
blood donors. First, PBMC were isolated by using Ficoll-Paque (GE Healthcare) density 
gradient centrifugation. Monocytes were isolated from PBMC by positive selection using 
anti-CD14 microbeads (Milteny Biotec). BDCA1+ mDC were isolated from PBMC by CD19+ 
cell depletion followed by positive selection using anti–BDCA1-PE and PE–conjugated 
microbeads (Miltenyi Biotec). Acceptable purity was minimally 95%, as assessed by flow 
cytometry. Standard culture medium was RPMI 1640 (Lonza), with 8% heat-inactivated fetal 
calf serum (FCS, Sigma), penicillin/streptomycin (Invitrogen), L-glutamin (Lonza) and 10 ng/
ml GM-CSF (Leukine, genzyme).    
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Hepatitis B surface antigen (HBsAg) and control proteins
HBsAg isolated from pooled serum of patients (pHBsAg; subtype ay; purity 98%) was 
purchased from American Research Products (ARP). Recombinant HBsAg (rHBsAg) and beta 
Nerve Growth Factor (beta-NGF), both produced in mammalian cells, and recombinant 
HBsAg produced in yeast cells (yHBsAg) were purchased from Prospec. Since many 
commercially obtained recombinant proteins contain endotoxin impurities [12], we carefully 
selected preparations with the highest purity. Furthermore, all proteins were tested at used 
concentrations for endotoxin impurities by Endolisa (Hyglos GmbH, Bernried, Germany), 
a specific and sensitive method to detect endotoxins [12], according to manufacturer’s 
instructions. Recombinant HBsAg and beta-NGF had endotoxin levels <0.1 EU/ml, which 
is below detection limit for BDCA1+ DC [12]. Unexpectedly, patient-derived HBsAg used at 
1 µg/ml contained low endotoxin impurities (Endolisa result 1.4 EU/ml), yet at 100 ng/ml, 
which was used in most experiments, pHBsAg endotoxin levels were < 0.1 EU/ml, which is 
below the reported detection limit for BDCA1+ DC [12]. Heat-treatment of 3x concentrated 
preparations of pHBsAg and LPS (Ultrapure, from S. Minnesota, Invivogen) was performed 
by boiling for 30 minutes at 100 degrees in a heat block [13]. Depletion of pHBsAg was 
performed via 2 different methods, starting with a stock of pHBsAg of 100 ug/ml diluted 
in medium. First, heparin depletion was performed by injecting HBsAg stock (untreated 
fraction) into a HiTrap Heparin HP column (GE Healthcare). Flowthrough was collected 
(depleted fraction), column was washed with PBS and bound HBsAg was eluted with TRIS 
buffer (350 mM NaCl, 20mM Tris, pH 7.4). Efficiency of HBsAg depletion, as measured by 
HBsAg ELISA, was 95.6% whereas recovery after elution was 52.2%. For specific immune 
depletion, pHBsAg was incubated with protein G sepharose beads (GE Healthcare) pre-
coated with either Hepatect (Biotest), a pool of human IgG specific for HBsAg, or mouse 
IgG1 (Abcam) for 2h at 4 degrees followed by centrifugation to obtain a HBsAg depleted 
supernatant. Delipidation of HBsAg was performed as described previously [14]. In brief, 
1 mg/ml of HBsAg was incubated for 2h at RT with the non-denaturing detergent β-D-
octyl glucoside (OG, Sigma-Aldrich) at 0% (control delipidation) or 2% [wt/vol in PBS] and 
subsequently dialysed 2x against PBS.
Exposure of mDC to HBsAg
Isolated mDC were incubated with medium or HBsAg at indicated concentrations. To assess 
the role of CD14 or TLR4, cells were pre-incubated with 0.2 μg/ml neutralizing antibodies to 
CD14 (clone MEM-18, mouse IgG1, Abcam), TLR4 (clone HT52, mouse IgG1, eBioscience) or 
mouse IgG1 isotype control (clone MG1-45, Abcam) for 1 hr at 37°C. After 20h of exposure 
at 37°C, mDC supernatants were harvested and stored at -20°C and cell surface markers 
were analyzed by flow cytometry. Antibodies used were mouse anti-BDCA1-PE (Miltenyi 
Biotec), mouse anti-CD14-eFluor450 (clone 61D3), mouse anti-CD83-Fi (clone HB15e) and 
mouse anti-CD40-APC (clone 5C3, all eBioscience). Samples were stained for 30 minutes at 
4˚C in flow buffer (PBS containing 1% BSA, 1% heat-inactivated human serum and 0.02% 
NaN3). Samples were acquired on a FACS Canto II cytometer (BD Biosciences) and data was 
analyzed by FlowJo software (Treestar). Concentrations of human IL-6 and IL-12p40 were 
measured in culture supernatants by ELISA (eBioscience). 
For experiments assessing the role of serum, standard medium was replaced by X-Vivo 
(Lonza) with 10 ng/ml GM-CSF, supplemented or not with 8% heat-inactivated FCS or 1% 
or 2% human serum/plasma, as indicated. Human plasma, from adult peripheral blood or 
umbilical cord blood was collected after Ficoll-Paque density gradient centrifugation and 
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stored at -80˚C. Plasma was centrifuged for 1 min at 3000 RPM before use in experiments.
Exposure of monocytes to HBsAg
Monocytes were pre-incubated with αCD14 or isotype control  for 1 hr and subsequently 
exposed to medium, 1 μg/ml pHBsAg or rHBsAg for 18 hr at 37˚C. During the last 16 hours 
of culture, brefeldin A (10 μg/ml; Sigma-Aldrich) was added. The cells were harvested, fixed 
with 2% formaldehyde (Merck), permeabilized with 0.5% saponin (VWR) in flow buffer and 
stained for CD14, IL-6 and TNFα (all from eBioscience).
In vitro uptake/binding experiments
pHBsAg was conjugated to DyLight 650 sulfhydryl-reactive dye (FL-HBsAg; Thermo Fisher 
Scientific). After conjugation, unbound conjugate was removed by 2x dialysis against PBS. 
For confocal microscopy analysis, mDC were seeded in 35mm poly-d-lysine coated glass 
bottom petri dishes (MatTek corporation) and exposed for 2 or 20h to 5 µg/ml FL-HBsAg. 
After exposure, DC were washed with PBS, stained for HLA-DR (clone LN3, eBioscience) and 
goat anti-mouse Dylight 488 (clone Poly4053, Biolegend) as a secondary Ab and fixed with 
2% formaldehyde. DC were acquired on a Zeiss LSM 510 inverted confocal microscope with 
Argon (488nm) and HeNe (633nm) lasers and 63x oil-immersed objective. Digital zoom 3x. 
Image J software was used to merge images. For flow cytometry analysis, PBMC depleted 
for CD14+ cells by MACS were pre-treated with medium, 1 μg/ml αCD14 or isotype control 
Ab, and subsequently exposed to 1 µg/ml FL-HBsAg for 2 hr, either at 4°C or 37°C. Cells were 
washed with cold PBS, stained with mouse anti-BDCA1-PE (Miltenyi Biotec) and mouse anti-
CD20-eFluor450 (eBioscience), fixed with 2% formaldehyde and analysed by flow cytometry. 
T cell activation and cross-presentation experiments
To examine the potency of HBsAg to enhance T cell stimulatory activity by DC, 25.000/well 
freshly isolated HLA-A2+ BDCA1+ mDC were pre-incubated for 30 minutes at 37 °C with 
1 μg/ml pHBsAg or medium as control and subsequently incubated with 100 ng/ml HBV 
Core18-27 peptide, for 20h at 37 °C. Subsequently, DC were washed 2 times and co-cultured 
with 50.000 HLA-A2-restricted HBV Core18-27-specific CD8+ T cells [15]. To examine cross-
presentation of HBsAg by DC, 25.000/well freshly isolated HLA-A2+ BDCA1+ mDC were pre-
incubated for 1h at 37 °C with 5 μg/ml rHBsAg or medium as a control. After 2  washes, DC 
were co-cultured with 50.000 HLA-A2-restricted HBsAg183-192-specific CD8+ T cells [15,16]. 
HBV-specific CTL were kindly provided by Prof. Dr. A. Bertoletti, Emerging Infectious Diseases,
Duke-Nus Graduate Medical School, Singapore). After 20h, supernatants were collected and 
IFNγ was measured by ELISA (eBioscience).
Analysis of sCD14 concentration and sCD14-HBsAg complexes by ELISA
CD14 concentration and sCD14-HBsAg complexes were analyzed by sandwich ELISA. For 
sCD14 and sCD14 – HBsAg complexes in serum, samples were diluted 1000x and 100x, 
respectively. Coating antibody was rat anti-human sCD14 (clone 55-3, BD Biosciences). 
Detection antibodies were biotinylated anti-human sCD14 (clone 3-C39, BD Biosciences) 
or biotinylated anti-HBsAg (clone 9H9)[17]. Assay diluent, used for blocking and sample 
dilution, streptavidin-HRP and TMB solution were all from eBioscience. Wash buffer was 
PBS + 0.05% Tween20. Reaction was stopped with 1:3 v/v of H2SO4. Optical density (OD) at 
450 nm was measured on Biorad imager.  
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Patients
Serum of sixty patients with HBV infection that visited our outpatient clinic (ErasmusMC) and 
fifteen age- and sex-matched healthy control individuals was collected and stored at -80°C. 
The sixty patients were all seropositive for HBsAg and represented a well characterized cohort 
belonging to different clinical phases of chronic HBV infection according to standardized 
criteria [18]. Serum HBV DNA was determined by realtime PCR using a Cobas 48 (Roche). 
HBsAg levels were determined on a Cobas 411 analyzer (Roche). Serum ALT was measured 
on an automated analyzer. Qualitative HBeAg and anti-HBeAg were measured on an Abbot 
Architect analyzer. For a subgroup of these patients, PBMCs were also collected and stored 
at -150°. The institutional ethical review board of the Erasmus MC, Rotterdam approved the 
clinical protocols, and written informed consent was obtained from all individuals prior to 
their donation of blood. 
Analysis of DC phenotype ex vivo
1 million thawed PBMC from patients with CHB (n=4/group) and healthy controls (n=7) 
were analyzed for mDC-specific activation markers by flow cytometry. Samples were stained 
for 30 minutes at 4˚C in flow buffer. Antibodies used were mouse anti-BDCA1-PE (Miltenyi 
Biotec), mouse anti-CD20-eFluor450, anti-CD80-FITC (mIgG1) or isotype control and anti-
CD83-APC (mIgG1) or isotype control (all eBioscience). Dead cells were excluded with Aqua 
dead cell stain (eBioscience). mDC were gated as BDCA1+/CD20-. Isotype controls were 
used to discriminate positive cells from non-specific background staining. 
Results
HBsAg induces maturation, cytokine production and enhanced T cell activation capacity 
in myeloid DC
The interaction between BDCA1+ mDC and patient-derived HBsAg (pHBsAg) was studied 
in vitro by exposing freshly isolated mDC to fluorescent pHBsAg (FL-HBsAg). After 2 hours 
of incubation with FL-HBsAg and subsequent co-staining for HLA-DR to visualize the cell 
membrane, confocal microscopy showed intracellular HBsAg positivity in the majority of 
DC, indicating that mDC can efficiently take up HBsAg (Fig. 1A). After 20 hours of incubation 
with FL-HBsAg, HBsAg+ DC formed clusters, indicating that HBsAg induced activation of DC. 
Therefore, the functional consequence of this interaction was further investigated by 
exposing BDCA1+ mDC isolated from healthy donors to different concentrations of 
HBsAg. Exposure of mDC to pHBsAg resulted in dose-dependent upregulation of the 
typical DC maturation marker CD83 and the co-stimulatory molecule CD40 (Fig. 1B), and 
dose-dependent secretion of L-6 and IL-12 (Fig. 1C). In addition to DC maturation and 
cytokine production, pre-incubation of mDC with pHBsAg enhanced peptide-specific IFNγ 
production by HBV core-specific CTL (Fig. 1D). Interestingly, HBsAg-positive DC were able to 
cross-present HBsAg-derived epitope to the cognate CTL, in the absence of any additional 
maturation stimulus (Fig. 1E).
Since antibodies capable of neutralizing the immune stimulatory effect of HBsAg are not 
available, we addressed the specific role of HBsAg by several approaches. Heat treatment 
at 100 °C completely abrogated the stimulatory activity of LPS whereas the stimulatory 
activity of HBsAg was maintained (Fig. 1F). Depletion of HBsAg from the preparation via 
either heparin chromatography or specific immune precipitation significantly reduced 
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Figure 1: Interaction 
with HBsAg induces mDC 
maturation and function.
(A) BDCA1+ mDC were 
incubated with medium 
(control) or fluorescently-
conjugated HBsAg for 
2 or 20h and binding/
uptake was measured by 
confocal microscopy after 
co-staining for HLA-DR. 
Representative merged 
confocal images of 2 
independent experiments 
are shown. (B/C) BDCA1+ 
mDC were incubated for 
20h with medium, 100 
ng/ml or 1000 ng/ml 
patient-derived HBsAg 
(pHBsAg). (B) CD83 and 
CD40 expression was 
determined by flow 
cytometry and displayed 
as % positive DC or mean 
fluorescense intensity 
(MFI), respectively. 
Representative FACS 
histograms show mDC 
incubated with medium 
(left) or 1000 ng/ml 
pHBsAg (right) and 
stained for CD83 (grey) 
or isotype control (white). 
(C) Concentrations of 
IL-6 and IL-12p40 in 
mDC supernatants were 
determined by ELISA. 
Paired Student’s t-test was 
used to compare means 
of 6-15 experiments with 
different donors. * P<0.05, 
** P<0.01, *** P<0.001. 
(D) IFNγ production by HBV Core-specific CTL after 20h co-culture with  HLA-A2+ BDCA1+ mDC pre-incubated 
with pHBsAg or medium and subsequently loaded with peptide HBV Core18-27. Summary of five experiments with 
DC from different subjects. (E) IFNγ production by HBsAg-specific CTL after 20h co-culture with HLA-A2+ BDCA1+ 
mDC incubated with rHBsAg or medium control (-). Shown is mean±SD of IFNγ from 2 experiments with DC from 
different subjects. (F) BDCA1+ mDC were exposed to increasing concentrations of pHBsAg (left graph) or LPS (right 
graph), either untreated (normal, black bars) or heated at 100°C (boiled, grey bars). Shown is mean±SD of %CD83+ 
DC from 2 experiments with DC from different subjects. (G-I) BDCA1+ mDC were exposed to (G) untreated pHBsAg 
(control) or a preparation depleted for pHBsAg via heparin affinity chromatography (depleted) or the depleted 
preparation supplemented with normal pHBsAg (depleted + add-back); (H) pHBsAg after immunoprecipitation 
with protG-isotype (isotype) or protG-Hepatect (depleted) or the latter with added normal pHBsAg (depleted + 
add-back); (I) pHBsAg that was treated with 2% OG (delipidation) or 0% OG (control) and pHBsAg treated with 2% 
OG and complemented with normal HBsAg (delipidation + add-back). Mean±SEM of relative %CD83+ mDC (G-I) 
and IL-6 concentration in mDC supernatant (G) based on three to five pooled experiments with DC from different 
subjects. % decrease of second bar compared to first bar is indicated. Paired Student’s t-test was used to compare 
means of IL-6 production (G). ** P<0.01
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upregulation of CD83 and secretion of IL-6 (Fig. 1G/H). When HBsAg was added-back to 
the depleted preparations, DC maturation and secretion of IL-6 was restored (Fig. 1 G/H) 
showing that the treatment by itself did not cause the reduced DC maturation and function. 
Heparin depletion of LPS did not reduce its ability to stimulate BDCA1+ DC (data not shown). 
Together, these experimental approaches demonstrated that the observed DC maturation 
and function was specifically dependent on HBsAg.  
In addition to patient-derived HBsAg, DC maturation and function was also induced by 
recombinant HBsAg (rHBsAg) produced in Chinese Hamster Ovary (CHO) cells, but neither 
by a control CHO-derived glycoprotein from the same company, recombinant Nerve Growth 
Factor beta (beta-NGF), nor by recombinant HBsAg produced in yeast (yHBsAg) (data not 
shown). The immune-stimulatory effect observed by both rHBsAg and pHBsAg, but not 
yHBsAg, suggests that the mammalian nature of the host-derived lipids and/or glycosylation 
may be important for its immune stimulatory effect. The role of lipids in the HBsAg particle 
was further addressed by exposing mDC to pHBsAg that was treated with 2% β-D-octyl 
glucoside (OG) to extract lipids from the particle, as described previously [14]. OG-treated 
but not sham-treated HBsAg totally lost its capacity to induce DC maturation (Fig. 1I), 
suggesting that the lipids play a major role in the immune-stimulatory effect of HBsAg on 
DC. In contrast, similar OG treatment of LPS only partly reduced its capacity to induce DC 
maturation and function (data not shown). Thus, exposure of freshly isolated mDC to HBsAg 
induces DC maturation, cytokine production and enhanced capacity to activate virus-specific 
CTL. Furthermore, the immune-stimulatory effect on myeloid DC is specific for HBsAg and is 
restricted to HBsAg particles from a mammalian host.  
 
HBsAg-induced DC maturation is dependent on CD14 and TLR4
Since monocytes are described to bind HBsAg via CD14 [19], we investigated the role of 
this molecule in cellular activation by HBsAg. First, we examined the role of CD14 in HBsAg-
induced activation of monocytes. pHBsAg efficiently induced secretion of IL-6 and TNFα in 
the majority of monocytes, which was largely absent when monocytes were pre-treated with 
αCD14 but not isotype control antibodies (data not shown). Next, we examined the role of 
CD14 in HBsAg-dependent activation of BDCA1+ mDC. To exclude a possible interference of 
endotoxin contamination, we used HBsAg concentrations that were tested free of endotoxin 
contamination by Endolisa (see Methods section). Pre-incubation of mDC with αCD14, but 
not isotype control antibodies completely abrogated pHBsAg-dependent upregulation of 
CD83, CD40 (Fig. 2A) and secretion of IL-6 and IL-12 (Fig. 2B), but did not affect pHBsAg 
uptake (Fig. 2C), suggesting a crucial role for CD14 in HBsAg-induced maturation and 
function of mDC. Given the essential role of CD14 as co-receptor for TLR4 [20], we also 
investigated the role of TLR4 in HBsAg-induced DC maturation. Interestingly, neutralizing 
antibodies to TLR4 also blocked HBsAg-mediated upregulation of CD83 (Fig. 2D), suggesting 
that HBsAg-induced DC maturation is dependent on both CD14 and TLR4. HBsAg-induced 
DC maturation by rHBsAg was also dependent on CD14 and partially dependent on TLR4 
(Fig. 2E). The observation that only a sub-population of about 11% BDCA1+ DC express CD14 
on their cell membrane (Fig. 2F) was not in line with the crucial observed role of CD14 in 
HBsAg-induced DC maturation. Additional depletion of CD14+ cells revealed that purified 
CD14- BDCA1+ DC were also activated by HBsAg in a CD14-dependent manner (Fig. 2G). 
Based on these results, the role of membrane-expressed CD14 (mCD14) in HBsAg-mediated 
DC maturation was brought into question and the data pointed towards a role for soluble 
CD14 (sCD14), which is naturally present in FCS and human serum and can facilitate cellular 
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Figure 2: HBsAg-induced DC maturation is dependent on CD14 and TLR4.
(A/B) mDC were pre-incubated with αCD14 or isotype control and subsequently incubated with medium or 100 
ng/ml pHBsAg for 20 hr. Mean±SEM of %CD83+ DC and CD40 MFI (A) and IL-6 or IL-12p40 (B) of 4-5 experiments 
with different donors. (C) PBMC depleted for CD14+ cells were pre-incubated with medium (-), αCD14 or isotype 
control and subsequently exposed to 1 μg/ml FL-HBsAg for 2 hr at 37°C.  mDC exposed to medium and FL-HBsAg at 
4°C were used as controls. %HBsAg+ cells of BDCA1+CD19-DC was determined by flow cytometry. Representative 
FACS histograms and summary of mean±SD of duplicate showing %HBsAg+ DC. Data is representative for three 
experiments with different donors. (D/E) mDC were pre-incubated with medium (-), αCD14, αTLR4, a combination 
of αCD14 and αTLR4 (combi) or isotype control and subsequently exposed to medium or 100 ng/ml pHBsAg (D) 
or recombinant HBsAg (rHBsAg) (E)  for 20 hr. Mean±SEM of %CD83+ DC of four (D) or three (E) independent 
experiments with different donors. Paired Student’s t-test: * P<0.05, ** P<0.01, *** P<0.001. (F) Example of flow 
cytometry analysis of CD14 and BDCA1 expression on PBMC. Indicated percentage represents %CD14+ of BDCA1+ 
cells. Representative plot of five experiments with different donors. (G) mDC, either isolated by standard procedure 
(white bars) or with additional CD14 depletion (black bars), were pre-incubated with αCD14 or isotype control and 
subsequently exposed to medium (-) or pHBsAg. Data represents mean±SEM %CD83+ mDC of three experiments 
with different donors.
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activation of cells that do not express mCD14 [21,22].
HBsAg-mediated DC maturation is dependent on sCD14 naturally present in FCS and 
human serum
To investigate the role of sCD14, HBsAg-dependent DC maturation was compared between 
serum-free cultures or cultures supplemented with FCS (Fig. 3A/B). Serum-free cultures 
neither impaired cell viability, nor induced a general defect in DC maturation, as TNFα/IL-
1β-induced DC maturation was still intact (data not shown). HBsAg-induced DC maturation 
and cytokine production was absent in serum-free cultures, but was restored by addition of 
FCS (Fig. 3A/B), suggesting that a serum component is needed to support HBsAg-induced 
DC maturation. Similar as with FCS, HBsAg-induced DC maturation and cytokine production 
was restored by adding human serum (Fig. 3C/D). Furthermore, in the presence of human 
serum, HBsAg-dependent DC maturation was totally blocked by pre-incubation with CD14 
neutralizing antibodies (Fig. 3C/D), suggesting a crucial role for serum factor sCD14 in 
facilitating HBsAg-dependent DC maturation.  
Figure 3: HBsAg-mediated DC 
maturation is dependent on sCD14 
naturally present in FCS and human 
serum.
mDC were pre-incubated with αCD14 
or isotype control and subsequently 
incubated with 100 ng/ml pHBsAg or 
medium in Xvivo serum-free medium 
with or without 8% FCS (A/B) or 
1% human serum (C/D) for 20 hr. 
Mean±SEM of %CD83+ mDC or CD40 
MFI (A/C) and mean±SEM of IL-6 and 
IL-12p40 (B/D) is displayed. Paired 
Student’s t-test was used to compare 
means of five (A/B) and three (C/D) 
experiments with different donors. 
Paired Student’s t-test: * P<0.05, ** 
P<0.01, *** P<0.001.
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Low CD14 in umbilical cord blood-derived plasma correlates with reduced HBsAg-induced 
DC maturation
Interestingly, plasma from umbilical cord blood contains significantly lower sCD14 levels 
than plasma from adults (Fig. 4A and [23]. To further establish the role of sCD14 in BDCA1+ 
DC activation by HBsAg, we tested if neonatal serum consequently has a reduced capacity 
to facilitate HBsAg-induced DC maturation compared to adult serum. HBsAg-dependent 
maturation of healthy control DC was compared in serum-free medium supplemented 
Figure 4: Low CD14 in neonates correlates with reduced HBsAg-induced DC maturation.
(A) Mean±SEM of sCD14 concentrations in plasma obtained from peripheral blood of healthy adults (n=17) or 
umbilical cord blood (n=20). Student’s t-test ***P <0.001. (B/C) mDC obtained from healthy adult donor were 
pre-treated with isotype control or αCD14 and subsequently exposed to 100 ng/ml pHBsAg in the presence of 
plasma from adult blood (n=17) or cord blood (n=20) for 20 hr. (B) Summary of mean±SEM of %CD83+ mDC 
(left) and correlation between sCD14 concentration and %CD83+ mDC (right) after exposure to HBsAg for each 
individual plasma sample. (C) Summary of mean±SEM of IL-6 or IL-12p40 in mDC supernatants and correlation 
between sCD14 concentration and IL-6 concentration after exposure to HBsAg for each individual plasma sample. 
Student’s t-test: ** P<0.01, *** P<0.001. Spearman correlation coefficient and P-value is shown. Data shown in B/C 
is representative for 3 independent experiments with DC of different donors. (D) mDC obtained from healthy adult 
donors were exposed to medium (-) or 100 ng/ml pHBsAg (+) in the presence of Xvivo medium supplemented with 
1 or 2% plasma from adult blood, cord blood or both. Mean±SD of %CD83+ mDC from 2 independent experiments 
with different mDC donors in which 3 different cord blood samples were separately tested. Paired Student’s t-test: 
** P<0.01.
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with plasma samples either derived from different adult individuals or different cord blood 
plasma samples. Upregulation of CD83 (Fig. 4B), CD40 (data not shown) and production of 
IL-6 and IL-12 (Fig. 4C) in response to HBsAg was indeed significantly reduced when cultures 
were supplemented with cord blood plasma samples compared to adult plasma samples. 
In both cultures, HBsAg-induced maturation and function were completely abrogated in the 
presence of CD14 neutralizing antibodies. Furthermore, the level of sCD14 in each individual 
plasma sample highly correlated with its capacity to mediate HBsAg-induced DC maturation 
and cytokine production (Fig. 4B/C). Increasing concentrations of cord blood plasma 
enhanced HBsAg-induced DC maturation (Fig. 4D), however, HBsAg-induced DC maturation 
never reached the level as observed with adult plasma (data not shown). Furthermore, 
addition of adult plasma together with neonatal plasma in a 1:1 ratio resulted in HBsAg-
induced DC maturation similar to the level induced by adult plasma alone (Fig. 4D). These 
data suggest that the reduced capacity of cord blood plasma to facilitate HBsAg-dependent 
DC activation is not caused by the presence of a dominant negative/inhibitory factor in 
cord blood plasma, but can be mainly attributed to a suboptimal concentration of sCD14. 
Together these results indicate that strength of HBsAg-induced maturation and function of 
DC is regulated by the concentration of sCD14.
Figure 5: sCD14-HBsAg 
complexes are detected in 
vitro and in serum of HBV-
infected patients.
(A) Schematical representation 
of sandwich ELISA to measure 
complexes of soluble CD14 
(sCD14) and HBsAg. (B) 
Detection of sCD14-HBsAg 
complexes (optical density, 
OD) by ELISA after 20 hr 
incubation of indicated 
concentrations pHBsAg with 
medium (-sCD14) or 630 ng/ml 
recombinant sCD14 (+sCD14). 
Data is representative of 3 
similar experiments. (C/D) 
Concentration of HBsAg (C) 
and abundance (OD) of sCD14-
HBsAg complexes (D) in sera 
of healthy controls and HBV-
infected patients categorized 
by clinical disease stages (HC= 
healthy controls, IT=immune 
tolerant, IA=immune active, 
IC=inactive carrier, E neg=E 
negative CHB patients). Data 
represent individual values and 
mean of n=15/group. Means 
were compared by ANOVA 
followed by Dunnett multiple 
comparison test to compare 
means of different groups to 
reference group, which was IC group (C) or HC group (D): **** P<0.0001, *** P<0.001, * P<0.05. n.s. not significant. 
(E) Correlation between OD of sCD14-HBsAg complexes and HBsAg level. Spearman r=0.7967, P<0.0001.
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sCD14-HBsAg complexes are detected in vitro and in serum of HBV-infected patients
Next, it was important to know whether HBsAg and sCD14 directly interact. To investigate this, 
we developed a sandwich ELISA to detect complexes of HBsAg and sCD14 (Fig. 5A). The ELISA 
specifically detected in vitro-formed complexes of pHBsAg and recombinant sCD14 but not 
pHBsAg or sCD14 alone (Fig. 5B). The detection of sCD14 – HBsAg complexes demonstrated 
that HBsAg and CD14 can directly interact. Furthermore, the dose-dependent detection 
of sCD14 – HBsAg complexes (Fig. 5B) indicated that the ELISA is also suitable for semi-
quantification of these complexes. To investigate whether these complexes are also present 
in vivo, we tested serum samples from HBV-infected patients and healthy control subjects 
for the presence and abundance of sCD14-HBsAg complexes. The patients represented 
different clinical disease stages, based on viral load, serum HBsAg (Fig. 5C) and ALT (Table 1). 
The HBsAg concentrations measured in serum of these patients could reach concentration 
of more than 5x10e5 IU/ml, which corresponds to approximately 1000 µg/ml (Table 1). This 
level exceeds more than 500x the concentrations used in our in vitro experiments which 
were thus well within the range found in patients. sCD14-HBsAg complexes were readily 
detected in serum of HBV-infected patients, but were non-detectable in serum of healthy 
control individuals (Fig. 5D). In addition, the sCD14-HBsAg complexes varied substantially 
in different HBV clinical disease phases; soluble CD14-HBsAg complexes were detected in 
serum of patients in immune tolerant (IT) and immune active (IA) stages, but were low in 
serum of patients in inactive carrier (IC) and E negative CHB stages (Fig. 5D, P < 0.001). The 
abundance of sCD14-HBsAg complexes correlated with the serum level of HBsAg (Fig. 5E) 
and the viral load but not with ALT (data not shown). 
sCD14-HBsAg complexes are associated with a more matured DC phenotype in vivo
To investigate whether the immune stimulatory effect of HBsAg on BDCA1+ DC is also 
relevant in vivo, we compared cell surface expression of maturation markers CD80 and 
CD83 on BDCA1+ DC directly ex vivo between CHB patients and healthy control individuals 
(Fig. 6A/B). We found that in agreement with our in vitro findings, CHB patients had 
higher percentages of CD80+ and CD83+ BDCA1+ DC compared to healthy controls (Fig. 
6B). Moreover, percentages of CD80+ and CD83+ DC were positively correlated with the 
concentration of HBsAg in serum (Fig. 6C) and with the abundance of sCD14 – HBsAg 
complexes (Fig. 6D), suggesting that HBsAg can activate BDCA1+ mDC, also in vivo.   
Discussion
Dendritic cells (DC) are considered important players in the regulation of anti-viral immunity. 
Proper activation of DC is a pre-requisite for the induction of effective virus-specific 
immunity. In the present study, we demonstrated that the main HBV envelop protein 
HBsAg can activate BDCA1+ myeloid DC leading to enhanced DC maturation and T cell 
stimulatory capacity including cross-presentation of HBsAg by DC. Patient-derived HBsAg 
was used at  concentrations also frequently found in serum of HBV-infected individuals. 
A positive correlation between HBsAg levels and percentage of activated BDCA1+ DC in a 
well-defined cohort of patients with chronic HBV infection (CHB) suggests that the observed 
immune stimulatory-effect of HBsAg is also present in vivo. Only a limited number of studies 
addressed DC phenotype of myeloid DC in CHB patients ex vivo, as reviewed in [8,24]. 
Enhanced mDC maturation in CHB patients compared to healthy control individuals was 
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previously reported by a single study from our group [25], whereas the majority of these 
studies did not find enhanced DC maturation in CHB patients [8,24]. We found a lot of 
variation between patients however, and because HBsAg levels were not taken into account 
in these previous studies it is possible that the effect on DC maturation may have been 
overlooked. In addition, our cohort consisted solely of untreated patients without certain 
co-morbidities or advanced fibrosis, factors that could influence DC maturation.
Interestingly, the immune-stimulatory effect of HBsAg observed here was specific and 
Figure 6: HBsAg concentration sCD14-HBsAg complexes are associated with matured DC phenotype in vivo.
(A) Gating strategy for analysis of CD80 and CD83 expression on gated BDCA1+ DC in total PBMC. Isotype control 
antibody was used to define background for CD80 and CD83. (B) Mean percentage of CD83+ (left) and CD80+ (right) 
BDCA1+ DC between patients with chronic HBV infection (HBV, n=16) and healthy control individuals (HC, n=7). 
Student’s t-test: * P<0.05, ** P<0.01.  (C) Correlation between HBsAg concentration and percentage CD83+ (left) 
or CD80+ (right) BDCA1+ DC. Spearman r and P is indicated. (D) Correlation between sCD14-HBsAg complexes and 
percentage CD83+ (left) or CD80+ (right) BDCA1+ DC. Spearman r and P is indicated.
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restricted to patient-derived HBsAg or recombinant HBsAg produced in mammalian cells, 
suggesting that the type of glycosylation and/or host-derived lipids/factors may be important 
for its immune stimulatory effect. A role for specific glycosylation would be in line with other 
viral glycoproteins that can activate DC, including the Fusion protein of Respiratory Syncytial 
Virus and HIV-derived gp120 as previously described [26,27]. 
In addition to the immune stimulatory effect of HBsAg, we demonstrated a novel and crucial 
role for CD14 in HBsAg-mediated activation of DC and monocytes, thus identifying CD14 
as a receptor for HBV. CD14 is a glycoprotein expressed on the cell surface of cells of the 
myeloid lineage and is most well-known for its role as PRR [20,28]. In contrast to HBsAg-
mediated DC activation, CD14 blockade did not reduce binding of HBsAg to DC. Based on 
our previous work showing a role for the mannose receptor in binding of HBsAg [6], it is 
likely that multiple receptors can facilitate HBsAg binding to DC and CD14 is redundant for 
binding, but not activation. 
CD14 serves as a co-receptor for several TLRs, including TLR4, and contributes to ligand 
recognition and cellular activation [20], but an autonomous signaling function on DC 
has also been described [29]. Since both TLR4 blockade and CD14 blockade resulted in 
abrogation of HBsAg-induced DC maturation, we conclude that recognition of HBsAg by 
mDC is mediated by the TLR4/CD14 receptor complex. In addition to the well-known role of 
CD14/TLR4 in recognition of bacterial products [20], this study and previous work together 
show that these receptors also have an emerging role in recognition of viral glycoproteins 
[26,27]. Similar to BDCA1+ DC, HBsAg can also activate other cells of myeloid origin including 
monocytes and Kupffer cells (KC) [9,11], but not BDCA3+ myeloid DC (data not shown) and 
plasmacytoid DC [30], which may relate to the absence of TLR4 on these cells [31,32]. The 
identification of CD14 and TLR4 as receptors for HBsAg may also have implications for HBV-
associated liver pathology in the chronic phase of HBV infection. Activated hepatic stellate 
cells, the most fibrinogenic cell type in the liver, have a functional CD14/TLR4 response [33] 
and may therefore be activated by interaction with HBsAg in the liver. 
In addition to membrane-bound CD14 (mCD14), CD14 exists in soluble form, which is 
either released from CD14+ cells [34,35] or secreted by hepatocytes [36,37] and can also 
be blocked by our antibody. Based on the findings that HBsAg-induced DC maturation 
could be abrogated by blocking CD14, DC maturation was not dependent on expression 
of mCD14 and required the presence of FCS or human serum, naturally containing soluble 
CD14 (sCD14), we concluded that HBsAg-dependent maturation of mDC is driven by sCD14. 
The pivotal role of sCD14 was further supported by the observation that sCD14 and HBsAg 
directly interact, both in vitro and in vivo. The abundance of sCD14 – HBsAg complexes 
correlated with percentage of activated DC in these patients. 
In the present study we observed that umbilical cord-blood derived plasma contained low 
levels of sCD14, as was previously reported in newborns [23,38], and had reduced capacity 
to support HBsAg-induced DC maturation and function. This low sCD14 concentration 
coincides with a high risk of developing chronic hepatitis B (CHB) upon HBV infection in 
newborns [39]. The immunological mechanisms underlying the high risk for neonates to 
develop CHB upon perinatal HBV infection are poorly understood. Based on our results, it 
is tempting to speculate that insufficient DC activation due to low sCD14 levels may be one 
of the factors contributing to inadequate HBV specific immunity in HBV-infected newborns. 
Seemingly paradoxical, Hong and colleagues recently showed that monocytes of HBV-
exposed newborns had an enhanced activation state compared to those from unexposed 
neonates [40]. Monocytes however, in contrast to the BDCA1+ DC we studied here, are not 
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able to induce activation of naïve virus-specific T cells and express membrane CD14 and 
thus do not depend on sCD14 for their activation. Thus, reduced sCD14 may in particular 
impact the initiation of HBV-specific immunity in these newborns via myeloid DC. Taken 
together, despite the recent work of Hong et al. and the work we present here, further 
research is required to identify the definite factors that determine the high risk to develop 
CHB in newborns.
We conclude that HBsAg can induce maturation of BDCA1+ mDC via a sCD14-dependent 
mechanism. These findings help to comprehend the early steps in development of HBV-
specific immune responses, which is essential to understand the inadequate HBV-specific 
immune responses in patients with chronic HBV infection and to facilitate the development 
of effective immuno-therapies for this disease.
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Hepatitis B virus infection is a major global health problem, as worldwide 250 million people 
are chronic carriers of HBV and at risk to develop severe liver diseases and hepatocellular 
carcinoma. To resolve HBV infection, induction of adequate HBV-specific immune responses 
is crucial. Thus far, it is poorly understood why the immune system of chronic hepatitis B 
(CHB) patients has failed to generate effective immunity against HBV.
DCs can bridge innate and adaptive immune responses by antigen presentation, and in 
addition can produce high levels of IFNs, which are essential for induction of effective 
antiviral immunity. Therefore, differential DC function could contribute to the lack of 
adequate HBV-specific immune responses in CHB patients. In addition, the central role of 
DCs in initiating and regulating antiviral immune responses suggests that these cells may be 
exploited for immunotherapy against CHB.
We and others have previously studied the function of BDCA1+ DCs and pDCs in CHB 
patients. More recently, an additional DC subset, BDCA3+CLEC9A+XCR1+ DCs (further referred 
to as BDCA3hi DCs), was identified. However, the role this DC subset may have in antiviral 
immunity has been less well investigated compared to other DC subsets, and its functional 
state in chronic HBV infection is still unknown. In this thesis, the functional characteristics of 
BDCA3hi DCs that make them relevant for HBV immunology and therapy design, in particular 
their IFN-λ-producing capacity and how they are affected by CHB, were studied.
BDCA3hi DC development
BDCA3hi DCs represent a distinct DC subset with specific phenotypic and functional 
characteristics that are extensively described in chapter 3. However, knowledge about this 
DC subset is still limited, and as the frequency of BDCA3hi DCs in blood and tissues is very 
low, extensive study of these cells is difficult. Over the years, in vitro generation of DCs from 
progenitor cells has provided a major contribution to understanding of DC biology. For this 
reason, attempts have also been made to develop culture systems to generate BDCA3hi-like 
DCs in large amounts. The first system for in vitro generation of BDCA3hi DCs was described 
by Poulin et al. (1). In this system, BDCA3hiCLEC9A+ DCs are generated from Lineage- cord 
blood cells in the presence of SCF, GM-CSF, IL-4 and Flt3L. However, the yield of this system 
was low. Therefore, we and others have attempted to develop a more efficient system to 
generate an in vitro counterpart. We have used the well-known system described by Caux et 
al. that generates DC-SIGN+ interstitial DCs and Langerin+ Langerhans cells from cord blood-
derived CD34+ hematopoietic progenitor cells (HPC) in the presence of SCF, TNF-α and GM-
CSF, and tested cultures with or without TGF-β and/or IL-4 (2, 3). Using this system, BDCA3+ 
DCs were generated, which not only upregulated BDCA3 expression but also co-expressed 
CLEC9A in the presence of both IL-4 and TGF-β, and produced large amounts of IFN-λ in 
response to TLR ligation (chapter 4). However, expression profiling of immune related genes 
showed that in other aspects these BDCA3+CLEC9A+ DCs were not identical to naturally 
occurring blood BDCA3hiCLEC9A+ DCs. 
In parallel to our study, three other systems to generate BDCA3hi DCs were presented by 
Thordardottir et al., Proietto et al. and Balan et al. (4-7). Although the cells in the first 
two systems (Thordardottir et al. and Proietto et al.), like in our model system, exhibited 
phenotypic and functional characteristics of BDCA3hi DCs, these studies did not determine 
to what extent the cells resembled blood DCs at the transcriptome level. Balan et al. 
on the other hand used an optimized version of the protocol described by Poulin et al., 
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which yielded higher BDCA3hi DC numbers, and using whole genome expression profiling 
demonstrated that these cells closely resembled blood BDCA3hi DCs (6). Because of the 
different quantitative and qualitative success of each model, comparison of these different 
culture systems yielding BDCA3hi DCs now also provides insight into the factors that contribute 
to development of bona fide BDCA3hi DCs. Balan et al. for example described that reduction 
of GM-CSF and IL-4 concentrations used by Poulin et al. enhanced the yield of BDCA3hi DCs. 
The concentration of GM-CSF and IL-4 in our system was twice as high as the concentration 
used by Poulin et al., and this may thus have caused the lack of bona fide BDCA3hi DCs. 
The negative effect of high GM-CSF concentrations on BDCA3hi DC development may be 
explained by the activation of STAT5 by GM-CSF, which inhibits induction of IRF8. IRF8 is 
a transcription factor that is highly expressed by blood BDCA3hi DCs and presumed to be 
required for their development, in analogy to their murine counterpart, CD8α+ DCs (8-11). 
Together, these studies indicate that although GM-CSF is indispensable for generation of 
myeloid DCs, a too high concentration of GM-CSF prohibits development of BDCA3hi DCs. 
Expression profiling revealed that the BDCA3+ DCs in our system do not completely resemble 
BDCA3hi DCs in vivo, and may lack certain functional aspects attributed to this cell type. 
Nonetheless, similar to naturally occurring BDCA3hi DCs, they do excel in the production of 
IFN-λ. Therefore, our system may represent a valuable model to study regulation of IFN-λ 
production by (BDCA3+) DCs. Although a side-by-side comparison of these two systems, to 
exclude differences between laboratories, should still be made, it seems that the use of cells 
from the system of Balan et al. is more relevant, as these BDCA3hi DCs also produce high 
levels of IFN-λ and do resemble blood DCs.  
Interaction between HBV and DCs, and subsequent DC activation
In order to induce an adequate HBV-specific immune response, DCs need to be activated 
by the virus via their pattern recognition receptors (PRR). If and how HBV is recognized by 
DCs is still poorly understood. For BDCA1+ DCs it was previously, and in this thesis, shown 
that they can interact with HBV or viral proteins in vitro and in vivo (chapter 8) (12, 13). The 
exact receptor involved in this interaction however remains to be determined. Previously, a 
role for the mannose receptor in the recognition and uptake of HBsAg by BDCA1+ DCs was 
identified (12). In addition, in chapter 8 is demonstrated that HBsAg can activate BDCA1+ 
DCs and that this occurs via a soluble CD14 (sCD14) and TLR4-dependent mechanism (Figure 
1). sCD14 that is present in serum and secreted by hepatocytes may thus allow activation 
of cells that do not express membrane-bound CD14 themselves. Interestingly, we also show 
that in neonates the serum levels of sCD14 are much lower than in adults and that these 
low CD14 levels are associated with impaired activation of BDCA1+ DCs by HBsAg in vitro. 
This suggests that the activation of BDCA1+ DCs upon HBV infection may be inefficient in 
neonates, which may be one of the contributing factors leading to the inadequate immune 
responses and an immunotolerant state observed in neonates. 
The role for CD14 in BDCA1+ DC activation by HBsAg is in line with CD14-dependent activation 
of monocytes by HBsAg (14). In addition, the enhanced activation status of BDCA1+ DCs of 
CHB patients indicates that activation of these cells by HBsAg also occurs in vivo. However, 
except for a study from our group, most previous studies showed that BDCA1+ DCs or 
monocytes isolated from CHB patients do not have an enhanced activated phenotype 
compared to healthy control individuals (15-18). This discrepancy may be due to variation 
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in patient population, especially variation in HBsAg levels, the use of frozen versus fresh 
material or other differences in experimental setup or laboratories. On the other hand, the 
sCD14-HBsAg complexes found in blood of CHB patients may serve a different or additional 
role in vivo. sCD14 could reduce binding of HBsAg to membrane-bound CD14 on monocytes 
by capturing HBsAg, thus preventing systemic activation of CD14+ cells such as Kupffer 
cells and monocytes (14). Such a mechanism may contribute to a lack of initial anti-HBV 
immune responses, but concurrently and on the long run may prevent induction of severe 
systemic inflammatory responses. Taken together, although our work demonstrates a role 
for sCD14 in the recognition of HBV by the immune system, further research is required to 
understand the exact role of CD14-HBsAg complexes during the course of HBV infection and 
their potential clinical or diagnostic importance. 
Figure 1. Effects of chronic HBV infection ex vivo and of HBsAg in vitro on BDCA3hi DCs and BDCA1+ DCs.
Chronic HBV infection reduces the capacity of BDCA3hi DCs to mature and produce IFN-λ upon TLR3 stimulation. 
On BDCA3hi DCs, HBsAg enhances expression of maturation markers CD40, CD80, and CD86, but reduces polyI:C-
induced IFN-λ production, via an indirect mechanism. HBsAg activates BDCA1+ DCs via a CD14- and TLR4-dependent 
mechanism, which results in upregulation of CD40 and CD83, as well as induction of IL-6 and IL-12 production.
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In chapter 7 is demonstrated that also BDCA3hi DCs acquire HBsAg when exposed to 
concentrations found in serum of patients, indicating that an interaction between BDCA3hi 
DCs and HBV/HBsAg is likely to occur in vivo. In depth analysis of the uptake of HBsAg 
by BDCA3hi DCs with inhibitors for different endocytic pathways demonstrated that this 
involved divalent cation-dependent receptor-mediated endocytosis, as well as phagocytosis 
(Figure 2). 
However, in contrast to BDCA1+ DCs, we found no evidence that BDCA3hi DCs are directly 
activated by HBsAg in vivo or in vitro (chapter 7). The fact that BDCA3hi DCs do not express 
TLR4 seems a reasonable explanation for this finding (19, 20). Although our experiments 
indicate that HBsAg is taken up but does not activate BDCA3hi DCs, it is at this moment 
not clear whether whole viral particles are taken up by BDCA3hi DCs, or whether BDCA3hi 
DCs are activated at all upon HBV infection and play a role in induction of HBV-specific 
immune responses during the natural course of infection. BDCA3hi DCs express the dsRNA 
receptor TLR3, but not the DNA receptors TLR7 or TLR9 (19). Although other viral products, 
such as HBeAg and HBcAg, may activate BDCA3hi DCs, it remains questionable whether 
BDCA3hi DCs become directly activated by HBV DNA-containing virions during (acute) 
infection. TLR3-mediated activation of BDCA3hi DCs requires access to TLR3 ligands such 
as pregenomic RNA, however, this is only present in infected hepatocytes. Since HBV is 
a non-cytolytic virus, internalization of dead virus-infected cells by DCs may occur upon 
liver damage mediated by NK cells in acute HBV infection. Because this innate response 
may be low or even lacking in patients that evolve into CHB (21), it is an intriguing thought 
that low exposure of BDCA3hi DCs to material from dead infected cells arising from this 
initial response could also contribute to inadequate induction of adaptive HBV immunity in 
these patients. During the chronic phases, that are associated with tissue damage caused 
by chronic inflammation, such material may also reach DCs, but a high viral burden and/or 
ongoing chronic inflammation may prevent the induction of an effective response at this 
stage of the disease. Thus, it will be very interesting to determine if and how BDCA3hi DCs 
become activated during the different phases of HBV infection.
Figure 2. BDCA3hi DCs take up HBsAg in vitro via 
receptor-mediated endocytosis and phagocytosis.
CD14+-depleted PBMC were incubated with APC-
labelled patient-derived HBsAg for 2 hours at 4°C 
or 37°C after 1 hour pre-incubation with or without 
inhibitors of endocytosis (Methyl-β), divalent cation-
dependent receptor-mediated uptake (EDTA), 
phagocytosis (Cytochalasin D) or macropinocytosis 
(EIPA). HBsAg uptake by BDCA3hi DCs was analysed 
by FACS. Mean±SEM percentages of BDCA3hi DCs 
containing HBsAg are depicted in (n=3). * p<0.05, ** 
p<0.01 by paired Student’s t-test.
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Effect of HBV infection on BDCA3hi DCs in vivo and in vitro
In chapter 7 we show that polyI:C-stimulated blood BDCA3hi DCs of CHB patients have an 
impaired capacity to become activated and to produce IFN-λ, but demonstrate normal TNF-α 
production (Figure 1). This may be the consequence of chronic inflammation and/or long-
term exposure to viral antigens in these patients. In support of the latter, exposure to HBsAg 
was shown to inhibit IFN-λ-producing capacity of BDCA3hi DCs from both blood and liver in 
vitro (chapter 7, Figure 1). The exact mechanism underlying impairment of IFN-λ production 
by HBsAg remains to be determined. We and others have previously shown that HBV and 
HBsAg can inhibit IFN-α production by pDCs in vitro in part indirectly by interfering with 
pDC-monocyte interaction (22, 23). Monocytes produce IL-6, TNF-α and IL-10 in response 
to HBsAg, and TNF-α was shown to inhibit IFN-α production by pDCs (15, 23). Shi et al. 
found that also IL-10 may inhibit IFN-α production by pDCs, but we did not detect such an 
effect (22, 23). The effect of these cytokines on IFN-λ production by BDCA3hi DCs, however, 
remains to be investigated. 
Besides a possible (indirect) action of HBsAg, chronic inflammation likely plays a major 
role in reduction of BDCA3hi DC function as well. During a chronic infection, regulatory 
mechanisms are present that balance immune activation to control viral replication on the 
one hand, and immune suppression to avert excessive collateral damage on the other hand. 
These regulatory mechanisms, such as elevated levels of IL-10 and TGF-β, may also impair 
DC function (24, 25). We have previously shown that the function of DCs from HBV patients 
is enhanced upon reduction of liver inflammation and/or viral load by antiviral therapy (26, 
27). However, the IFN-α-producing capacity of pDCs inversely correlates with ALT, but not 
with viral load (16, 22). These findings suggest that the chronic inflammatory status in CHB 
patients rather than the virus itself affect BDCA1+ mDCs and pDCs, and a similar scenario 
may be true for BDCA3hi DCs.  Additional studies should be performed to determine the 
contribution of viral proteins/particles and chronic inflammation in the impairment of 
DC function during CHB. Experimental work so far however indicates that diminished DC 
function is present in some CHB patients, and that it thus may be necessary to reduce HBsAg 
levels and/or chronic inflammation by antiviral therapy prior to DC-targeted immunotherapy 
in order to enhance DC function and achieve an optimal effect. 
 
Due to experimental difficulties and the low availability of patient liver material, most of 
our studies were performed on BDCA3hi DCs from blood. However, the situation may be 
different for liver DCs. Analysis of intrahepatic DC indicates that BDCA3hi DCs of CHB patients 
can produce IFN-λ upon polyI:C stimulation. Preliminary results, however, indicate that in 
contrast to blood BDCA3hi DCs, the number of BDCA3hi DCs from patient livers producing 
IFN-λ in response to ex vivo stimulation is even increased compared to those from control 
livers (Figure 3). It is very well possible that this discrepancy arises from the pro-inflammatory 
intrahepatic environment in these patients, which may prime the DCs and make them more 
responsive to stimulation. This hypothesis is supported by our preliminary observation that 
also DCs from livers with non-HBV related inflammation are more responsive (Figure 3). 
Likewise, polyI:C-induced IFN-λ production by BDCA3hi DCs from perfusate of HCV-infected 
livers was also enhanced compared to healthy donor livers (28). Nevertheless, despite the 
increased percentage of IFN-λ-producing cells in HBV-infected livers, these cells may still 
produce less IFN-λ on a per-cell base and be subject to inhibition by HBsAg or other viral 
factors. A more in-debt side-by-side comparison of BDCA3hi DCs from inflamed HBV and 
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non-HBV livers is thus required to shed more light on this matter.   
Regardless of the role of BDCA3hi DCs during the natural course of infection, the observations 
that BDCA3hi DCs are present in HBV-infected livers and able to produce IFN-λ makes these 
cells viable targets for immunotherapy. Especially because BDCA3hi DCs are not only a source 
of high amounts of IFN-λ, but have also been described to be excellent cross-presenting 
cells. Targeting these cells with HBV antigens/peptides in combination with TLR3 ligands 
may thus boost HBV-specific adaptive immune responses and deliver local IFN-λ at the same 
time. As a next step towards such therapy we need to assess the capacity of (intrahepatic) 
BDCA3hi DCs to (cross)present HBV antigens. 
As BDCA3hi DCs can take up HBsAg (Figure 2), we anticipate that these cells can also cross-
present HBsAg peptides. Indeed, preliminary data demonstrate that BDCA3hi DCs are able 
to cross-present HBsAg (Figure 4). Further research is now required to determine whether 
BDCA3hi DCs in CHB patients can still do so to warrant that BDCA3hi DCs are feasible targets 
for immunotherapy to boost and/or induce HBV-specific cytotoxic T cell (CTL) responses. 
Cross-presentation of HBV antigens may occur in vivo, but since blood BDCA3hi DCs of CHB 
patients do not have an activated phenotype (chapter 7), this may induce cross-tolerance 
in these patients or sub-optimal T cell skewing. Optimal cross-presentation and induction 
of effective CTL responses in CHB patients may thus not only require targeting of DCs with 
HBV-specific peptides, but may also require additional stimulatory signals. 
Figure 3. IFN-λ production by intrahepatic BDCA3hi DCs.
Liver cells were isolated and stimulated for 5 hours with or 
without 20 μg/ml polyI:C. Production of IFN-λ1 by BDCA3hi 
DCs was measured by ICS. Mean±SEM percentage IFN-λ1-
producing BDCA3hi DCs of control livers (n=8), HBV-infected 
livers (n=5), and livers with inflammation not caused by 
a virus (n=2) are shown. Open dots represent cells from 
donor livers and filled dots represent cells from peri-tumor 
liver tissue. **p < 0.01, Mann-Whitney test.
Figure 4. Cross-presentation of HBsAg by BDCA3hi DCs.
Peripheral blood BDCA3hi DCs of healthy controls (25.000 cells/150 μl) 
were incubated with 5 μg/ml patient-derived HBsAg (pHBsAg) or 5 μg/
ml recombinant HBsAg (rHBsAg) in the presence of 20 μg/ml polyI:C. 
After 1 hour cells were washed and co-cultured with 50.000 T cells in 
150 μl. After 20 hours supernatant was harvested and IFN-γ levels were 
determined by ELISA (n=1).
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Regulation of IFN-λ production
The lack of an IFN-λ response in HBV patients (29, 30) and the diminished IFN-λ production 
in BDCA3hi DCs by HBsAg (chapter 7) implies that in chronic HBV infection the IFN-λ response 
is dampened or even actively inhibited. To be able to understand how IFN-λ production 
can be suppressed, it is important to first scrutinize the regulatory mechanisms underlying 
production of IFN-λ in DCs. 
In chapter 6 we therefore assessed the regulation of IFN-λ production in the major IFN-
λ-producing cells, BDCA3hi DCs, and demonstrated that the NFκB pathway and PI3K-PKB-
mTOR pathway are involved in both polyI:C-induced IFN-λ1 as well as IFN-λ2 production. 
Whether these pathways are dysregulated in CHB, which may explain the diminished IFN-λ-
producing capacity, is thus far unknown. We previously showed that PI3K-mTOR-mediated 
phosphorylation of S6 is disturbed in pDCs of HBeAg-positive CHB patients, and that also 
the IFN-α-producing capacity of these cells is diminished (31). As in chapter 7 only DCs from 
HBeAg-negative patients were used for functional characterization, it would be interesting 
to analyze the IFN-λ-producing capacity of DCs from HBeAg-positive patients as well. Further 
research is required to obtain more insight into the signaling pathways underlying IFN-λ 
production, which will contribute to discovery of targets for IFN-λ-manipulating therapy. 
The culture systems generating IFN-λ-producing CD34+-derived DCs described above may 
be useful to perform this research.
Most studies on regulation of IFN-λ production have focused on IFN-λ1, -2 and -3. As IFN-λ4 
was discovered more recently than the other IFN-λ subtypes, and is only produced in 
individuals with a certain genotype, this member of the IFN-λ family has been studied less 
well compared to the others. It will be interesting however, to assess whether the same 
regulatory mechanisms are involved in IFN-λ4 production. 
Concluding remarks
DCs are pivotal players in the induction of antiviral immune responses. Although the 
function of BDCA1+ DCs and pDCs has been thoroughly studied, the function of BDCA3hi 
DCs is still poorly understood due to the difficulty of creating knock-out mouse models 
and differences between murine and human DCs. The known functions of BDCA3hi DCs 
point towards an important role in orchestrating antiviral immunity. However, assessment 
of human BDCA3hi DCs is challenging because of low BDCA3hi DC numbers in vivo and, as 
also demonstrated in this thesis, BDCA3 is co-expressed also on other DC subsets, which 
makes it even more complex to isolate these cells. The research described in this thesis is 
focused on the functional characteristics of BDCA3hi DCs and their function in CHB infection. 
Our results provide insight into the effect of HBV infection on BDCA3hi DCs, as well as 
the interaction and functional consequences of the viral envelope protein HBsAg on the 
function of BDCA3hi DCs and BDCA1+ DCs in vitro. CHB has previously been shown to affect 
pDC and BDCA1+ DC function in a subset of patients. In addition to this, we demonstrate 
here that also the function of blood BDCA3hi DCs, including IFN-λ-producing capacity, is 
impaired in CHB patients. As the signaling pathways underlying IFN-λ production, which 
may be dysregulated in HBV infection, are still incompletely understood, this requires 
further investigation. Development of models by which IFN-λ-producing BDCA3hi DCs can be 
generated in vitro will contribute to this research, however, the currently available systems 
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are still not optimal. Other important questions that remain to be answered are whether 
BDCA3hi DCs become activated during the course of an HBV infection and play a role in 
the induction of an HBV-specific immune response, as well as what mechanisms cause the 
impaired BDCA3hi DC function we here observed. To answer these questions, assessment of 
intrahepatic DCs is essential. However, accessing liver material and isolation of intrahepatic 
DCs is even more challenging. 
Although the function of BDCA3hi DCs in CHB patients requires further investigation, BDCA3hi 
DCs seem a viable target to induce HBV-specific antibody and T cell responses for treatment 
of CHB. Answers to the above-mentioned questions will contribute to better understand the 
lack of HBV-specific immunity in CHB patients and development of effective (DC-targeted) 
therapy.
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Achtergrondinformatie
Hepatitis B is een ontsteking van de lever die veroorzaakt wordt door HBV. HBV kan 
worden overgedragen van moeder op kind bij de geboorte, door bloed-bloed contact of 
via onbeschermd seksueel contact, en infecteert vervolgens specifiek de lever. Wereldwijd 
zijn ongeveer 250 miljoen mensen chronisch geïnfecteerd met HBV, wat kan leiden tot een 
chronische ontsteking van de lever. Deze chronische ontsteking kan resulteren in de vorming 
van littekenweefsel in de lever (leverfibrose en levercirrose), leverfalen en leverkanker. In 
90% van de mensen die op volwassen leeftijd geïnfecteerd raakt, is het immuunsysteem 
in staat om het virus zelf op te ruimen en immuniteit tegen het virus te ontwikkelen. In 
de overige 10% is dat niet het geval, waardoor een chronische infectie ontstaat. Echter, 
van de pasgeborenen en kleine kinderen die besmet zijn geraakt met HBV, ontwikkelt maar 
liefst 90% een chronische infectie. Het is op dit moment onbekend welke factoren bepalen 
of een infectie onder controle komt van het immuunsysteem of in een chronische infectie 
resulteert. 
Voor de afweer van virussen is een goed werkend immuunsysteem van belang. Het 
immuunsysteem kan onderverdeeld worden in twee delen; het aangeboren (innate) 
afweersysteem dat een ziekteverwekker herkent, geactiveerd raakt en vervolgens snel op 
een vrij a-specifieke manier virusreplicatie en infectie remt, en het verworven (adaptive) 
immuunsysteem dat door het aangeboren afweersysteem op een ziekteverwekker-specifieke 
manier wordt geactiveerd en gericht kan aanvallen/opruimen en vervolgens zorgt voor 
een langdurige bescherming. Het aangeboren immuunsysteem bevat verschillende cellen, 
waaronder DC. DC zijn in bloed, lymfe en weefsels aanwezig en scannen hun omgeving 
op ziekteverwekkers. Deze cellen zijn van groot belang voor de antivirale immuunrespons 
aangezien ze virussen niet alleen opruimen door ze op te nemen en te vernietigen, maar 
ook de unieke functie hebben om activatie te initiëren van cellen van het verworven 
immuunsysteem die virusgeïnfecteerde cellen doden en langdurige bescherming tegen het 
virus bieden. 
Wanneer DC een virus herkennen raken ze geactiveerd, wat gepaard gaat met het 
verschijnen van activatiemarkers op het oppervlak van de cel en secretie van oplosbare 
eiwitten, cytokinen. Deze activatiemarkers en cytokinen zijn nodig om andere immuuncellen 
te activeren. Daarnaast worden kleine delen van het opgenomen virus op het celoppervlak 
gepresenteerd. Deze kleine delen worden antigenen genoemd, en het presenteren ervan 
antigeenpresentatie. DC kunnen de gepresenteerde antigenen op verschillende manieren 
verkrijgen, namelijk via infectie van de DC zelf, via opname van het virus uit de omgeving, 
en via interactie met of opname van virusgeïnfecteerde cellen. Antigeenpresentatie via 
de laatstgenoemde route wordt kruispresentatie genoemd. De gepresenteerde antigenen 
kunnen worden herkend door cellen van het verworven immuunsysteem, waaronder CD8+ 
T cellen, die vervolgens mede door de activatiemarkers en cytokinen geactiveerd raken en 
virusgeïnfecteerde cellen kunnen doden.
Naast het activeren van andere immuuncellen hebben veel cytokinen die geproduceerd 
worden door DC ook een directe antivirale werking. Belangrijke antivirale cytokinen zijn 
interferonen (IFN). Deze IFN remmen de productie van virus, beperken de infectie van 
ongeïnfecteerde naburige cellen, en reguleren de werking van andere immuuncellen. De 
IFN worden verdeeld in 3 typen; type I IFN (IFN-α/β), type II IFN (IFN-γ) en type III IFN (IFN-λ). 
Vanwege de bovengenoemde functies spelen DC een belangrijke rol in het aanzetten 
van afweerreacties tegen virussen. De familie van DC bestaat uit verschillende subtypen, 
waaronder plasmacytoide DC, BDCA1+ myeloide DC en BDCA3+ myeloide DC. Deze subtypen 
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kennen veel overeenkomsten, zoals de unieke capaciteit om T-cellen te activeren, maar 
hebben ook elk hun specifieke functies, zoals het produceren van verschillende cytokinen. 
De BDCA3+ DC subset is relatief recent gekarakteriseerd en kenmerkt zich door een zeer 
hoge expressie van BDCA3 op het celoppervlak. BDCA3+ DC hebben excellente functionele 
capaciteiten wat betreft kruis-presentatie van antigenen aan CD8+ T-cellen en het produceren 
van IFN-λ. Hoewel er over de rol van BDCA3+ DC in antivirale immuunresponses nog relatief 
weinig bekend is, wijzen deze eigenschappen op een belangrijke rol voor BDCA3+ DC in het 
induceren van antivirale immuniteit. 
Vraagstelling
Gezien het belang van DC in het aanzetten van antivirale immuunresponsen, zou het virus 
voor zijn overleving baat hebben bij een sub-optimale functie van DC in HBV-geïnfecteerde 
patiënten waardoor een chronische infectie kan ontstaan en voortbestaan. De sleutelrol 
van DC impliceert dat het gericht activeren en instrueren van DC in HBV-geïnfecteerde 
patiënten ook gebruikt zou kunnen worden als therapie om responsen van het verworven 
immuunsysteem op te wekken die het virus specifiek kunnen opruimen. Om het ontstaan 
van een chronische infectie, in het bijzonder hepatitis B, beter te kunnen begrijpen en 
therapieën die gericht zijn op DC te kunnen ontwikkelen, is het belangrijk te begrijpen hoe 
antivirale functies van DC gereguleerd worden, hoe DC reageren op blootstelling aan HBV, 
of en waar DC in HBV-geïnfecteerde patiënten met (chronische) hepatitis B aanwezig zijn, 
en wat hun functionele capaciteit is. Het onderzoek in dit proefschrift is daarom gericht op 
eigenschappen en functies van DC die van belang zijn bij de afweer tegen virale infecties in 
het algemeen, de interactie met en het effect van het HBV envelop eiwit HBsAg op DC, en 
de functionele staat van DC bij chronische HBV infectie. Aangezien de functie van BDCA3+ DC 
in HBV-geïnfecteerde patiënten nog geheel onbekend is, is het bovengenoemde onderzoek 
met name gericht op deze DC subset.
Resultaten
In hoofdstuk 1 wordt een algemene introductie gegeven van onder andere het verloop 
van een HBV infectie en de algemene antivirale immuunrespons en de rol van DC hierin. 
Vervolgens worden de huidige inzichten in de rol van DC en interferonen in HBV infectie 
uiteengezet, en een overzicht gegeven van de mogelijkheden voor hepatitis B therapie. Ten 
slotte zijn de doelen en hoofdlijnen van dit proefschrift beschreven. In aanvulling hierop toont 
hoofdstuk 2 een overzicht van de verschillende mechanismen die DC gebruiken voor (kruis-)
presentatie van virale antigenen aan T-cellen. Uit dit overzicht blijkt dat kruis-presentatie 
een zeer efficiënt mechanisme is voor de inductie van virus-specifieke immuniteit.
In vergelijking tot andere DC subsets hebben BDCA3+ DC de beste capaciteit voor kruis-
presentatie van antigenen afkomstig van cellen, wat zou kunnen wijzen op een belangrijke 
rol voor deze cellen in het induceren van antivirale immuunresponsen. In hoofdstuk 3 
wordt een overzicht gegeven van de eigenschappen van BDCA3+ DC met betrekking tot hun 
uiterlijk, functie en ontwikkeling. Een belangrijk en specifiek karakteristiek van BDCA3+ DC is 
dat ze grote hoeveelheden van het antivirale cytokine IFN-λ kunnen produceren. Daarnaast 
hebben de BDCA3+ DC specifieke moleculen op hun celoppervlak, zoals XCR1 en CLEC9A. 
CLEC9A is een receptor die dode cellen kan herkennen en bijdraagt aan een extra goede 
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opname van dode cellen en daaropvolgende kruis-presentatie van antigenen aan T-cellen 
door BDCA3+ DC. Deze excellente IFN-λ productie en kruis-presentatie van antigenen van 
dode cellen duiden erop dat BDCA3+ DC een belangrijke rol spelen in het aanzetten van 
antivirale immuunresponsen, maar aanvullend onderzoek is noodzakelijk om dit te bewijzen.
Onderzoek naar de BDCA3+ DC wordt sterk bemoeilijkt door het lage aantal van deze cellen 
in het lichaam en het ontbreken van een homoloog in de muis. In hoofdstuk 4 is daarom 
getracht om BDCA3+ DC uit een specifiek soort stamcellen te kweken, CD34+ stamcellen, zodat 
grotere hoeveelheden cellen verkregen kunnen worden voor onderzoek. In het ontwikkelde 
kweeksysteem konden BDCA3+ cellen gedetecteerd worden, maar gedetailleerde analyse 
van deze cellen toonde aan dat ze niet volledig hetzelfde waren als BDCA3+ DC in het 
lichaam. Dit systeem kan dus niet gebruikt worden voor verder onderzoek naar BDCA3+ DC, 
maar aangezien de cellen in het systeem wel in staat zijn om grote hoeveelheden IFN-λ te 
produceren, is het een waardevol model om IFN-λ productie te bestuderen.
Hoewel BDCA3+ DC hun naam ontlenen aan de expressie van BDCA3 op hun celoppervlak, 
blijkt dus dat cellen met BDCA3 expressie niet perse tot de specifieke BDCA3+ DC subset die 
in het lichaam aanwezig is behoren. Daarnaast is bekend dat BDCA3 ook tot expressie kan 
worden gebracht door een deel van de BDCA1+ DC populatie. Het is echter niet bekend of 
er een verschil is tussen de BDCA3+ en BDCA3- cellen binnen de BDCA1+ DC populatie en 
of de BDCA3+BDCA1+ DC meer op BDCA3+ DC lijken dan BDCA3-BDCA1+ DC. In hoofdstuk 
5 zijn daarom de overeenkomsten en verschillen in genexpressie en functie tussen zowel 
BDCA3+BDCA1+ DC en BDCA3-BDCA1+ DC, als BDCA3+BDCA1+ DC en BDCA3+ DC onderzocht. 
De resultaten tonen aan dat BDCA1+ DC een apart subtype is van BDCA3+ DC, ongeacht de 
expressie van BDCA3 op de BDCA1+ DC. De functie van BDCA3 op DC is nog onbekend, maar 
BDCA3+BDCA1+ DC lijken meer geactiveerd te zijn en hogere hoeveelheden cytokinen te 
produceren dan BDCA3-BDCA1+ DC.
Een DC produceert niet zomaar cytokinen, zoals IFN. Een signaal van buitenaf, zoals 
bijvoorbeeld een virus dat bindt aan bepaalde receptoren op de cel, zorgt voor het aan- of 
uitzetten van verschillende functies van cellen. Deze signalen worden in de cel vertaald via 
signaalroutes, waarlangs het signaal wordt doorgegeven tot het uiteindelijk tot productie 
van een molecuul leidt. Hoe de productie van type I IFN en type II IFN in een cel aangezet 
wordt en welke processen daar bij betrokken zijn is tot in detail beschreven. Voor het recent 
ontdekte type III IFN, IFN-λ, is dat echter niet het geval. In hoofdstuk 6 is onderzocht welke 
processen in BDCA3+ DC betrokken zijn bij de productie van IFN-λ. In dit hoofdstuk wordt 
beschreven dat twee signaalroutes, namelijk de PI3K-PKB-mTOR route en NFκB route, 
betrokken zijn bij de productie van IFN-λ door BDCA3+ DC. Deze kennis is van belang om 
bijvoorbeeld te begrijpen hoe virussen de productie van IFN-λ in een cel kunnen verhinderen 
door deze signaalroutes te onderbreken, en om bijvoorbeeld therapie te ontwikkelen die de 
productie van IFN-λ manipuleert. 
Een verlaagde IFN-λ producerende capaciteit van BDCA3+ DC in HBV-geïnfecteerde patiënten 
met chronische hepatitis B (CHB) wordt getoond in hoofdstuk 7. Dit hoofdstuk beschrijft 
zowel de frequentie en functie van BDCA3+ DC in lever en bloed van CHB patiënten, als 
het effect van het envelopeiwit van HBV, HBsAg, op de functie van BDCA3+ DC in vitro. 
Het aantal BDCA3+ DC in HBV-geïnfecteerde levers is verhoogd vergeleken met levers van 
ongeïnfecteerde personen. De functie van BDCA3+ DC in bloed van CHB patiënten is echter 
verminderd. Deze BDCA3+ DC raken minder goed geactiveerd na stimulatie en de capaciteit 
om IFN-λ te produceren is verlaagd. Deze verminderde functie zou veroorzaakt kunnen 
zijn door de chronische leverontsteking in de patiënten of door het virus zelf. Wanneer 
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immuuncellen uit bloed blootgesteld worden aan het envelopeiwit HBsAg wordt de IFN-λ 
productie door BDCA3+ DC verminderd. Dit geeft aan dat de verminderde IFN-λ productie in 
patiënten (deels) veroorzaakt zou kunnen zijn door dit eiwit, dat onderdeel is van het virus, 
maar ook los in het bloed van patiënten voorkomt. 
De vermindering van IFN-λ productie door BDCA3+ DC na blootstelling aan HBsAg zoals 
getoond in hoofdstuk 7, vindt alleen plaats indien er andere immuuncellen aanwezig zijn. Dit 
impliceert dat HBsAg een directe functionele interactie aangaat  met andere immuuncellen. 
Eén van de typen immuuncellen waarvan de functie direct door HBsAg beïnvloed wordt zijn 
BDCA1+ DC. De receptoren voor HBsAg op BDCA1+ DC die een effect hebben op de functie 
van deze cellen zijn echter nog niet bekend. In hoofdstuk 8 is daarom de interactie tussen 
HBsAg en BDCA1+ DC en het effect hiervan op BDCA1+ DC functie bestudeerd. Blootstelling 
van BDCA1+ DC aan HBsAg in vitro resulteert in opname van HBsAg, verhoogde expressie van 
activatiemarkers, productie van cytokinen en verhoogde activatie van T-cellen door BDCA1+ 
DC. Daarnaast wordt in dit hoofdstuk aangetoond dat CD14, dat ook als oplosbaar eiwit in 
bloed aanwezig is, en TLR4 de receptoren zijn die HBsAg herkennen en betrokken zijn bij 
de activatie van BDCA1+ DC. Kortom, HBsAg kan worden herkend door BDCA1+ DC en deze 
cellen activeren, wat een belangrijke stap zou kunnen zijn in de initiatie van HBV-specifieke 
immuunresponsen en van belang kan zijn voor de ontwikkeling van immunotherapie tegen 
hepatitis B.
Een samenvatting en discussie van bovengenoemde resultaten is beschreven in hoofdstuk 9.
Conclusie
DC zijn van groot belang in het induceren van antivirale immuunresponsen. Vergeleken met 
andere DC subtypen is over de functie van BDCA3+ DC echter nog relatief weinig bekend. De 
functies van BDCA3+ DC die beschreven zijn duiden op een belangrijke rol in het tot stand 
brengen van antivirale immuniteit. Het bestuderen van BDCA3+ DC is gecompliceerd doordat 
de aantallen van deze cellen in het lichaam zeer laag zijn en doordat BDCA3 ook op andere 
cellen voorkomt, waardoor het nog complexer is om deze cellen uit het lichaam te isoleren. 
Het onderzoek beschreven in dit proefschrift is gericht op de eigenschappen van BDCA3+ DC 
en hun functie in CHB. De resultaten bieden inzicht in zowel het effect van HBV infectie op 
BDCA3+ DC in vivo, als de consequenties van de interactie van BDCA3+ DC en BDCA1+ DC met 
het virale envelop eiwit HBsAg in vitro. In het verleden is aangetoond dat in een deel van de 
CHB patiënten de functie van BDCA1+ DC en plasmacytoide DC is aangetast. In toevoeging 
hierop wordt in dit proefschrift aangetoond dat ook de functie van BDCA3+ DC, waaronder 
IFN-λ productie, verminderd is in CHB patiënten. De signaalroutes die betrokken zijn bij 
IFN-λ productie zijn nog niet volledig ontrafeld. Om onder andere de verminderde IFN-λ 
productie door BDCA3+ DC te doorgronden is verder onderzoek naar deze signaalroutes 
van belang. De ontwikkeling van kweeksystemen waarmee IFN-λ producerende BDCA3+ DC 
gegenereerd kunnen worden in vitro, zal bijdragen aan dit onderzoek, al zijn de momenteel 
beschikbare systemen voor de generatie van BDCA3+ DC in vitro nog niet optimaal. Overige 
vragen die nog beantwoord dienen te worden zijn of BDCA3+ DC geactiveerd raken tijdens 
het verloop van een HBV infectie, of deze cellen een rol spelen in het induceren van een 
HBV-specifieke immuunrespons, en welke mechanismen de hier aangetoonde verminderde 
BDCA3+ DC functie veroorzaken. Om deze vragen te beantwoorden is het bestuderen van 
intrahepatische DC in de lever essentieel. Het verkrijgen van levermateriaal en het isoleren 
van intrahepatische DC is echter gecompliceerd. Al is meer onderzoek naar de functie 
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van BDCA3+ DC in CHB patienten vereist, BDCA3+ DC lijken een geschikt doelwit voor het 
induceren van HBV-specifieke immuunresponsen ter behandeling van CHB. Antwoorden op 
bovengenoemde vragen zal bijdragen aan het doorgronden van het ontbreken van HBV-
specifieke immuniteit en ontwikkeling van effectieve (DC-gerichte) therapie.
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Dankwoord
De afgelopen jaren hebben niet alleen figuurlijk, maar ook letterlijk bloed (véél bloed), 
zweet en tranen gekost… Maar ik had ze voor geen goud willen missen! Ik wil hier dan ook 
alle mensen bedanken die deze tijd zo onvergetelijk hebben gemaakt.
Andrea, ik heb ontzettend veel van je geleerd in de afgelopen jaren en vond het fijn 
samenwerken. Je georganiseerde en rechtlijnige manier van denken en werken lagen me 
erg goed. Je positieve feedback werkte zeer motiverend en hebben me meerdere keren 
een extra zetje in de rug gegeven. Bedankt daarvoor! Ik heb respect voor hoe jij privé met 
niet één, maar twee drukke banen weet te combineren. Heel veel succes met het vervolg 
daarvan!
Harry, dank voor het bewaren van het overzicht van vooruitgang in de verschillende projecten. 
Andrea en jij herhaalden met name tijdens onze eerste meetings dat ‘de aanhouder wint’. 
En dat motto is uiteindelijk wel de leidraad voor mijn PhD gebleken. Bedankt voor alles.
Maikel, bedankt voor je input tijdens de seminars en jaargesprekken, en voor je deelname 
in de commissie. 
Prof.dr. de Gruijl, Prof.dr. Geijtenbeek, Prof.Dr. Rimmelzwaan, Prof.Dr. Adema en Dr. Blom, 
hartelijk dank voor het deelnemen in de commissie. Het is een eer om met u over het hier 
beschreven onderzoek te mogen discussiëren, ik zie ernaar uit. 
De HBV groep…
Paula, ik ben je heel veel dank verschuldigd voor al het werk dat je (overdag, maar ook in 
de late uurtjes) hebt verricht. Zonder jou zou dit boekje maar half gevuld en nog lang niet 
af zijn geweest. Ik vind je een fantastisch persoon; bescheiden, maar overal voor in! Een 
kampeerkoningin waarmee je gerust een dansje op de tafel of bij Editors kunt maken en die 
haar hand niet omdraait voor een gezamenlijke bruggenloop. Bedankt dat je me ook de 10e 
wilt vergezellen bij het bereiken van de finish!
Nadine, het samenwerken met jou begon al tijdens mijn stage. Jij en Lianne hebben me 
vanaf dag 1 enthousiast gemaakt voor dit onderzoek en weten te overtuigen dat het doen 
van promotieonderzoek me heus wel zou lukken en echt de moeite waard is. En jullie hadden 
helemaal gelijk! Ik heb heel veel van je geleerd, zowel op werk-inhoudelijk als persoonlijk 
vlak. Ik denk met veel plezier terug aan onze trip naar LA en moet iedere keer weer lachen 
bij de gedachte aan ons drieën in die rode Mustang...! Bedankt dat je de 10e naast me zal 
staan! 
Sonja, bedankt voor alle hulp en input. De laatste maanden zouden zeker te weten een stuk 
minder soepel zijn gegaan zonder jou. Ik bewonder je enthousiasme en zeer gedreven, maar 
tegelijkertijd relaxte werkhouding. Dat vond ik erg fijn en motiverend werken. Daarnaast 
heb ik ook ontzettend veel bewondering voor je kennis van Duitse tophits ;) Bedankt voor 
de samenwerking en gezelligheid!
Lianne, ook jij stond aan het begin van dit alles. Lange tijd werd ik gezien als jouw opvolgster, 
wat geen gemakkelijke positie was, aangezien jij de lat wel heel erg hoog had gelegd ;) Ik 
vond het ontzettend leuk dat we de samenwerking ook na je vertrek naar Gent nog voort 
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hebben kunnen zetten en tot een mooi paper hebben kunnen brengen. Miami beach en 
fietsen in de Everglades (slingerend om de alligators op het fietspad te ontwijken) was mooi! 
Bedankt voor alles en veel succes in Utrecht!
Aniek, je bent een topper op het lab en ook daarbuiten, en ik vond het dan ook erg leuk 
om met je in dezelfde groep te werken. Jouw harde werken, nauwkeurigheid, nuchterheid, 
maar vooral gezelligheid zijn onmisbaar voor de HBV! Keep up the good work!
Yingying, I really enjoyed working with you and want to thank you for the collaboration on 
cross-presentation assays. It was nice to share buckets of beer in Frankfurt, and to organize 
the hotpot/gourmet dinner together. Hopefully, we can do this again some time. Good luck 
with finishing your PhD!
Arjan, je bent al een tijdje weg, maar ook jij hoorde bij het HBV cluppie (en aangezien jij 
net als de HBV dames ook van bakken en high tea houdt paste dat uitstekend ;)). Het was 
onwijs gezellig om met jou op het lab te werken, cake van de week te vieren, naar de NVVI 
te gaan en een biertje of twee te drinken in Birmingham. Dat biertje in Utrecht moeten we 
nog steeds een keer doen!
Monique, aan jou gaf ik het figuurlijke PhD stokje door binnen de groep. Ik wens je heel veel 
succes met je project, maak er een mooie tijd van! 
Fadime, ik heb je met veel plezier mogen begeleiden tijdens je afstudeerstage. Je hebt heel veel 
werk verricht voor het IHC project, wat mooie plaatjes heeft opgeleverd. Dankjewel daarvoor! 
Yoga, thank you for your help with the DC isolation experiments. Que, thank you for your 
help with the HBsAg uptake and cell-death experiments.
 
En natuurlijk de HCV groep (die niet zo HCV meer is)…
Andre, dank voor al je hulp en input tijdens de meetings, maar ook daarbuiten. Ik heb meer 
dan eens bij je bureau gestaan met vragen, bedankt dat je altijd bereid was om antwoorden 
te geven en manuscripten van commentaar te voorzien. Dank ook voor de connectie voor 
de Nanostring analyse, dat is van groot nut geweest! 
Gertine, buurvrouw van de overkant , bedankt voor alle hulp rondom het verzamelen van 
patiënten-materiaal en je expertise bij de RNA isolatie! Anthonie, bedankt voor de geweldige 
organisatie van Elp (ik denk dat we in Kootwijk een aardig alternatief gevonden hebben), en 
de gezelligheid op het lab en bij de borrels. Mocht dat feestje op de pannenkoekenboot ooit 
nog georganiseerd worden, dan houd ik me aanbevolen ;) Kim, dankjewel voor al je hulp en 
expertise mbt de IHC, dat heeft me veel geholpen! Marieke, dank voor alle sorts, dat zijn 
er héél veel geweest. Bedankt!! Dowty, although we had quite a different PhD project, we 
ended up at the same company. Thanks for your time and answers to my questions about 
Crucell! Thomas, bedankt voor je input en discussie tijdens de meetings. Jun, I enjoyed 
celebrating oktoberfest with you. Don’t forget to keep your collagen active ;)! Bisheng, good 
luck with your work in Leiden. Lauke, onze gezamenlijke tijd in Na-1002 was helaas kort, 
maar niet minder gezellig. Er zijn er weinig die zo gedreven in hun PhD onderzoek zijn als jij. 
Heel veel succes met het vervolg, en vergeet niet af en toe gewoon weekend te vieren ;-)
Team BOTM… 
Jullie hebben er voor gezorgd dat de afgelopen jaren mooier waren dan ik ooit had kunnen 
bedenken. De vele vrijdagavonden, Cadzand, pubquizzen, honkbaltoernooi, Rot.Jong, 
Reijngoud, etc. waren top!
Elmer, ik ken weinig mensen waarover meer lovend werd/wordt gesproken dan over jou, 
en ik sluit me helemaal aan bij deze lof. Je bent een en al positiviteit en gezelligheid en ik 
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vind het geweldig dat ik de afgelopen jaren mee heb mogen genieten van je escape room, 
honkbaluitje, verjaardagsfeestjes en natuurlijk promotie (al was het als backup, de eer was 
niet minder groot en het cadeau zelfs beter ). 
Wesley, jij was toch wel de kern van de harde kern. Na je vertrek zijn de BOTMs en overige 
vrijdagavondactiviteiten significant afgenomen. Ondanks dat het jou op het lab niet altijd 
mee zat, wist jij de sfeer erin te houden! En na de afronding van je PhD staat je nu een 
volgende uitdaging te wachten… ik ben heel benieuwd naar jullie nieuwe aanwinst! En nee, 
je hoeft me niet te bellen voor de entertainment op toekomstige kinderfeestjes ;)
Rik, we zijn ongeveer tegelijk gestart en geëindigd. Het was een fantastische race (zoals alles 
bij jou een wedstrijd is), die ik niet had willen missen. Al dacht ik heel even een zeer rustige 
mede-PhD student ontmoet te hebben, het tegendeel bleek waar... Zonder jou waren de 
afgelopen jaren niet half zo mooi geweest. Ik zal de herinneringen aan Birmingham, Cadzand, 
Oktoberfest, en uiteraard jouw manier van het openen van wijn niet snel vergeten.
Michelle, jij was de eerste van ons ‘cluppie’ die de titel te pakken had en hebt daarmee 
een fantastisch voorbeeld gesteld! Vanaf het begin hebben we een super tijd gehad en 
niet alleen genoten van gezamenlijke meetings en congressen, maar ook van de nodige 
ontspanning in o.a. LMFAO outfit. Bedankt voor de leuke tijd en heel veel succes met de 
laatste loodjes in Londen! 
Martijn, het was gezellig om jou als overbuurman te hebben! Of we nu in LA zitten of op de 
hei in Kootwijk, zolang er een goed biertje te krijgen is weet jij je overal te vermaken. Ik hoop 
dat we in de toekomst nog eens een mooie combi van BOTM en kamperen kunnen maken! 
Heel veel succes met je nieuwe baan en de afronding van je project.
Vincent, als er iemand is die alles uit een PhD wil halen wat er maar te halen valt ben jij het 
wel. Projecten, studenten, commissies, alles wordt bij jou gekarakteriseerd door ‘veel’. Ik 
weet zeker dat het je ver gaat brengen en een heel dik proefschrift op zal leveren! 
Renée, jij doet dingen net even in een andere volgorde, maar de resultaten zijn er niet 
minder om! Ik vond het erg gezellig dat je ook na afloop van je PhD contract nog af en toe 
op de afdeling te vinden was en van de partij was bij etentjes. Succes in Groningen!
Eelke, ook al moest je je aandacht en tijd verdelen tussen heelkunde en MDL, jouw 
interesse in anderen is eindeloos, wat maakte dat je toch 100% bij het lab betrokken was. 
Je enthousiasme, optimisme en interesse zijn een top combi die je zeker te weten helpt om 
een fantastische arts te zijn. Heel veel succes met je opleiding!
My roommates…
Werner, ik denk met veel plezier terug aan de tijd in L-464. Onze kerstversiering was toch 
echt de beste  Wouter,  bedankt voor de gezelligheid, leuke gesprekken en uiteraard de 
vele prikacties!  Jasmijn, hoe jij 1001 projecten en examens met even zoveel vakanties én 
het kennen van alle lyrics weet te combineren is gewoonweg bijzonder. Je wist Na-1002 
altijd op te vrolijken met een toepasselijke hit. Blijf dat doen ;) 
Angela, Henk, Pauline, Veda, Waqar, Sergey, Yuebang, Lei, Xingying (Cindy), Rajesh, Juan 
(Amy), Pratika, Maria, Hakim, Changbo, it was nice to share L-464 or Na-1002 with you. 
I enjoyed our discussions about work, achievements, frustrations, and Dutch vs. Chinese 
culture. Thanks for the great time we had together!
En alle anderen…
Estella, you are one of the most hard-working people in the lab, yet you always have time 
for a chat. I hope your future jobs will allow you to have more regular working hours ;) 
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Thanks for the liver material you provided me with and good luck with finishing your PhD!
Leonie, de leukste secretaresse van de hele wereld! De chutney en tapas avondjes waren 
zeer gezellig, en niet alleen vanwege de uitstekende wijn-voorziening ;-) Bedankt voor al je 
hulp rondom de promotie!
Gwenny, trouw lid van het BOTM-vrijdagavond-team, bedankt voor de lekkere en gezellige 
biertjes!
Raymond, bedankt voor alle hulp buiten het lab.
Alexander, thank you very much for providing me with liver tissue in the first years of my 
PhD. I hope you’re doing well in Mexico.
Het lab is inmiddels te groot om iedereen hier apart te bedanken, maar mijn dank en 
herinneringen aan de rest van het lab zijn er niet minder om! Ik heb genoten van alle 
gezelligheid aan de koffietafel, labuitjes, (karaoke-)feestjes, Chinese New Year, Elp en 
Kootwijk.
Jan, Martine, Buddy, Frances, Ester, Auke, Greta, Rogier, Patrick, Emmeloes, 
Kostas, Shanta, Wenshi, Xiaolei, Effie, Pratika, Kelly, Jesse, Pieter, Monique, 
Jasper, Colin, Suomi, Elvira, Wendy, Susanne, Abdullah, Wanlu, Wen, Wenhui, 
Kan, Hakim, Hester, Luc, Petra, Ron, Jaap, Hugo, Marcel, Hanneke, BEDANKT! 
Margriet, dankjewel voor alle logistieke hulp tijdens de afgelopen jaren.
Ik wil hier ook alle patiënten bedanken die bloed of levermateriaal hebben gedoneerd, 
en alle artsen en verpleegkundigen die het verzamelen van dit materiaal mogelijk hebben 
gemaakt. In het bijzonder Rob de Knegt, veel dank voor alle leverbiopten die ik heb mogen 
gebruiken.
Er zijn ook heel veel mensen buiten het lab die in de afgelopen jaren met me hebben 
meegeleefd. Al was het misschien niet makkelijk te begrijpen wat mijn project precies 
inhield, toch waren velen altijd geïnteresseerd in de voortgang ervan.
Daan, je bent een fantastische vriendin die altijd voor me klaar staat, dankjewel daarvoor. 
Je bent een topper! 
Robert, Marinke, Marco, Myrthe, Ellen, Jeroen, Christy, Sander, Amanda, Wendy, Bart, 
Eunice, Ko, Wietske, Ruben, Ingeborg, Truke, Paul, Mariska, Ben; bedankt voor jullie 
vriendschap, lieve woorden, en vooral alle gezelligheid en nodige ontspanning die jullie me 
de afgelopen jaren gegeven hebben!
Richard, Max, Frank, Mark, Bart, Miryam, bedankt voor de mooie jaren LST 
die aan dit alles vooraf gingen en alle daaropvolgende etentjes en weekenden! 
Evelien, helaas was studeren met jou van korte duur, maar de vriendschap daarentegen 
niet, ik hoop dat we dat nog lang zo houden ;) 
En ten slotte mijn familie, bedankt voor jullie support en belangstelling in de afgelopen 
jaren.
Esther en Miriam, wat een geweldige zussen zijn jullie!
Es, ik vind het fantastisch hoe jij de halve wereld al over bent gegaan en je eigen ding weet 
te doen (maar wel fijn dat je nu gewoon dichtbij bent, wie weet voor hoe lang…). Mir, jij 
bent net begonnen aan een nieuwe uitdaging, ik weet zeker dat je daar geweldig in zal 
zijn. En dichterbij dan dit wordt het niet… Ik hoop binnenkort meer tijd te hebben om 
buurtbarbecues (of misschien toch gewoon een etentje in de stad) te organiseren ;) 
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Mam, pap, er is te veel om jullie voor te bedanken. Zonder jullie had ik dit niet kunnen doen 
en was ik niet gekomen waar ik nu ben. Bedankt voor jullie steun in de afgelopen jaren! 
P, bedankt voor de les die al van jongs af aan begon; om te allen tijde zelf na te denken (het 
klinkt zo logisch), dit boekje is een bewijs dat het zijn vruchten enigszins afgeworpen heeft…
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Myeloid Dendritic Cells via a Soluble CD14-Dependent Mechanism. J Virol. 2016 Jun 
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is associated with high IFN-λ production by CD34(+)-derived dendritic cells generated in 
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PhD portfolio
Name of PhD student: Evelyn van der Aa 
Department:   Gastroenterology and Hepatology, Erasmus MC University
   Medical Center, Rotterdam
PhD period:  September 2011 – December 2015
Promotor:  Prof.dr. Harry L.A. Janssen
Co-promotor:  Dr. Andrea M. Woltman
General academic and research skills: courses
2014 Course Biostatistical Methods,  Netherlands Institute for Health Sciences 
(NIHES), Rotterdam
2013 Course Integrity in Research, Dept. of Medical Ethics and Philosophy, 
Erasmus MC University Medical Center, Rotterdam
2013 Course Scientific English Writing, Netherlands Institute for Health 
Sciences (NIHES), Rotterdam
2013 Course Molecular Immunology, Erasmus Postgraduate school Molecular 
Medicine (MolMed), Erasmus University, Rotterdam
2012                Course qPCR, Life Technologies, Leiden 
2012 Course Presenting Skills, Erasmus Postgraduate school Molecular 
Medicine (MolMed), Erasmus University, Rotterdam
Oral presentations
2015 T cell consortium meeting, Erasmus MC
2015 MolMed day, Erasmus Postgraduate school Molecular Medicine, Erasmus 
University, Rotterdam
Chronic HBV infection affects BDCA3+ dendritic cell frequency and IFN-l production.
2014 Dutch Society for Immunology (NVVI) annual meeting, Kaatsheuvel.
IFNl is mainly produced by BDCA3-expressing myeloid dendritic cells and regulated 
by the NFkB and PI3K-PKB-mTOR pathway.
Chronic HBV infection affects BDCA3+ dendritic cell frequency and IFNl production.
2013 Dutch Society of Hepatology (NVH), Dutch Liver Retreat, Spier
Characterization and quantification of intrahepatic dendritic cells in healthy and 
diseased livers.
Poster presentations
2015 Dutch Society for Immunology (NVVI) annual meeting, Noordwijkerhout.
Chronic hepatitis B virus infection affects BDCA3+ dendritic cell frequency and IFN-l 
production
2015 International Meeting on Molecular Biology of Hepatitis B Viruses, Bad-Nauheim, 
Germany.
Chronic hepatitis B virus infection affects BDCA3+ dendritic cell frequency and IFN-l 
production.
2015 Dutch Experimental Gastroenterology and Hepatology (DEGH) meeting,
 Veldhoven
Interaction of BDCA3+ dendritic cells with HBsAg specifically inhibits IFN-λ 
production.
2014 Dutch Society for Immunology (NVVI) annual meeting, Kaatsheuvel.
Interaction of BDCA3+ dendritic cells with HBsAg specifically inhibits IFN-λ 
production.
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2014 International Meeting on Molecular Biology of Hepatitis B Viruses, Los Angeles, 
CA, USA
Interaction of BDCA3+ dendritic cells with HBsAg specifically inhibits IFN-λ 
production.
2014 Dutch Experimental Gastroenterology and Hepatology (DEGH) meeting,
 Veldhoven
Characterization and quantification of intrahepatic dendritic cells in healthy and 
diseased livers.
2014 MolMed day, Erasmus Postgraduate school Molecular Medicine, Erasmus 
University, Rotterdam
Characterization and quantification of intrahepatic dendritic cells in healthy and 
diseased livers.
2013 Keystone, Understanding Dendritic Cell Biology to Advance Disease Therapies
In vitro generation of CD34+-derived IFN-λ-producing BDCA3+ dendritic cells, 
resembling the BDCA3+ dermal dendritic cell subset.
2013 MolMed day, Erasmus Postgraduate school Molecular Medicine, Erasmus 
University, Rotterdam
In vitro generation of CD34+-derived IFN-λ-producing BDCA3+ dendritic cells, 
resembling the BDCA3+ dermal dendritic cell subset.
2013 Dutch Society for Immunology (NVVI) annual meeting, Noordwijkerhout.
Intrahepatic BDCA1+ and BDCA3+ dendritic cell subsets differ in their location and 
response to chronic viral infection.
2012 Dutch Society for Immunology (NVVI) annual meeting, Noordwijkerhout. 
In vitro generation of CD34+-derived IFN-λ-producing BDCA3+ dendritic cells, 
resembling the BDCA3+ dermal dendritic cell subset.
Additional conferences attended
2013 Dutch Society for Immunology (NVVI) Symposium, Lunteren.
 APCs revisited: the function of antigen presenting cells in health and disease.
2012 European Association for the Study of the Liver (EASL) Monothematic Conference: 
Immune Mediated Liver Injury, Stratford upon Avon, UK.
2011 Dutch Society for Immunology (NVVI) annual meeting, Noordwijkerhout.
Grants and awards
2015 Travel grant, Dutch Society for Hepatology
2015 Poster prize, Dutch Experimental Gastroenterology and Hepatology (DEGH) 
meeting, Veldhoven
2014 Travel grant, Dutch Society for Hepatology
2013 Travel grant, Erasmus Trustfonds
2013 Research award, Dutch Society for Hepatology
2013 Travel grant, Dutch Society for Immunology
2013 Travel grant, Erasmus Trustfonds
Teaching activities
April 2014 – March 2015   Que Zhu, MSc thesis, Wageningen University
October 2013 – December 2013 Yoga Vignesh Chancra Mohan, MSc thesis, University
    of Kaiserslautern, Germany 
November 2012 – July 2013 Fadime Ayhan, MSc thesis, UVA
October 2014, 2013, 2011  Organization of labrotations for MSc students
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Curriculum vitae 
Evelyn van der Aa werd op 5 augustus 1988 geboren te Sliedrecht. In 2006 behaalde zij 
haar VWO diploma aan De Lagewaard in Papendrecht. Vervolgens startte zij met haar studie 
Life Science and Technology aan de Universiteit Leiden en Technische Universiteit Delft. 
Haar bachelor sloot zij af met een onderzoeksstage op de afdeling Humane Genetica van 
het Leids Universitair Medisch Centrum (LUMC) onder begeleiding van Dr. Yvonne Krom en 
Prof.dr. Silvère van der Maarel. Tijdens deze stage werd de spierfunctie in een muismodel 
voor facioscapulohumorale spierdystrofie (FSHD) gekarakteriseerd. In 2009 begon zij aan de 
master Research in Life Science and Technology aan de Universteit Leiden. In het eerste jaar 
van haar master deed zij ervaring op in het bedrijfsleven door middel van een stage bij Crucell 
onder begeleiding van Dr. Pieter Rijken en Els van Deventer. Deze stage stond in het teken 
van de ontwikkeling van een high-throughput assay voor de bepaling van de oplosbaarheid 
van antilichamen. Het tweede jaar van haar master startte zij met een onderzoeksstage aan 
de afdeling Maag-, Darm- en Leverziekten van het Erasmus MC in de onderzoeksgroep van 
Dr. Andrea M. Woltman. Tijdens deze stage, waarbij zij begeleid werd door Dr. Lianne van 
de Laar en Dr. Nadine van Montfoort, optimaliseerde zij een kweeksysteem voor de in vitro 
ontwikkeling van BDCA3+ dendritische cellen. Na het behalen van haar mastertitel in 2011 
kwam zij terug bij de Maag-, Darm-, Leverziekten afdeling van het Erasmus MC en startte zij 
haar promotieonderzoek, waarvan de resultaten in dit proefschrift beschreven staan. Het 
promotieonderzoek vond plaats onder leiding van co-promotor Dr. Andrea M. Woltman en 
promotor Prof.dr. Harry L.A. Janssen. Sinds april 2016 is zij werkzaam bij Janssen Vaccines 
and Prevention in Leiden als scientist op het gebied van bacterial vaccines.
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